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Influenza A viruses (IAVs) belong to the group of (-)RNA viruses, in particular, to the 
Orthomixoviridae, that is a family of enveloped viruses with a single-stranded (ss) negative-
sense (-) and eight-segmented RNA genome. They are the most prevalent pathogens for both 
humans and animals, causing the so-called seasonal flu, that affects every year approximately 
5-10% of the adult and 20-30% of the pediatric population.  
IAV virion consists of a lipid envelope out of which two glycoproteins, hemagglutinin (HA or 
H) and neuraminidase (NA or N), protrude. Embedded within the lipid envelope bilayer, the 
viral integral membrane protein M2 is present, while M1 protein forms a matrix layer 
underneath the envelope of the virion. Regarding the genetic material, each segment of the 
RNA genome is wrapped-up in multiple copies of NP and is associated with the RNA-
dependent RNA polymerase, (RdRp). Each NP-encapsidated RNA segment, together with its 
RdRp, constitutes a viral ribonucleoprotein complex (vRNP). There are several subtypes of 
IAV, according to the combination of HA and NA expressed on the surface of the virus: to 
date, eighteen different HA subtypes and eleven different NA subtypes have been identified.
 
Different subtypes of IAV were responsible for widespread pandemics since the 16
th
 century: 
the most important have been the 1918 Spanish flu (H1N1), the 1957 Asian flu (H2N2), the 
1968 Hong Kong flu (H3N2); but also, the 2009 swine-origin pandemic flu (2009 pH1N1) as 
well as the 1977 Russian flu (H1N1). 
The process of viral infection consists of seven steps: adsorption, penetration, uncoating, 
transcription, translation, assembly and release. A key enzyme for all the infection process is 
RdRp. It is a heterotrimeric complex of about 250 kDa that is composed of three different 
subunits: PA (polymerase acidic protein), PB1 and PB2 (polymerase basic proteins 1 and 2). 
Starting from the ss(-)RNA viral genome, RdRp is responsible for the synthesis of the 
positive-strand messenger (mRNA), used for viral protein production, and for the synthesis of 
complementary RNA (cRNA), useful to obtain new viral genome. In particular, the catalytic 
site is in PB1; PB2 includes the capped-RNA recognition domain, that is necessary for the 
generation of the primer for the transcription, while PA is responsible for “cap-snatching”, the 
cleavage of host cell pre-mRNA to utilize its cap for viral generation of the primer for the 
transcription, and it is also important in the complex assembly. 
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Vaccination is regarded as the major prophylactic and therapeutic treatment of influenza 
infections, although the genetic drift in viral genome make it necessary to formulate new 
vaccines each year and the highly variable nature of the surface glycoproteins HA and NA 
does not make possible the development of a universal influenza vaccine. A part from the use 
of vaccines, viral infections can be inhibited at several crucial steps by the use of antiviral 
agents. It is possible to have an antiviral effect both targeting important proteins for the virus 
life cycle and targeting host proteins that play crucial roles during influenza virus infection. 
Playing a critical role during the life cycle of the virus, RdRp has become a promising target 
for the development of anti-influenza drugs in recent years. Based on the mechanism of the 
interactions between inhibitor and polymerase, compounds targeting RdRp can be subdivided 
into four subtypes: PA endonuclease inhibitors, PB1 inhibitors, PB2 cab-binding (PB2-CBD) 
inhibitors and RdRp disrupting compounds. 
Among these four classes of antiviral compounds, the latest seems to be one of the more 
promising. These compounds are called protein-protein interaction inhibitors (PPI inhibitors) 
because of their interference or inhibition of the protein-protein interaction in the RdRp 
assembly. Among the interactions between the three different subunits of the RdRp, the PA-
PB1 is probably the most interesting one for the development of new inhibitors. This 
interaction has been characterized and is known to occur between the C-terminal region of PA 
(PA-C) and the N-terminal region of PB1 (PB1-N). The interaction between PA-C and PB1-N 
is an innovative promising target because it has a high degree of conservation among virus 
strains that suggests that its inhibitors may be active against many viral subtypes and less 
prone to drug-resistance. Moreover, this interaction involves few amino acids and so it could 
be inhibited by small molecules. My research doctorate activity was focused on the synthesis 
and biological evaluation of novel anti-influenza agents acting as PPI inhibitors, in particular, 
disrupting the PA-PB1 interaction. 
From a high-throughput docking approach used to screen the Asinex database (703,200 
molecules), compounds possessing a 4,6-diphenyl-3-cyanopyridinic nucleus were identified 
as weak inhibitors of the PA-PB1 interaction. Moreover, for a better understanding of the 
underlying SAR, a series of 4,6-diphenyl-3-cyanopyridine derivatives was synthesized, by 
performing modification or replacement of molecule portions. Starting from these studies, I 
decided to synthesize a library of molecules characterized by a hybrid structure constituted by 
the promising 3-cyano-4,6-diphenylpyridinic core together with an aminoacidic side chain in 
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C2 (CHAPTER 4., Paragraph 4.2.).
 
With the aim to enhance the ability of 3-cyano-
diphenylpyridine compounds to completely displace PB1 and increase their affinity toward 
the target protein PA, I decided to synthesize at first hybrid derivatives combining the 
cyanopyridine core linked to the last three amino acids of PB1-N (Met-Asp-Val), then to 
explore better the C2 side chain introducing in this position different L- or D-amino acids as 
methyl or benzyl esters.
 
The synthesis of these compounds allowed to explore the potential 
antiviral activity of this new class of hybrid derivatives and to do SAR evaluations. Moreover, 
some derivatives showed a promising antiviral activity acting as IAV RdRp PPI inhibitors. 
Since SAR and molecular dynamic simulation studies seem to show that the cyano group is 
not essential for the antiviral activity, and considering that it is often related to potential 
cytotoxicity, it was decided to remove the CN group in C3 position of the pyridine core and to 
include the nitrogen atom in the ring. Following a rational design process, I synthesized a 
library of phenyl pyrimidine derivatives, maintaining in C2 the 2-mercapto-N-(m-
tolyl)acetamide chain that was present in the promising compound identified in the previous 
screening study, and I explored the effect of different aromatic substituents in C4 and C6 of 
the pyrimidine ring (CHAPTER 4., Paragraph 4.3.). This new synthesized library of 
pyrimidine compounds allowed to extend SAR evaluations and to get further insights into this 
new promising class of antiviral molecules, exploring the effect of different aromatic 
substituents in C4 and C6 positions of the pyrimidine core. Moreover, it was possible to find 
promising IAV RdRp PPI inhibitors which will be a good starting point for further 
development. Since during the previous screening work a representative pyridine derivative 
showed good biological results, I decided to try to synthesize some pyridine derivatives, 
maintaining, as done for the pyrimidine library, the 2-mercapto-N-(m-tolyl)acetamide chain in 
C2 and exploring the effect of different substituents in C4 and C6 positions (CHAPTER 4., 
Paragraph 4.4.). All modeling studies have been developed in collaboration with the 
University of Siena, while biological tests have been performed in collaboration with the 
University of Padua. 
Another part of my PhD work was devoted to the synthesis of substituted pyrazolo[3,4-
b]pyridines as A1 adenosine antagonists. Adenosine is an endogenous neuromodulator which 
mediates its effects by interacting with four G-protein-coupled receptor subtypes distributed 
in a wide variety of tissues, named A1, A2A, A2B and A3. In particular, A1 adenosine receptor 
(A1AR) is the more preserved receptor subtype among different species and is widely 
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expressed in many parts of the body. A1AR activation inhibits the activity of adenylate 
cyclase, activates potassium channels, blocks calcium transient (T) channels and increases the 
intracellular levels of calcium and, due to the phospholipase C (PLC) activation, of inositol-
1,4,5-triphosphate (IP3). An excessive stimulation of A1ARs is related to different 
pathologies, such as various forms of dementia, including Alzheimer’s disease, depression, 
congestive heart failure, bradyarrhythmias, asystolic arrest, sepsis and cirrhosis of the liver. 
Because of A1AR stimulation plays a central role in a lot of pathologies, the discovery of 
human A1 selective antagonists is very significant. 
 
In this context, the research group where I worked synthesized a wide library of 4-
aminopyrazolo[3,4-b]pyridine-5-carboxylic acid esters, introducing various substituents at the 
N1, C4 and C5 positions of the central scaffold. Many of these compounds turned out to be 
active as A1AR antagonists both on bovine and human receptors. Starting from these results, I 
decided to synthesize two small libraries of 4-aminopyrazolo[3,4-b]pyridine-5-carboxylic 
acid ester derivatives. These two series of compounds have in C5 of the pyrazolo-pyridine 
scaffold the ethyl ester chain, while in C6 there are different substituents. Some of them have 
a 2-chloropropyl chain in N1, while others have the bulkier 2-chloro-2-phenylethyl chain 
(CHAPTER 5.). Since previous studies indicated that human A1AR contains a binding 
pocket smaller than that of bovine receptors, the aim of my work was that of obtaining more 
potent and selective antagonists for hA1AR and evaluating their possible different affinity for 
bovine and human receptors. With this work it was possible to enrich our library of A1 
antagonists belonging to the class of pyrazolo[3,4-b]pyridines, to extend SAR evaluations 
and, importantly, to confirm that the binding site of the human A1AR is smaller than that of 
the bovine A1AR. In the complex, the synthesized compounds represent a step forward in the 
research for active compounds on A1AR, a field that was not so much explored but that could 
lead to interesting results in therapy thanks to a modulatory effect on target tissues. For this 
part of my work, docking studies and biological tests have been developed in collaboration 
with the University of Pisa. 
During the third year of my PhD, I spent three months at the Department of Chemistry at the 
University of Basel, within the research group of Prof. Dr. Olivier Baudoin. The research of 
this group is focused on the development of step-economical transition-metal-catalyzed 
methods for the functionalization of non-activated C-H bonds, employing catalysis by Pd(0) 
complexes. Transition-metal catalysis has emerged as a powerful tool to functionalize 
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otherwise unreactive C-H bonds and to create a variety of carbon-carbon and carbon-
heteroatom bonds. In the context of enantioselective Pd(0)-catalyzed reactions, Baudoin and 
co-workers are working on the development of a bifunctional molecule that can act as ligand 
and as base at the same time. The model reaction for the optimization of the catalyst 
transforms the substrate into a fluoradene derivative. Fluoradenes seem to be key 
intermediates for the synthesis of buckybowls, interesting compounds having five- and six-
membered rings and a curved surface that can be employed, for example, in host-guest 
chemistry or for light-emitters. In this context, the work that I have done during my three-
months internship within Baudoin’s group is related to different aspects linked to C-H 
activation reactions, and could be divided into three main topics: the synthesis of the key 
intermediate to get the binaphtyl bifunctional ligand, the performing of some enantio and 
racemic C-H activation reactions and attempts to obtain new substrates for C-H activation 
reactions (CHAPTER 6.). 
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CHAPTER 1. Introduction 
 
1.1 General features and classification of viruses 
Viruses are the smallest infectious agents for humans, and the most common and abundant 
biological entities on Earth
1
. They can display different morphologies, from rather spherical 
forms (about 100 nm in diameter) to extended filamentous strains (several micrometers long); 
the morphological changes are influenced by viral and host cell factors as well as mutations 
that allow viruses to adapt in different situations. Several studies demonstrate that spherical 
and filamentous morphologies are linked at least in part to the matrix protein 1 (M1), a 
bifunctional membrane/RNA-binding protein that mediates the encapsidation of RNA-
nucleoprotein cores into the membrane envelope; in particular, different studies reported that 
mutations in the M1 gene of influenza A viruses (IAVs), in particular, including residues 41, 
95, 102, 204, and 218, can affect virion morphology
2-7
. Indeed, it seems that filamentous 
morphology gives a selective advantage in vivo, while viruses with exclusively spherical 
morphology are more fit in laboratory substrates
8
, and that this difference of structure is 
correlated to functional differences, such as neuraminidase (NA or N) activity
9
. 
Viruses can contain a single-stranded (ss) or double-stranded (ds) RNA or DNA, either linear 
or circular, as genome. DNA or RNA viral genome is protected by a proteic membrane, called 
capsid; the capsid together with the viral nucleic acid is called nucleocapsid. In some viruses 
the nucleocapsid contains important viral enzymes such as, in the case of the influenza virus, 
the RNA-dependent RNA polymerase (RdRp). Additional lipidic or carbohydrates layers may 
be present around the nucleocapsid; they differ according to the type of virus and may contain 
proteins encoded by viral genes. The complete structure of the virus is called virion.  
Viral taxonomy is complex: there are different classifications of viruses based on shape and 
structure of their capsids, type of genome, chemical-physical properties, structure of the 
associated proteins, strategy of replication, etc. Classical virology taxonomy is the Baltimore 
classification that is based on the replication-expression strategies, in particular, on the form 
of nucleic acid that is incorporated into virions. According to this classification, viruses are 
divided into six classes: dsDNA viruses (class I) (e.g. Adenoviruses, Herpesviruses, 
Poxviruses), ssDNA viruses (class II) (e.g. Parvoviruses), dsRNA viruses (class III) (e.g. 
Reoviruses), positive (+) ssRNA viruses (class IV) (e.g. Picornaviruses, Togaviruses), 
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negative (-) ssRNA viruses (class V) (e.g. Orthomyxoviruses, Rhabdoviruses) and RNA tumor 
viruses and other viruses which have a DNA intermediate in their growth and a ssRNA 





Figure 1. Baltimore classification of viruses. Adapted from: Chem Soc Rev., 45(15), 4074-4126. 
 
Today, we refer to the Universal Scheme of Virus Classification of the International 
Committee on Taxonomy of Viruses (ICTV)
11
. The essential principles of this nomenclature 
are intended to ensure stability of the naming system by avoiding or rejecting the use of 
names which might cause error or confusion, and preventing the unnecessary creation of 
names. Changes in this classification take place every year, as the result of a multi-stage 
process: proposals submitted to the ICTV Executive Committee (EC) undergo a review 
process, then are presented for ratification to the full ICTV membership by publication on the 
ICTV website; the name of a taxon is not official until it has been approved by ICTV. For the 
ICTV, viruses are divided into orders (Bunyavirales, Caudovirales, Herpesvirales, 
Ligamenvirales, Mononegavirales, Nidovirales, Ortevirales, Picornavirales, Tymovirales), 





1.2. Influenza viruses 
Influenza viruses belong to the group of (-)RNA viruses, in particular, to the 
Orthomixoviridae, that is a family of enveloped viruses with a single-stranded (ss) negative-
sense (-) and eight-segmented (types A and B) or seven-segmented (types C) RNA genome. 
More recently, in addition to these three types of influenza viruses, a fourth type D was 
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. In the ICTV taxonomy, Orthomixoviridae family is subdivided into seven 
genera: Alphainfluenzavirus (or influenza type A, IAV), Betainfluenzavirus (or influenza type 
B, IBV), Gammainfluenzavirus (or influenza type C, ICV), Deltainfluenzavirus (or influenza 
type D, IDV), Isavirus, Quaranjavirus and Thogotovirus
10
. The most relevant are the first 
three classes, divided in types A, B, C according to the antigenicity of their nucleoprotein 
(NP), a structural protein which encapsidates the (-)RNA, and the matrix protein M1
14
.  
RNA segments of type A and type B viruses encode eleven proteins while RNA segments of 
type C viruses encode nine proteins. Within the virion, RNA segments form ribonucleoprotein 
(RNP) complexes. More specifically, the highly conserved 5΄ and 3΄ termini of RNA interact 
through base-pairing to form a partially double-stranded structure which is bound by the 
RdRp complex, while the rest of the RNA associates with NPs (one NP for approximately 
every 24 nucleotides), with high affinity and without sequence specificity, to form a flexible 
helical filament closed by a loop at the opposite pole to the genomic ends. The interaction 
between NPs and RNA polymers is via the phosphate backbone, so that RNA should be 
accessible for pairing or genome duplication
15,16
. Influenza virus strains have an identification 
code according to their antigenic type (A, B, C or D), the host of origin (omitted if human), 
the geographical origin, strain number, year of isolation and, in the case of IAVs, the 
hemagglutinin (HA or H) and NA subtype. For example, the code “influenza A/chicken/Hong 
Kong/220/97(H5N1) virus” refers to IAV, H5N1 subtype, strain number 220, isolated from 




1.2.1. Influenza A virus and pandemics 
Influenza A virus (IAV) is the most prevalent pathogen for both humans and animals (birds, 
horses, pigs and bats)
18
, causing the so-called seasonal flu, that affects every year 
approximately 5-10% of the adult and 20-30% of the pediatric population
19
. There are several 
subtypes of IAV, according to the combination of HA and NA proteins that are expressed on 
the surface of the virus and that are essential for entry into and release from the host cell. To 
date, eighteen different HA subtypes (HA1-18) and eleven different NA subtypes (NA1-11) 
have been identified
20
. Aquatic birds are thought to be the primary reservoir for IAV because 
they can be infected with nearly every subtype of the virus, providing a large pool of virus 
gene segments that can contribute to novel reassortant viruses. Only the recently discovered 
subtypes H17N10 and H18N11 have not been found in birds, but in bats
21
. 
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Different subtypes of IAV were responsible for widespread pandemics since the 16
th
 century: 
the most important have been the 1918 Spanish flu (H1N1), the 1957 Asian flu (H2N2), the 
1968 Hong Kong flu (H3N2); but also, the 2009 swine-origin pandemic flu (2009 pH1N1) as 
well as the 1977 Russian flu (H1N1) (Figure 2.). 
The Spanish flu has been recorded as the worst pandemic in history; it caused the death of 
approximately 675,000 people in the USA and more than 50-100 million people worldwide. 
Most of the deaths resulted from respiratory complications, such as bronchopneumonia with 
bacterial invasion and progressive cyanosis and collapse. It seems that the pathogenicity of 
the H1N1 virus was amplified by a concomitant bacterial infection by S. pneumoniae and S. 
pyogenes. After the pandemic period, the virus kept accumulating mutations for several years 
and disappeared in 1957, only to reappear in circulation in 1977. In 1957 another influenza 
pandemic, the Asian flu, caused by the H2N2 strain of IAV, occurred. The new H2N2 strain 
was detected in February 1957 in China, and by the summer of 1957 it had spread to the rest 
of the world. Although the overall impact on mortality was one-tenth of that observed during 
the 1918 pandemic, in the USA it caused almost 60,000 deaths from September 1957 to 
March 1958 and about 115,700 worldwide. In 1968, a new influenza virus strain (H3N2) led 
to the third pandemic. The H3N2 strain was first isolated in Hong Kong in July 1968 and, 
although it was highly transmissible, caused a milder disease than the Asian flu. The virus 
mainly spread due to international air travels and it caused an estimated 98,100 deaths in the 
years 1968-1971. It is important to underline that both H2N2 and H3N2 influenza viruses 
were avian-human reassortants in which avian gene segments were introduced into a human-
adapted virus that was already in circulation. In the spring of 2009 there was the emergence 
of a novel subtype of IAV (H1N1), which caused the first pandemic of the 21
st
 century, 
being transmitted very fast worldwide. According to a study done from 15 April 2009 
through 23 January 2010 in the USA, the rates of hospitalization were higher in children, 
with 272 paediatric deaths
22,23
. 
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Figure 2. A timeline of major influenza pandemics and the responsible IAV strains. Adapted from: Arch Virol., 
163, 831-844 (2018).  
 
 
1.2.2. Influenza B virus  
Influenza B viruses (IBVs) are classified into two co-circulating phylogenetically and 
antigenically distinct lineages, named viruses B/Yamagata/16/88 (Yamagata-lineage) and 
B/Victoria/2/87 (Victoria-lineage), that diverged in the 1970s. The B/Victoria lineage 
predominated during the 1980s, while the B/Yamagata lineage during the 1990s. In 2001, the 
B/Victoria lineage re-emerged in Europe and USA and the two lineages have co-circulated 
ever since
24
. IBV changes two-three times less rapidly than type A
25 
and consequently has less 
genetic diversity
26
. The lower antigenic mutation rate, combined with a poor range of hosts 
(which prevents an antigenic displacement between different species) ensures the 
impossibility of IBV pandemics
27
. It is important to underline that, despite the difference of 
virus infection frequency between IAV and IVB, an equivalent fatality rate between both 




1.2.3. Influenza C and D viruses 
Influenza C virus (ICV) infects humans and pigs. There are many co-circulating ICV variants 
belonging to different lineages: C/Yamagata/26/81, C/Aichi/1/81, C/Aomori/74 and 
C/Mississippi/80. Despite the significance of genetic reassortment in ICV epidemiology is 
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totally unknown, several ICV reassortant strains (C/Yamagata/64, C/Kanagawa/1/76, 
C/Miyagi/77, C/England/83, C/Nara/1/85, C/Yamagata/9/88 and C/Yamagata/5/92) have been 
identified
29
. Although seroepidemiological studies revealed that ICVs are widely distributed 
throughout the world, outbreaks of illness caused by the virus have rarely been detected and 
clinically appear to cause only minor disorders
30-32
. 
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CHAPTER 2. Influenza A virus 
 
2.1 Structure and life cycle  
The different types of IAVs are the most dangerous for humans because they are responsible 
for the seasonal flu, that each year affects millions of people, and for important pandemics 
that have cyclically hit the world. For this reason, my research has focused on finding new 
molecules that are potentially active against type A viruses. From now on I will therefore only 
refer to IAV. 
IAV virion consists of a lipid envelope out of which two surface spike-like projections, 
consisting of HA and NA glycoproteins, protrude. Embedded within the lipid envelope 
bilayer, the viral integral membrane protein M2 is present, while M1 protein forms a matrix 
layer underneath the envelope of the virion. The genetic material consists of an eight-
stranded, negatively charged RNA. Each strand is wrapped-up in multiple copies of NP and is 
associated with three proteins responsible for transcription and replication: PB1, PB2, and PA 
(the viral polymerase complex), creating the distinctive panhandle structure. Each NP-
encapsidated RNA segment, together with its heterotrimeric polymerase, constitutes a viral 





Figure 3. General structure of IAV. Adapted from: Nature Rev Microbiol., 3, 591-600 (2005). 
 
The process of viral infection consists of seven steps: adsorption, penetration, uncoating, 
transcription, translation, assembly and release (Figure 4.)
16,35
. 
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During the adsorption, the virus attacks to the epithelial cells using a specific bond between 
HA of the virus and glycoconjugates ending with N-acetylneuraminic acid, generally known 
as sialic acid, located on the surface of the host cell. In particular, HA recognizes glycan 
structures terminating with sialic acid, linked to galactose in a β-1,4 linkage to glucosamine 
(GlcNAc). The linkage of the sialic acid to the penultimate galactose is considered to be a 
determinant of species specificity: avian HA binds to α-2,3 sialic acid while human HA to α-
2,6. This specificity normally prevents the transfer of influenza viruses between avian species 
and humans; however, this restriction can be overcome, as observed in culture where viruses 
can adapt to their host through mutations in the receptor-binding site of the viral HA gene. 
Internalization processes could be mediated by different events: the majority seems to be 
clathrin-coated pits mediated, but internalization via caveolae, macropinocytosis, and by non-
clathrin, non-caveolae pathways have also been described. 
The penetration and the uncoating of the virion occur by fusion between the viral and 
endosomal membranes, stimulated by acidification of the endosome, that causes a structural 
change in the viral HA and leads the fusion peptide (FP) of its HA2 subunit to interact with 
the endosome membrane. The concerted structural change of several HA molecules opens up 
a pore through which the vRNPs pass into the cytosol of the cell. The virus-associated M2 
protein allows the influx of H
+
 ions into the endosome; this causes the disruption of the 
protein-protein interactions and the subsequent release of vRNPs free of the M1 protein.  
After being released into the cytosol of the cell, vRNPs are transported to the host nucleus. 
vRNPs are too large to passively diffuse into the nucleus and so they must rely on active 
transport by the nuclear import machinery. The transport process begins with the recognition 
of the nuclear localization signal (NLS) by α-karyopherin; then a trimeric complex with β-
karyopherin allows vRNP binding with the nuclear pore of the host cell nuclear membrane. 
Inside the nucleus, the viral RNA (vRNA) is transcribed and replicated. In detail, vRNPs are 
transcribed to produce viral mRNAs in a process that is called “primary transcription”, 
independent of de novo viral protein synthesis and primer-dependent. The primers used for 
this purpose, namely 7-methylguanosine-capped pre-mRNAs with 10-13 associated 
nucleotides, are obtained through “cap-snatching” of cellular mRNAs by the RdRp. This 
allows polyadenylation of viral mRNAs once the influenza virus has shut down the host cell 
polyadenylation processing. Once the caps are acquired, transcripts are generated by 
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replication from a vRNP template, while poly-A tails are produced by reiterative stuttering 
and copying of the poly-U sequence motif at the conserved 5′ end of the vRNA.  
After the primary transcription, viral mRNAs are exported to the cytoplasm and translated 
into viral proteins by cellular ribosomes; subsequently, the components of vRNPs are 
imported into the nucleus where progeny vRNP complexes are assembled. The negative-
stranded RNA is used for the synthesis of full-length positive-stranded RNA, called 
complementary RNA (cRNA), which in turn acts as a template for the synthesis of new RNA 
molecules. The enzyme that catalyzes all these reactions is the viral RdRp that enters the host 
cell nucleus with the vRNP complex. 
At this point, the assembly and the nuclear export can take place: RNA is packaged into 
vRNP containing two viral proteins, NP and M1. NP coats and protects the sugar phosphate 
backbone of the RNA, while M1 mediates the interaction of the RNP with the viral NEP/NS2 
protein, which in turn interacts with host cell chromosomal maintenance 1 (CRM1) nuclear 
export protein, allowing the export of the complex from the nucleus. In particular, it seems 
that NEP simultaneously interacts with M1, the PB1 subunit of the vRNP-associated RdRp 
and the CRM1 nuclear-export receptor
36
. It is known that the CRM1 nuclear export pathway 
is essential for vRNP nuclear export; in fact, vRNPs are retained in the nucleus of infected 
cells in the presence of leptomycin B (LMB), a specific CRM1 inhibitor. Interestingly, LMB 
treatment leads also to vRNP accumulation at the nuclear periphery, in association with 
chromatin, suggesting that this localization pattern represents an intermediate step in vRNP 
nuclear export, preceding vRNP passage through the nuclear pore complex
37-39
. The fact that 
infected cells microinjected with anti-M1 antibodies exhibit NP confinement to the nucleus
40 
and that exogenous M1 expression with impaired “late” gene expression (“late” genes include 
HA, M1, M2 and NA, and exhibit delayed expression relative to the NP gene)
41 
rescued the 
ability of vRNPs to accumulate in the cytoplasm
42
, indicate that also the M1 protein is directly 
implicated in the regulation of vRNP nuclear export. The influenza NEP protein (or NS2) also 
plays an important role in vRNP nuclear export; as seen for M1 protein, when anti-NEP 
antibodies are microinjected into the nucleus of infected cells, NP is retained in the nucleus, 
suggesting that this process is impaired when NEP protein functions are blocked
43
. Further, 
influenza viruses lacking NEP expression could not be recovered by reverse genetics, 
indicating that NEP is essential for the life cycle. 
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Also human host factors, such as cellular protein kinase activity, could affect vRNP nuclear 
export. Specifically, it has seen that this process is impaired in infected cells treated with a 
protein kinase C inhibitor
42
, an inhibitor of the Raf/MEK/ERK MAPK signaling cascade
44
, a 
receptor tyrosine kinase inhibitor
45
, and a serum- and glucocorticoid-regulated kinase 1 
inhibitor
46
, implying that phosphorylation of viral and/or cellular factors is required for vRNP 
export from the nucleus. Also HA seems to have an indirect role in promoting vRNP nuclear 
export, that can be enhanced by viral HA-mediated activation of the cellular Raf/MEK/ERK 
MAPK signaling pathway, which occurs when HA is expressed at the plasma membrane
47,48
. 
In addition, because HA is abundant in virus particles and vRNPs must “meet” HA at plasma 
membrane sites to form progeny viruses, HA-mediated Raf/MEK/ERK induction could be 
used as a signal to activate vRNP nuclear export when the budding sites are “ready”. It is 
important to underline that, although specific phosphorylation events and the kinases involved 
in promoting vRNP nuclear export have not yet been defined, NP, M1 and NEP exist all as 
phosphoproteins in infected cells
49-53
.  
Following nuclear export, progeny viral RNPs are transported across the cytoplasm in a 
Rab11- and microtubule-dependent manner to the budding site near the cell membrane, where 
assembly of new virions takes place
16
. In particular, shortly after nuclear export, vRNPs 
accumulate near the microtubule organizing center (MTOC), that is located immediately 
adjacent to the nucleus, and then they are aligned with microtubule networks. There is strong 
evidence that microtubule networks are essential for vRNP cytoplasmic transport: cells 
treated with microtubule depolymerizing agents exhibit altered vRNP distribution and 
reduced microtubule-like movement. Moreover, live cell imaging studies with fluorescently 
tagged vRNP components demonstrate vRNP movement along microtubule tracks
54-57
. Both 
vRNA and vRNPs co-localize extensively with Rab11-positive recycling endosomes in 
infected cells, suggesting that vRNPs use Rab11 vesicles for the movement through the 
cytoplasm. A specific role for Rab11 in mediating vRNP cytoplasmic transport is clearly 
demonstrated because it has seen an impaired vRNP association with Rab11-positive vesicles, 
a disruption of vRNP accumulation at the plasma membrane and a sharply reduction of 
infectious progeny virus output in cells with a Rab11 protein knockdown and an exogenous 
overexpression of a dominant-negative Rab11 mutant protein. Probably, when vRNPs are 
near the budding site, their extraction from Rab11 vesicle surfaces occurs, and only vRNPs 
are incorporated into budding virions; this is confirmed by the lack of Rab11 detection in 
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. Two components of host RNP, that regulate translation of 
cellular mRNAs, Y box binding protein 1 (YB-1) and double-stranded RNA-binding protein 
Staufen homolog 1 (STAU1), are associated with influenza vRNPs during late-stage 
infection. The YB-1 protein seems to be connected with the vRNP nuclear export and the 
delivery of vRNPs. The connection between YB-1 and the vRNP export process is due to the 
fact that this protein is localized with vRNA into the nucleus of infected cells and later it is 
found in the cytoplasm, in complex with α-tubulin, Rab11 and vRNPs, suggesting that YB-1 
can undergo nuclear export in complex with vRNPs. It seems also that YB-1 facilitates the 
delivery of vRNPs to Rab11 endosomes, immediately after leaving the nucleus, even if direct 
evidence in support of this hypothesis is lacking. The role of STAU1 is less clear, although 
this factor is thought to promote a late aspect of the influenza virus life cycle, because its 
knockdown does not impair viral protein expression or vRNP nuclear export
61,62
. 
Final virus assembly is initiated at the budding site by the entry of the HA, NA and M2 
proteins into the endoplasmic reticulum of the host cell; here HAs and NAs are folded and 
glycosylated. HAs are assembled into a trimer which is exported along with NAs and M2 
proteins to the Golgi apparatus, where palmitoylation of cysteine residues on HA and M2 
takes place. The budding of the new viral particles is initiated by the accumulation of M1 
protein at the inner leaflet of the host cell membrane. As previously said, the Rab11 protein 
does not appear to be incorporated into a new virion, implying that another mechanism exists 
for vRNP recruitment at the budding site. Several studies suggest that the M2 protein is 
required for this process and that it occurs through a direct interaction between M1 and the 
M2 cytoplasmic tail
63-65
. In the final budding stage, NA hydrolyses the sialic acid conjugates, 
leading the release of a new virion from the host cell
34
. 
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2.2. Key proteins for viral life  
The genome of IAV was mapped during the 1970s
66,67
. Since that time, it was believed that 
eight viral genome segments encode ten proteins: the polymerase basic proteins 1 (PB1) and 2 
(PB2), the polymerase acidic protein (PA), nucleoprotein (NP), hemagglutinin (HA), 
neuraminidase (NA), matrix proteins 1 (M1) and 2 (M2), and non-structural proteins 1 (NS1) 
and 2 (NS2). However, in 2001 an eleventh IAV protein, PB1-F2, was discovered. PB1-F2 is 
translated from a nucleic acid sequence that does not contain a stop codon in a given reading 
frame, the so called alternative open reading frame (ORF)
68













 have been 
found and/or re-discovered (Figure 5.). 
 
 
Figure 5. IAV proteins encoded by each segment of the viral genome. Adapted from: 
https://viralzone.expasy.org/. 
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2.2.1. Hemagglutinin  
Hemagglutinin (HA or H) is a membrane-anchored homotrimer encoded by the fourth 
negative-stranded RNA segment, essential for virus-cell adsorption and endocytosis
75
. The 
fourth RNA segment encodes the precursor protein HA0 with 566 residues; HA0 is post-
translationally glycosylated and trimerized with chaperons in the endoplasmic reticulum of 
the infected cell and it undergoes an extra- or intra-cellular cleavage process into HA1 and 
HA2. Each monomer of HA is composed of a globular head (HA1 domain) of approximately 
327 residues organized in antiparallel β-sheets, and a fibrous stalk-like region (HA2 domain) 
of α-helices of approximately 222 residues. The HA1 and HA2 subunits are linked by a single 
disulfide bond to form a “mushroom” structure stuck in the viral envelope (Figure 6.)
76
.  
At neutral pH, the trimeric structure of viral HA is stabilized by the electrostatic interactions 
between positively charged inner surface sites of HA1 and negatively charged sites of HA2. 
The globular head of HA1, which comes out of the surface of the virus, plays a central role in 
virus-host interactions: it binds host receptors, is recognized by host antibodies and is 
responsible for the evasion of host immunity system through mutations and glycosylations at 
specific epitopes. In the HA1 domain there is the receptor binding site that is characterized by 
four structural key features: the 190-α helix, the 130-loop, the 220-loop and a hydrogen-
bonded network of conserved amino acids at positions 98, 153, 183 and 195, which constitute 
the base of the site. In the HA2 domain, the first 23 residues, starting from the N-terminal 
end, form the so called fusion peptide (FP), which is accommodated in a hydrophobic pocket 
partially formed by the fusion domain of HA1. The sialic acid is bound with chair geometry 
and with the face of the sugar directed toward the floor of the binding site, while the N-acetyl 
group is located in a hydrophobic pocket. In all HA subtypes, the binding site and all key 
structural elements are similar, also in length. It is important to underline that, relatively small 
changes in length of loops between different viral strains are responsible for changes in the 
architecture of the site and, subsequently, in the interactions with different conformations 
associated with the glycosidic linkage type. An example of the connection between HA 
mutations and receptor preference is represented by the fact that most avian-infecting virus 
strains carry glutamine in position 226 (Q226), which provides a useful environment for 
ligands with the α-2,3 bond between sialic acid and galactose; in fact, both oxygens from the 
carboxyl group on sialic acid and the oxygen from the glycosidic bond can interact with the 
hydrophilic side chain of glutamine. On the other hand, if in position 226 there is a leucine 
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(L226) that has a hydrophobic side chain, it promotes ligands with the α-2,6 linkage. 
Sometimes the Q226 mutation has been found in strains with the human receptor preferring 
HA. This is probably due to the fact that the hydrophobic effect of the leucine residue can be 
emulated by residues at 138, 186 and 221, as in the case of some H7 strains
75,77,78
. 
In a recent study, Ni and colleagues
79
 demonstrated that the different length in the 130-loop of 
HA binding site in pandemic H1 HA vs H2/H3 HAs is correlated with virus human 
adaptation. From this study, the 130-loop appears to be the key determinant to understand the 
different mutational routes employed by pandemic H1 or H2/H3 HA. In particular, the length 
of the 130-loop and, more importantly, the sitting position of the sialic acid moiety of the 
receptor can help first establish if a given HA would likely behave as H1 or H2/H3. 
The different antigenic subtypes (1-18) of HA are divided into two groups, based on 
phylogenetic analysis. The first group includes H1, H2, H5, H6, H8, H9, H11, H12, H13, 
H16, H17 and H18 subtypes, while the second contains H3, H4, H7, H10, H14 and H15 
subtypes. Subtypes 1-16 were identified in avian species, while H17 and H18 were found only 
in bats
80
. It is important to underline that H17 and H18 should be considered to be only HA-
like proteins, because they lack the ability to bind glycans terminated with sialic acid and, 
furthermore, there is no evidence that the viral genomes identified in bats can be assembled 
into a real virus or is able to exchange genetic material with IAV from other subtypes
81
. Even 
in different subtypes, the HA structures are relatively similar; despite these similarities, the 
rotation of the membrane-distal subdomains relative to the central stem can be different. The 
variation seems to be related to differences in the structure and positioning of a loop in HA2 
that links α-helix A (HA2 residues 38-58) and α-helix B (HA2 residues 75-127). Additionally, 
the location and nature of ionisable residues near the FP (HA2 residues 1-10), that could be 




The HA protein can also be found in IBV but, as previously said, IBV strains are not 
classified into subtypes based on properties of the HA and NA proteins. In ICV one external 
protein called hemagglutinin-esterase-fusion (HEF) combines in a single protein both the 
roles of HA and NA. It recognizes compounds terminated with N-acetyl-9-O-
acetylneuraminic acid instead of N-acetylneuraminic acid like HA of IAV and IBV
82
. 
To date, there are more than 350 crystal structure of HA of IAV available in the PDB; the 
majority of them are of good quality and have their HA1 and HA2 subdomains solved with X-
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ray diffraction. However, these structures represent only 73 strains, which is only a fraction of 
all the available HA sequences. In the last years, several new structures of HA have been 
solved. For example, in 2016 the structure of the drug Arbitol in complex with HAs from the 
H7N9 and H3N2 viruses was proposed and compared with structures solved with the fusion 
inhibitor terz-butyl-hydroquinone (TBHQ); it is important to underline that in this work, a 
pocket between the monomers of the HA trimer was described, which can be targeted by 
other small compounds to stabilize the HA2 in its normal pH conformation. In 2017, the 
structure of HA from the H15 subtype was solved in complex with the avian receptor analog 
30SLN (NeuAca2-3Galb1-4GlcNAc) and in the apo form. The structure of HA from the H10 
subtype with a preference toward human-type receptors was proposed and compared with a 
structure from the wild-type H10; during this study, the role of the 150-loop in modifying 





Figure 6. Trimeric HA, with one monomer colored gray, another black, and the third in blue (HA1) and red 
(HA2). The location of the receptor binding pocket for the monomer is highlighted by the gray circle, and this 
region is magnified and reoriented in the right panel to depict the location occupied by bound sialic acid, shown 




Neuraminidase (NA or N) is a homotetrameric protein encoded by the sixth negative-stranded 
RNA segment. It is an exosialidase that cleaves the α-ketosidic linkage between the sialic acid 
and an adjacent sugar residue. Its activity is required at the time of the budding of newly 
formed viral particles from the surface of the infected cell, to prevent aggregation of viral 
particles and, in addition, to cleave neuraminic acid residues from the respiratory tract 
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mucins, facilitating viral movement to the target cell. NA protein is formed by 470 amino 





                      
Figure 7. On the left: IAV NA homotetramer with the catalytic site shaded in gray; on the right: superimposition 
of the catalytic site of the N9 subtype onto the N1 subtype (shown in green). Adapted from: Int J Mol Sci., 18, 
1541 (2017). 
 
Nine subtypes of NA are described for IAV, while only one was revealed for the IBV and 
ICV. As previously said, for ICV we do not refer to NA but to HEF protein that combines 
both the roles of HA and NA and promotes the O-deacetylation of the N-acetyl-9-O-
acetylneuraminic acid
82
. The nine subtypes of NA found in IAV are divided into two 
phylogenic groups: the first group consists of NA of N1, N4, N5 and N8 subtypes and the 
second one consists of N2, N3, N6, N7 and N9 subtypes. 
The active site is located within the head domain and it consists of functional amino acids, in 
particular, Arg118, Asp151, Arg152, Arg224, Glu276, Arg292, Arg371 and Tyr406 and 
structural amino acids Glu119, Arg156, Trp178, Ser179, Asp (or Asn in N7 and N9) 198, 
Ile222, Glu227, Glu277, Asp293, and Glu425.  
The functional amino acid residues are in direct contact with sialic acid, the product of the 
enzymatic reaction, and they all form polar contacts with it, excluding Arg224, whose 
aliphatic part forms a non-polar contact with the glycerol fragment of the N-acetylneuraminic 
acid residue. The structural amino acids provide only a structural framework for the 
functional residues. Both functional and structural amino acids are constant for all NA 
subtypes of IAV and IVB. Asparagine residues, especially Asn146, which form the 
glycosylation site as well as proline and cysteine residues, which provide the required folding 
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of the polypeptide chain and stabilize the 3D structure of the molecule, are strictly 
conserved
83
. In addition to the active site, the head domain contains a calcium binding site, 
which stabilizes the enzyme structure at low pH values. In some strains there is also a 
secondary sialic acid binding site
84
. The key step in the hydrolysis mechanism of NA is the 
formation of the oxocarbonium ion at the C2 atom of sialic acid, stabilized by multiple 
contacts between the intermediate product and the amino acids of the active site. This allows 
the conformational changes from chair to half-chair, due to strong ionic interactions between 
the carboxylate of the substrate and the guanidine groups of Arg118, Arg292 and Arg371, 





Figure 8. Hydrolysis mechanism of viral NA. Key NA residues are labelled in blue. Adapted from: Patrick, G. 
L. An Introduction to medicinal chemistry, 5th ed. Oxford University Press. EdiSES s.r.l. 
 
The three dimensional structures of some NA subtypes have been identified. These findings 





2.2.3. Matrix proteins 1 and 2  
Matrix protein 1 (M1) and matrix protein 2 (M2) are produced by the seventh RNA segment: 
in particular, M2 is produced by an alternative splicing
90
. M1 protein is a 60-Å long rod that 
forms a matrix layer underneath the envelope of the virion; it touches the virion membrane 
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and apparently it is not inserted but associated with it through electrostatic interactions
91
. It 
consists of two domains, C-terminal and N-terminal, connected by a linker sequence, and 
differently charged: one side of M1, characterized by the presence of lysine and arginine as 
amino acids, is positively charged, while the other side has negative charges (Figure 9.)
92
.  
The molecular details of M1 action during the viral replication cycle and its interactions with 
the membrane are not yet well understood. It has been observed that M1 binds to the inner 
leaflet plasma membrane at first probably as a dimer and eventually multimerizes, forming 
large clusters. Multimer growth seems to occur through the interaction between already bound 
M1 and M1 that are still in solution. This is possible probably because, once bound to the 
bilayer, M1 undergoes a conformational change or, stably exposes a side that favors 
interaction with unbound M1 molecules
93
. In a recent study, Bobone and colleagues show that 
M1 interacts with negatively charged membrane lipids, in particular, with 
phosphatidylserine
94
, while regarding M1 protein involvement in the viral replication cycle, it 
has been shown that it directly interacts with NP
91,95-99
. Since M1 protein acts as a bridge 
between cellular membrane lipids and viral genome, and because of its interaction with 
cytoplasmic tails of HA, NA and M2, it is very important in the viral reproduction cycle. In 
particular, it induces, with the aid of NS2 (NEP)
100
, the export of the newly formed RNP 
complexes from the nucleus to the cytoplasm
94





Figure 9. The surface potential of the M1 monomer structure (pH 7). On the right the positively charged 
residues; on the left the negatively charged surface area (rotation by 180°). Adapted from: Virology, 279 (2), 
439-446 (2001). 
 
M2 protein is a pH-regulated proton channel of IAVs and IBVs. Despite the different 
structural solutions between M2 channel in IAVs and IBVs the result is similar. Both 
tetramers form well-defined hydrophilic pores with residues constricting the N and C termini 
of the pore
102
. The M2 proton channel of IAVs is a homotetrameric integral membrane 
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protein passing through the viral envelope, with each chain containing 96 amino acids. Each 
chain is formed by a N-terminal extracellular domain, a transmembrane domain (TM domain) 
and a cytoplasmic tail. The most important part is the TM domain that consists of four parallel 
left-handed α-helices of 19 amino acids, forming the proton channel pore, which has the N-
terminal region packed tightly and the C-terminal region splayed slightly apart from each 
other. In the TM domain there are five important residues that are Val27, Ala30 and/or Ser31, 
Gly34, His37 and Trp41 (Figure 10.)
103,104
. At the N-terminal end of the TM domain, Val27 
side chains form a hydrophobic gate of the channel pore
105
. The pore size increases gradually 
to reach its maximum value near Gly34 and is occluded again by Trp41 at the C-terminal end 
of the TM domain that, with its indole side chain, prevents outward proton flux
106-108
. The 
oxygen atoms in the backbone carbonyl groups of Ala30 and Gly34 and the oxygen atom of 
Ser31 side chain, acting as hydrogen bond acceptors, facilitate hydration of the channel pore; 
the water molecules in the channel pore facilitate proton conduction and stabilize the 
conformations of the pore, facing residues such as Trp41. His37 residue is the pH sensor and 
the proton filter, allowing conduction of protons but not of other cations
109
. The mechanism of 
action is dependent on the pH outside the virion: when pH is high, the channel is closed 
because His37 is not charged, and Trp41 obstructs the pore near its cytoplasmic end, while, 
when pH is low, His37 is charged and associates with Trp41 via interaction between the 





Figure 10. Crystal structure of the M2 proton channel (PDB ID: 3LBW). Only three of the four subunits are 
shown for clarity. Gly34 was mutated to Ala34 in this structure. The protein backbone is shown in white, 
whereas the side chains of several key residues and water molecules are shown in the stick and space-filling 
model, respectively. The carbon, nitrogen, and oxygen atoms of the residues are in cyan, blue, and red, 
respectively. The oxygen atoms of the water molecules are in light blue. Hydrogen bonds between the water 
clusters and the protein residues are in red lines. Adapted from: Trends Pharmacol Sci., 34, 571-580 (2013). 
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M2 protein is required for uncoating and release of the viral genome into the cytoplasm and 
for equilibration of the intraluminal pH of the trans Golgi network with that of the cytoplasm, 





 demonstrated that IAV M2 can be ubiquitinated and that an amino acid 
residue that is present in the cytoplasmic domain, Lys78, plays a central role in this process. 
The ubiquitination mediates the coordination of efficient packaging of the viral genome into 
virions and the timing of viral-induced cell death. A M2-K78R mutation (from lysine to 
arginine at position 78), which produces ubiquitination-deficient M2, causes a severe defect in 
production of infectious virion. In particular, this mutant progeny has about twice the amount 
of HA protein, lower levels of viral RNAs, NP and M1 protein. M2-K78R virus is also 
characterized by a weaker M1-M2 interaction that can explain why many M2-K78R virus 
particles failed to incorporate internal viral proteins and vRNAs. Moreover, the differences in 
the biological, physical, and chemical properties of M2 proteins between wild-type and M2-
K78R viruses may impact virus-host interactions: in fact, mutant virus triggers autophagy and 
apoptosis more easily and earlier compared to the wild-type ones. 
 
2.2.4. Non-structural proteins 1 and 2  
Non-structural proteins 1 (NS1) and 2 (NS2) are derived from an alternative splicing of the 
eighth RNA segment; in particular, NS2 is derived from the splicing, while NS1 is produced 
from the unspliced transcript. NS1 is a multifunctional protein that is not incorporated in the 
virus, while NS2 is a structural component of the virion, associated with M1 protein
119
.  
NS1 is a virus virulence factor that, depending on virus strain, is composed of 230-237 amino 
acids. It has several well-characterized functional domains: the first 73 amino acids form the 
RNA-binding domain that contains NLS, 10-15 amino acids represent a linker domain, 
residues 88-202 form the effector domain and 11-33 amino acids form the C-terminal tail
120
. 
To support efficient viral replication, NS1 interacts with cellular components either in the 
cytoplasm or in the nucleus. It counteracts different components of the RIG-I/IFN signaling 
pathway to efficiently inhibit IFN expression, it represses innate antiviral mechanisms of the 
host cell, acting on type I interferon system through direct interaction with protein kinase R 
(PKR) and with tripartite motif-containing protein 25 (TRIM25) or through the sequestration 
of dsRNA
121-125
. NS1 inhibits also nuclear export of cellular mRNA through the interaction 
with cleavage and polyadenylation specificity factor subunit 4 (CPSF4) and with 
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polyadenylate-binding nuclear protein 1 (PABPN1)
126
, and it seems to hijack the RNA 




NS2 protein is responsible, as previously said, for the export of the newly formed RNP from 
the nucleus to the cytoplasm, via its interaction with CRM1
129
. In addition, because of its 
interaction with nucleoporins, it probably acts as an adaptor between RNPs and the nuclear 
pore complex
43
, and it seems also to have a role in viral transcription and replication
130
. 
However, many functions of NS2, in particular, its transit through the cytoplasm and its 
incorporation into the viral particle, are not fully understood. 
There are lots of NS1 and NS2 interactors that have been identified and described in the 
literature: these interacting host cell proteins are generally expressed in the respiratory 
epithelium and are potentially involved in many steps of the virus life cycle and some of them 




2.2.5. Influenza RNA-dependent RNA polymerase 
Influenza RNA-dependent RNA polymerase (RdRp) is a heterotrimeric complex of about 250 
kDa that is composed of three different subunits: PA (polymerase acidic protein), referred as 
P3 in the case of ICV, PB1 and PB2 (polymerase basic proteins 1 and 2). These subunits are 
encoded by the three largest segments of the viral RNA genome; in particular, segment one 
encodes for PB2, segment two for PB1 and segment three for PA. RdRp associates with the 3’ 
and 5’ ends of each RNA genome segment, forming, together with RNA and NPs, the vRNP 
complex. Starting from the ss(-)RNA viral genome, RdRp is responsible for the synthesis of 
the positive-strand messenger (mRNA), used for viral protein production, and for the 
synthesis of complementary RNA (cRNA), useful to obtain new viral genome (Figure 
11.)
131,132
. Both the transcription and the replication of vRNA take place in the nucleus of 
infected cells and therefore, the RdRp has to be transported into the nucleus. Although the 
NLS is identified in all three RdRp subunits and it is demonstrated that individually expressed 
PB1, PB2, and PA can enter the nucleus
133-139
, different processes have been proposed for the 
assembly of the RdRp complex. A dimer of PB1-PA could form in the cytoplasm and be 
transported into the nucleus, where it binds to PB2
140
 or a PB2-PB1 dimer could form in the 
cytoplasm and be transported into the nucleus, where it interacts with PA
141
. 
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The structure of RdRp is highly conserved among A, B and C viral strains
142
. The recent 





complexes bound to their vRNA promoter sequences and apo-RdRp from influenza C
145
, led 
to an important breakthrough in the understanding of the replication machinery and in the 
atomic-level mechanistic insight of RdRp. The catalytic site is in PB1; PB2 includes the 
capped-RNA recognition domain, that is necessary for the generation of the primer for the 
transcription, while PA is responsible for “cap-snatching”, the cleavage of host cell pre-
mRNA to utilize its cap for viral generation of the primer for the transcription, and it is also 




              
Figure 11. On the left: the structure of viral RNP complex. On the right: the role of RdRp in viral gene 
expression and regulation pathways. Red lines represent negative-sense RNA; blue lines represent positive-sense 
RNA. Adapted from: http://cronodon.com/BioTech/Virus_Tech_3.html and http://library.open.oregonstate.edu/ 
microbiology/chapter/the-viruses/. 
 
The IAV RdRp has a U-shaped structure, with approximate height, width and depth of 115 x 
100 x 75 Å, respectively, and it is characterized by a complex intertwining of the three 
subunits. The two protruding arms are formed by the N-terminal domain of PA (PA-N) and 
PB2 cap-binding domain, which face each other across a solvent channel. The bottom of the 
U is formed by the large C-terminal domain of PA (PA-C) and one of the sides by the C-
terminal part of PB2 (PB2-C). The body of the trimer is formed by PB1, decorated on one 
side by the N-terminal part of PB2 (PB2-N) and on the other side by the linker (PA-linker) 
that connects PA-N endonuclease with PA-C. The trimer contains a large, internal, catalytic 
and RNA-binding cavity, formed by PB1 and PB2-N parts, that is partially open at the top to 
the solvent channel between the PA-N endonuclease and PB2 cap-binding domains (putative 
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template/product exit channel). This cavity is accessible via two narrow side tunnels, the 
putative nucleoside triphosphate (NTP) and template entrance channels (Figure 12.). 
The structure of the RdRp, together with the RNA promoter, can undergo considerable 
conformational changes to convert the pre-initiation state into the active initiation and 





Figure 12. Two views (rotation by 180°) of the overall structure of the bat influenza A polymerase complex with 
the vRNA promoter. Imagine on the right: Side-view in space-filling representation showing emergence of 
vRNA duplex at the interface of all three subunits. Adapted from: Nature, 355, 516 (2014). 
 
 
2.2.5.1. PB1 subunit 
Influenza PB1 protein is the core subunit of the heterotrimeric polymerase complex; it 
contains in its central region a typical right-handed RdRp fold, comprising fingers, fingertips, 
palm and thumb domains. There are several characteristic features of PB1: N- and C-terminal 
extensions that make inter-subunit contacts with PA and PB2, respectively, and an unusually 
long (55Å) solvent-exposed, flexibly hinged β-ribbon and a β-hairpin insertion in the finger 
domain (Figure 13). 
As previously said, the catalytic center responsible for template directed nucleotide addition is 




















. Motif I, containing the conserved active site Asp305, 
promotes catalysis, motif II is methionine-rich and is probably involved in stabilizing the base 
pair between the incoming NTP and the template, motif III is the key functional domain that 
is present in other RNA- and DNA-dependent viruses
148
, while motif IV contains conserved 
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Lys 480 and Lys 481 residues that are involved in NTP binding. As in other polymerases, in 
PB1 there are the NTP tunnel and the putative template entrance channel. The first, with 
positively charged residues, connects the internal cavity to the outside and seems to 
electrostatically attract and channel NTPs into the active site; the second has conserved 





Figure 13. a General structure of PB1 subunit with highlighted the characteristic elements including the PB1-C 
extension, the β-ribbon and the β-hairpin. b. As in a but rotated roughly 90°, to show the internal cavity occupied 
by the putative priming loop and the PB1-N extension. Adapted from: Nature, 355, 516 (2014). 
 
 
2.2.5.2. PA subunit 
The two domains of PA, the PA-N endonuclease domain
149,150 
and the large PA-C domain are 
on opposite sides, connected by the PA-linker which wraps around the external face of the 
PB1 fingers and palm domain. The endonuclease domain is solvent-exposed and faces the 
cap-binding domain. It is anchored to the rest of the polymerase through contacts with PB1-C 
that interacts with PB2-N, so that all the three subunits are involved in positioning the 
endonuclease
143
. The crystal structure revealed that PA-N is a member of the PD-(D/E)XK 
nuclease superfamily. It is composed of seven α-helices and a mixed five-stranded β-sheet, 





). The active site is characterized by a cluster of three acidic 
residues (Glu80, Asp108 and Glu119) and a putative catalytic lysine (Lys134) that, together 
with His41, are all absolutely conserved in influenza viruses (Figure 14.)
149,151
 In particular, 
Lys134 is supposed to act as a catalyst of the endonuclease activity; in fact, the mutation of 
the lysine in position 134 with an alanine (K134A) has been shown to specifically abolish the 
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. PA-N cleaves single stranded RNA accordingly to two-metal-ion 
mechanism
153
. This mechanism implies that the first ion supports formation of attacking 
nucleophile by withdrawing electrons, while the second facilitates the exit of leaving group 




Structural reports are not consistent concerning the type and number of ions in the structures 
of PA-N. In the crystal structure of the first 197 residues of influenza H5N1 PA-N determined 
by Yuan
150
, the binding metal appears to be a magnesium ion (Mg
2+
), while in the study of 
Dias and coworkers
149
 and Kowalinski and collaborators
157
 there are two Mn
2+
 atoms in the 
active site. DuBois et al.
151
 localized two Mn
2+
 ions in both sites coordinated by the same 
residues as for Kowalinski and co-workers. Pflug and colleagues in their work described in 
PA-N the presence of two divalent cations
143
 while more recent structures of complete 







 is one of the most abundant divalent cations in the living cells (~1 
mM)
159
 and it is found to be the most frequently used by the nucleic acid enzymes. However, 
when the Mg-dependent enzyme is activated with other ions, the efficiency and/or substrate 









less stringent coordination requirements, which lowers the substrate specificity and might 




 is reported as a better Lewis acid and more 
efficiently than Mg
2+
 facilitates the formation of the attacking nucleophile
160
. A recent 
study
163
, applying calculations of ion occupancy based on thermodynamic data, suggests Mg
2+
 
to be a canonical metal in PA-N processing of RNA in vivo. 
 
 
Figure 14. General structure of PA subunit. Adapted from: Nature, 355, 516 (2014). 
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2.2.5.3. PB2 subunit 
The PB2 subunit is divided into the N-terminal part (PB2-N) and C-terminal portion (PB2-C), 
each of them formed by several folded sub-domains. PB2-N comprises a series of linked 
modules that wrap around one edge and face of PB1, interacting mainly with the C-terminal 
portion of PB1 and the polymerase thumb domain, opposite to where the PA linker binds. 
PB2-C forms a single, arc-shaped unit divided into sub-domains, which constitutes one arm of 
the polymerase U-shape. At one end of the arc there is the cap-binding domain, and, at the 
other end, the PB2 nuclear localization sequence (NLS) domain with, juxtaposed, the 627-
domain, the main responsible for virus host-specificity which carry the host-specific PB2 
residue 627 (lysine in human, glutamic acid in avian viruses and serine in bats). The central 
part of the PB2-C arc is composed of two disconnected but interacting sub-domains: the PB2 
mid-domain that directly precedes the cap-binding domain, and the cap-627 linker. They seem 
not to make extensive interfaces with other polymerase subunits. (Figure 15.)
143
. The cap-
binding domain has a compact, well-ordered α-β fold and it can initiate the “cap-snatching” 
and direct the capped primer first toward the endonuclease site and then into the polymerase 
active site for virus transcription
164,165
. As previously said, the 627-NLS-domain is an 
important determinant for the virulence and host adaptation of influenza viruses; in fact, 
different studies demonstrated that 627-mutants can greatly affect the virus in several aspects 
including replication, transcription, temperature sensibility and transmission
166-169
. 
The loop carrying the host-specific residue 627 is in a solvent-exposed position remote from 





Figure 15. General structure of PB2 subunit. Adapted from: Nature, 355, 516 (2014). 
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2.2.6. Other viral proteins 
The viral genome, in addition to that mentioned so far, codifies for other more recently 
discovered proteins, such as PB1-F2, PB1-N40, PA-X, PA-N155, PA-N182, M42, NS3 and 
PB2-S1, produced by open reading frames (ORFs) or ribosomal frame-shift. All these 
proteins play regulatory roles in virus replication acting as virulence factors or influencing 
viral transcription and replication
170
.  
PB1-F2 is expressed by some viral strains and it originates from the transcription of an 
alternative ORF on segment two of the IAV genome; it is expressed via a different translation 
initiation process from the fourth AUG codon. PB1-F2 is absent from some animal 
(particularly swine) influenza virus isolates, it has variable expression in individual infected 
cells, rapid proteasome-dependent degradation and mitochondrial localization
68,171
, although 
some studies also show additional cytoplasmic or nuclear localization
172,173
. PB1-F2 is a 
virulence factor, associated with proapoptotic effects
68,174
; in fact, its oligomers assemble in a 
pH-dependent manner and form amyloid-like structures, inducing cell membrane damage and 
cytotoxicity in epithelial cells
175,176
. PB1-F2 also interacts with a number of host proteins 
modulating the IFN response or apoptosis; it interferes with the RIG-I/MAVS signaling 
pathway and activation of the host immune response
177-179
. Additionally, expression of PB1-
F2 down-regulates the host superoxide anion dismutase 1 (SOD1), which increases the levels 
of reactive oxygen species, causing cell damage
180
. It also seems that PB1-F2 regulates the 
viral polymerase activity
172,181




The PB1-N40 is a 718-amino acid N-terminally truncated protein encoded by leaky ribosome 
scanning by discarding the first 39 codons from the regular 757-amino acids PB1 on segment 
two of the viral RNA. It is translated from the fifth AUG codon that is in-frame with the PB1 
start codon. PB1-N40 sequence is identical to PB1 except for the 39 missing N-terminal 
amino acids that normally are responsible for the interaction with PA. Although PB1-N40 
does not interact with PA and lacks transcriptase function, it can bind with other viral 
proteins, such as PB1 and its interaction partners PB2, NP, and PB1-F2. The localization of 
PB1-N40 is predominantly cytoplasmic, although in virus-infected cells its nuclear uptake is 
observed. PB1-N40 is able to affect the efficiency in the replication of IAVs, influencing the 
RdRp activity. Although viruses that lack PB1-N40 show slower replication kinetics, 
regulatory roles of the protein are not yet completely clear. It is important to underline that the 
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expression of PB1-N40, PB1-F2 and PB1 are interdependent; in particular, one of the 




PA-X is a ribosomal frame-shift product of the segment three of the viral RNA; it is a fusion 
protein incorporating the N-terminal endonuclease domain of PA (191 amino acids) with a 
short C-terminal domain (61 amino acids) encoded by an overlapping ORF. PA-X modulates 
the host response and viral virulence, acting as a cellular gene expression repressor. It has 
been seen that PA-X modulates IAV virulence in a mouse infection model, acting to decrease 
pathogenicity and that loss of PA-X expression leads to changes in the kinetics of the global 




PA-N155 and PA-N182 are translated from the eleventh and thirteenth in-frame AUG codons 
in the PA mRNA, respectively, via an alternative translation initiation process and are, 
therefore, N-terminally truncated forms of PA. The eleventh and thirteenth AUG codons are 
highly conserved among IAVs, suggesting that PA-N155 and PA-N182 expression is a 
universal feature. These N-truncated PAs do not show polymerase activity when expressed 
together with PB1 and PB2. However, these proteins have important functions in the 
replication cycle of IAV, as demonstrated by the fact that mutant viruses lacking PA-N155 




M42 is encoded by the alternative splicing of the seventh RNA segment. It is a M2-related 
protein with an antigenically distinct ectodomain that can functionally replace M2, despite 
showing clear differences in intracellular localization, being largely retained in the Golgi 
compartment. M42 is clearly non-essential for virus replication, as long as sufficient M2 is 
expressed. It is important to underline that the expression of two distinct ion channel proteins 
(M2 and M42) is not unique to laboratory-adapted viruses but, most notably, was also a 




NS3 is a product of alternative-splicing due to the NS1 nucleotide substitution of the alanine 
in position 374 with a glycine (A374G). NS3 is shown to provide replicative gain-of-function: 
in particular, it seems to be strongly associated with the virus ability to switch from avian to 
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mammalian hosts, including human, swine and canine populations, suggesting its role in host 
adaptation and overcoming species barrier
72
. 
PB2-S1 is encoded by spliced mRNA derived from the PB2 segment (N-terminal 495 amino 
acids of PB2-S1 are identical to those of PB2). PB2-S1 is localized to mitochondria, inhibits 
the RIG-I-dependent interferon signaling pathway, and interferes with the RdRp activity by 
binding to PB1. This viral protein appears to be highly conserved among pre-2009 human 
pandemic H1N1 virus, but not among human pandemic H1N1 and H3N2 viruses. Moreover, 
its deficiency has no effect on viral growth kinetics in cultured cells or on virus pathogenicity 
in mice. These findings suggest that probably PB2-S1 functions as an inhibitory factor for 
RIG-I-dependent IFN signaling during infection in animals other than mice, or that NS1, 
which exhibits strong inhibitory effects on innate immune responses, masks the effects of 





2.3. Antigenic drift and antigenic shift  
The two major factors in influenza epidemics and pandemics are genetic drift and genetic 
shift. Antigenic drift leads to substitution of the amino acids on the surface of the viral 
transmembrane proteins (HA, NA and M2) that are recognized by existing antibodies. 
Some regions of these proteins are more susceptible to change than others and these 
modifications should be ‘neutral’, as they do not affect the conformation of the proteins, or 
can cause conformational changes such that the binding of host antibodies is affected. 
Consequently, infecting viruses can no longer be inhibited effectively by host antibodies, 
allowing the virus to spread more rapidly among the population. Antigenic drift occurs on 
average every 2-8 years, in response to selection pressure to evade human immunity. In 
particular, it occurs in all strains of IAV and IBV, although the observed evolutionary patterns 
are dependent on the viral strain. It is possible that drift variants co-circulate with multiple co-
existing lineages, allowing the re-emergence of old strains or the emergence of new variants 
that replace the old ones. Antigenic shift is a consequence of a process known as 
reassortment; it is only seen in IAVs, and results from the replacement of HA (and less 
frequently NA) subtypes with novel ones; this results in new viruses that have never been 
present in human circulation or last circulated decades before. Antigenic shift is estimated to 
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occur approximately three times every 100 years, which is in line with the three antigenic 
shifts (and resulting pandemics) that occurred during the 20th century (1918, 1957 and 1968). 
Once a virus has undergone antigenic shift, it remains susceptible to antigenic drift; in fact, all 
currently circulating influenza viruses are drift variants of previous pandemic influenza 
strains. An important process that contributes to major shifts in influenza antigenicity is 
genetic reassortment, which is due to co-circulation of different IAV and IBV subtypes. It 
consists in mixing of genetic material between different viral strains and, although genetic 
reassortment can contribute to antigenic drift, it is primarily responsible for antigenic shift.  
In particular, the genetic reassortment between human and avian IAV strains is important 
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CHAPTER 3. Therapeutic treatments 
 
Influenza is an acute disease that causes inflammation of epithelial cells that are present in the 
upper and lower respiratory tracts. The virus replicates starting from the time of inoculation 
and peaking after 48 hours, on average. While mild cases show only less pathological changes 
in the respiratory tracts, severe cases show clear evidence, such as redness and inflammation 
with mucous and purulent discharge macroscopically, desquamation and destruction of the 
pseudo-stratified epithelium of the trachea and bronchi with only the basal layer remained 
viable but inflamed, microscopically. 
The immune reaction to the viral infection and the interferon response are responsible for the 
viral syndrome that includes high fever, coryza, cough, sore throat, myalgia, headache, runny 
nose, congested eyes and body aches. The acute symptoms persist for seven to ten days; in 
healthy persons the disease is self-limited, while high-risk groups who have chronic lung 
diseases, cardiac disease and pregnancy are more prone to severe complications, such as 
primary viral pneumonia, secondary bacterial pneumonia, hemorrhagic bronchitis, etc. Severe 





3.1. Vaccination  
Vaccination is regarded as the major prophylactic and therapeutic treatment of influenza 
infections, although the genetic drift in viral genome make it necessary to formulate new 
vaccines each year and the highly variable nature of the surface glycoproteins HA and NA 
does not make possible the development of a universal influenza vaccine.  
Since their introduction in the 1940s, influenza vaccines have come a long way. Early 
vaccines were inactivated whole-virus vaccines that were generated in embryonated chicken 
eggs and inactivated by treatment with formalin. Today the major type, besides the 
conventional vaccines that consist of purified virus particles inactivated by treatment with 
formalin or β-propiolactone, are live attenuated influenza virus (LAIV) vaccines. LAIV 
vaccines are made using virus strains that are cold adapted, temperature sensitive, and 
attenuated to prevent them from causing illness. They have shown high efficacy in children 
when compared to inactivated vaccines, because they activate mucosal, systemic humoral, 
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and cellular immunity, just like natural influenza viruses. However, constantly updated 
knowledge of the antigenic properties of the new circulating strains is necessary for the timely 
production of vaccines. Since perfect updates are often unavailable, some strains will not be 
covered by the vaccines. Apart from the traditional vaccines, other approaches include the 
development of DNA vaccines against different influenza virus antigens, the research of a 
possible universal influenza vaccine targeting the HA stalk domain, and the use of influenza-





3.2. Antiviral agents targeting viral proteins  
A part from the use of vaccines, viral infections can be inhibited at several crucial steps, such 
as entry, assembly and release, by the use of antiviral agents that act as supplementary 
protective and therapeutic treatments during seasonal influenza epidemics. Antivirals are also 
capable of reducing the unpredictable impact of a fast-moving pandemic. It is possible to have 
an antiviral effect both targeting important proteins for the virus life cycle and targeting host 
proteins that play crucial roles during influenza virus infection. Among antiviral agents 
targeting functional viral proteins, there are two classes of FDA licensed drugs: 







) and laninamivir (CS-8958), this latest approved only in Japan, and the 





). Very recently (October 2018), FDA approved the cap-
dependent endonuclease inhibitor baloxavir marboxil (Xofluza
®
). However, there are other 
agents in late stage development or in clinical trials as influenza therapeutics, acting on 
different key steps of the viral replication; for example, favipiravir, which targets the viral 
RdRp, is conditionally approved in Japan (Figure 16.)
188, 189
. Below, I will mention the main 
anti-influenza drugs and the most promising molecules, natural and synthetic, recently 
developed; the molecules are inserted within the different paragraphs according to the target 
on which they act. 
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Figure 16. Mode of action of the most important approved influenza virus antivirals. FDA approved drugs are 




3.2.1. HA inhibitors  
Among HA inhibitors, there are some natural products, as well as synthetic antiviral drugs 
that have been approved for the influenza treatment or are being tested in clinical trials. In the 
1970s, gossypol, 1a, a natural phenolic aldehyde extracted from cotton plant, was found to be 
effective against pneumonia caused by influenza virus
190
. Starting from this study, Yang and 
co-workers synthesized a series of gossypol and gossypol acid derivatives, 1b and 2 
respectively, and tested them in vitro for their anti-H5N1 activity. This lead to the discovery 
of some gossypol-related molecules having a good anti-H5N1 activity, with the HA2 protein 
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 and theaflavin 6
197,198 
are multitarget antiviral agents, 
acting especially as HA inhibitors. 
 
                                        
 
                               
 
In 1996, Luo and colleagues found and characterized a novel inhibitor of influenza virus: 
BMY-27709, 7. This compound contains a salicylamide scaffold and has been identified as 
specific for the IAV. In particular, it has an IC50 of 3-8 μM for A/WSN/33 virus and is active 
against H1 and H2 subtypes, while is inactive against H3. The fact that BMY-27709 is active 
in the early infection stages, suggests that the target for inhibition is the HA protein. This was 
confirmed through the use of reassortant viruses and the isolation of a virus resistant to BMY-
27709. The isolated resistant virus contained a mutated amino acid in the HA2 subunit (a 
phenylalanine substituted with a serine in position 110). This single mutation is responsible 
for the acquisition of resistance to BMY-27709, as demonstrated through reverse genetics: 
transfectant viruses harboring only the mutation in position 110 were shown to be resistant to 
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BMY-27709, while the control viruses without this mutation remained sensitive to the 
inhibitor
199
. Further studies done by the same group indicated that BMY-27709 blocks the 
HA-mediated fusion process, and it may act either by prematurely promoting the 
conformational change or through the inhibition of the low pH-induced conformational 
change of HA; both mechanisms result in the same outcome, the inactivation of the fusion 






Another HA inhibitor that was found in the ‘90s is stachyflin, 8. Similarly to BMY-27709, it 
is active against the H1 and H2 subtypes of IAV. Experiments have suggested that stachyflin 







Thiazolides are powerful broad-spectrum antiviral drugs. In the case of IAVs, it has been 
shown that they act at a post-translational level, by selectively blocking the maturation of the 
viral HA, impairing HA intracellular trafficking and insertion into the host plasma membrane, 
a key step for correct assembly and exit of the virus from the host cell
202
. Among thiazolides, 
nitazoxanide, 9, is active against a great number of RNA and DNA viruses, such as 
respiratory syncytial virus, coronavirus, rotavirus, norovirus, hepatitis B and C, dengue, 
yellow fever, japanese encephalitis virus and human immunodeficiency virus in cell culture 
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. Belardo and co-workers showed that nitazoxanide inhibits also a broad range of 
IAV and IBV, with IC50 values ranging from 1.0 to 3.2 μM against different viral strains in 
Madin-Darby canine kidney (MDCK) cell-based CPE (cytopathic effect) assay. They made 
also combination therapy studies, in order to investigate the effect of nitazoxanide when 
administered in combination with oseltamivir or zanamivir, using as a model the H1N1 
PR8/IAV strain in MDCK cells; the results show that nitazoxanide-neuraminidase inhibitor 
combination treatments are synergistic
205







Recently, Stachulsky and co-workers developed a series of nitazoxanide derivatives, 
providing important new lead compounds; some of them show good activity against an H1N1 







CL-385319, 11, an N-substituted piperidine, was proved to be effective in inhibiting infection 
of H1-, H2-, and to a lesser extent, H3-type IAVs by interfering with the fusogenic function 
of the viral HA. In particular, CL-385319 is effective in inhibiting infection of highly 
pathogenic H5N1 IAV in MDCK cells with an IC50 of 27.0 μM and low cytotoxicity. 
Computer-aided molecular docking analysis suggests that CL-385319 might bind to the cavity 
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Compound 12 is a trivalent glycopeptide mimetic, having a trisubstituted acid derived core 
which is bound by flexible hexyl chains to a nonapeptide linkers ending with a flexible alkyl 
chain and the sialic acid epitope. It is an inhibitor of HA (H5) of avian influenza, with a Ki of 
15 μM, and binding studies showed that it has an affinity for hemagglutinin H5 
(A/Vietnam/1203/2004) increased by a factor of 4,000 compared to the natural ligand α-






One year later, Dang and colleagues found that a series of podocarpic acid derivatives (for 
example, compound 13) exhibited potent activities, having EC50 values ranging from 140 to 
640 nM against MDCK cells infected with an adapted influenza virus (A/PuertoRico/8/34, an 
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Also natural pentacyclic triterpenoids show inhibitory activity against influenza viruses, 
which are comparable to or even more potent than that of oseltamivir. Mechanistic studies 
show that these molecules bind tightly HA, disrupting the interaction between HA and the 
sialic acid receptor and thus the attachment of the virus to the host cell. Among them, 
compound 14 is effective against the influenza A/HuNan-ZhuHui/1222/2010 H3N2 strain 
(amantadine- and ribavirin-resistant), A/LiaoNing-ZhenXing/1109/2010 H1N1 strain 
(oseltamivir-resistant), and even the influenza B/ShenZhen/155/2005, with EC50 values of 






In 2015, Chen and colleagues found that the indole alkaloids obtained from the marine fungus 
Erotium rubrum have antiviral activity. In particular, neoechinulin B, 15, shows a potent 
inhibition against H1N1 virus in MDCK cells, and is able to inhibit a panel of influenza virus 
strains including those amantadine- and oseltamivir-resistants. The EC50 values of 
neoechinulin B against A/LiaoNing-ZhenXing/1109/2010 H1N1, A/HuNan 
ZhuHui/1222/2010 H3N2 and A/WSN/33 H1N1 are 16.89, 22.22 and 27.4 μM, respectively, 
in MDCK cell-based CPE assay. Mechanisms of action studies indicate that neoechinulin B 
binds to HA, disrupting its interaction with the sialic acid receptor and the attachment of 
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viruses to host cells. The high potency and broad-spectrum activities together with low drug 







Another natural product, aureonitol 16, a tetrahydrofuran derivative obtained from fungi, has 
demonstrated inhibitory effects in the nanomolar range against both IAV and IBV adsorption. 
Molecular modeling studies indicate that aureonitol forms hydrogen bonds with highly 
conserved HA residues. Altogether, these results suggest that the chemical structure of 






Curcumin 17 is a multi-target natural product that can also inhibit the IAV entry acting on 
HA, with an EC50 of approximately 0.47 μM in plaque reduction assay (PRA)
215
. Simulation 
docking of curcumin with the HA structure revealed that the molecule binds to the region in 
which there are sialic acid anchoring residues. It seems that the presence of the double bonds 
in the central seven-carbon chain of curcumin is important for the antiviral activity and 
interferes with virus entry by interacting with the receptor binding region of viral HA 
protein
216
. More recently, Liu and collaborators identified curcumin as an inhibitor of RNA 
binding by NP, highlighting this structure as a potential lead for further drug development in 
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Arbidol (known also as umifenovir) 18a shows efficacy against influenza viruses by targeting 
the HA fusion machinery. In 2017, Kadam and co-workers determined crystal structures 
of arbidol in complex with influenza virus HA from H3N2 and H7N9 viruses. It was seen that 
arbidol binds in a hydrophobic cavity in the HA trimer stem, primarily making hydrophobic 
interactions with the binding site but also, inducing some conformational rearrangements to 
form a network of inter- and intra-protomer salt bridges. By functioning as molecular 
glue, arbidol stabilizes the prefusion conformation of HA inhibiting the large conformational 
rearrangements associated with membrane fusion in the low pH of the endosome
218
. Wright 
and co-workers designed and synthesized several molecules to try to improve the antiviral 
activity of arbidol. They found a new arbidol analogue 18b with significantly improved 
binding to HA in comparison to the parent compound; in particular, 18b has 98-fold and 






A number of monoclonal antibodies that target viral HA are recently being investigated as 
potential influenza therapeutics. All these antibodies bind to the more conserved stalk portion 
of HA, and thus, they have broad antiviral activity against several IAV subtypes. The 
compounds in clinical development include MEDI8852 (MedImmune, LLC), MHAA4549A 
(Genentech, Inc.), VIS-410 (Visterra, Inc.), CT-P27 (Celltrion, Inc.), CR6261 and CR8020 
(both Crucell, from 2011 acquired by J&J, Inc.)
220
. Mechanistically, these HA antibodies 
work by preventing the fusion of the virus with the host cell, and stimulating antibody 
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dependent cell-mediated cytotoxicity in vivo
221,222
. Some antibodies, for example MEDI8852, 
have been shown to be superior or at least as effective as oseltamivir in preclinical animal 
studies, depending on the virus subtype
223
. Among engineered human antibody, is worth to 
mention VIS410, an IgG1 antibody that targets a unique, conserved conformational epitope 
on the stem of HA protein of IAV
224
. Preclinical studies demonstrated that VIS410 is active 
against several IAV strains and is able to rapidly reduce viral titers
225
. A more recent phase I 
clinical trial (NCT02045472) showed that it is generally safe and well tolerated, even at the 
relatively high dose levels
226
. Today VIS410 is in phase II clinical trial sponsored by Visterra, 
Inc. (NTC03040141), for evaluating its efficacy and safety of its intravenous administration in 
addition to oseltamivir in hospitalized adults with influenza A infection. Regarding 
MHAA4549A, it has shown to be well tolerated in healthy volunteers without IAV infection 
in two phase I studies
227
 and results from an earlier phase II trial (NCT01980966), evaluating 
its safety and efficacy in an influenza model, show that MHAA4549A is well tolerated and 
significantly reduces viral loads
228,229
. Two phase II clinical trials (NCT02603952 and 
NCT02293863) to evaluate the effects of MEDI8852 and MHAA4549A alone or in 






3.2.2. M2 channel blockers 
The M2 channel is an important target for antiviral drugs, although mutations surrounding the 
binding site lead virus to escape drug inhibition. Three major amantadine-resistant M2 
mutants have been identified: serine in position 31 to asparagine (S31N), valine in position 27 
to alanine (V27A) and leucine in position 26 to phenylalanine (L26F). Among these, S31N is 
the predominant mutant and is present in more than 95% of currently circulating influenza 
viruses
230
. M2 inhibitors can be classified in two groups based on their structure. The first 
group includes the adamantanes, formally named tricyclo[3.3.1.1]decanes, and their 
analogues; all these compounds have a hydrophilic head and a hydrophobic body, and, due to 
these features possess the ability to penetrate the bilayer lipid membrane. The second group is 
composed of non-adamantane derivatives. 
The adamantane-based compounds have been approved for a wide spectrum of indications 
(antivirals, antidiabetics and against Alzheimer's and Parkinson's disease). For example, 
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memantine 19 was investigated for its antiviral activity, and recently proposed for the 
treatment of the neuronal death induced by Zika virus infection
231
. Apart from the memantine, 
the two first major antiviral molecules in the class of the adamantanes are amantadine 
(Symmetrel
®
) 20 and rimantadine (Flumadine
®
) 21, approved for clinical use in 1966 and in 
1993, respectively. They inhibit virus multiplication by interfering with the transmembrane 
domain of M2 protein of IAVs and with virus assembly. At low concentration (< 1 µg/mL) 
amantadine and rimantadine inhibit the replication of IAV by blocking the M2 channel, while 
at higher concentration (> 50 µg/mL), because of their basicity, they buffer the endosomal pH 
and reduce the acidity of the environment that is essential for the fusion between the viral 
membrane and the endosome, mediated by HA. It is important to underline that rimantadine is 
four/ten time more active than amantadine and has less collateral effect, probably because of 
its extensive biotransformation. Neurotoxic effects (such as confusion, disorientation, anxiety, 
jitteriness, etc.) caused by amantadine are usually common, especially when the drug is used 
more than a week. Moreover, today drug resistance has limited adamantane clinical use
34
. 
Currently, amantadine and rimantadine cannot be recommended as a prophylactic drug for the 
treatment of influenza both in children and in adults. Nevertheless, if we consider that they 
are safe drugs and take into account the possibility that the next pandemic virus is susceptible 
to this class of compounds, as indicated in former pandemics, we can still consider these 




                                                                           
 
Adamantane derivatives 22 e 23 are rimantadine analogs developed by Tataridis and co-
workers. In compound 22 the α-methyl group of rimantadine is replaced with a α-(amino 
methyl) group, while compound 23 resulted by the introduction of a piperidine ring on the 1-
aminoethyl pharmacophore group. They are about 2- or 3-fold more potent than amantadine 
and are equipotent to rimantadine. The presence of two primary and two secondary amino 
groups, respectively, make the molecules capable of forming favorable hydrogen bonds and 
Van der Waals interactions with the M2 receptor
233
. Spiropiperidine-adamantanes, such as the 
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spiro[adamantane-2,2’-piperidine] 24, are also effective against M2 protein and show 
activities against amantadine-resistant viruses
234
. Du and co-workers developed a series of 
adamantane-based inhibitors with the introduction of a supplementary pharmacophore group, 
synthesizing compounds 25 and 26. These molecules have a significantly enhanced ability in 
inhibiting the M2 channel in comparison with amantadine and rimantadine, although the 





                                               
 
Many efforts have been made to discover new small molecular inhibitors of amantadine-
resistant mutant forms of IAV M2 channel. Wang and colleagues developed a class of benzyl-
substituted amantadine derivatives with activity against both S31N and wild-type M2 viral 
channel, among which compounds 27 and 28 are the most potent dual inhibitors
230,236,
. Wu 
and collaborators found other M2 channel blockers that are able to inhibit the wild-type and 
the S31N mutant comparably with amantadine inhibition of wild-type influenza virus. The 




                                          
 
Regarding the V27A mutation of the M2 ion channel, Rey-Carrizo and colleagues synthesized 
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undecane scaffold, designed as analogs of amantadine; the most active of them, compound 30, 






Further studies by the same research group on mutants of the M2 channel led to the discovery 
of amine 31 and guanidine 32 as low micromolar inhibitors of the wild-type channel and the 




                            
 
Regarding non-adamantane derivatives, polyamines, such as spermine 33 and spermidine 34, 
are effective against influenza virus, acting on a specific binding site at the M2 protein. Lin 
and colleagues showed that the M2 channel inhibition activity of polyamines occurs at lower 
concentration in conditions in which there is a depletion for Na
+





 gradient, suggesting that influenza M2 protein possesses a binding site 
for polyamines, distinct from the amantadine binding site, which is normally masked by Na
+
. 
The proposed binding site could be an interesting target for the development of selective 
antiviral inhibitors
240
. It is important to underline that spermine is one of the component of a 
polycationic sphingolipid (ceramidecarbamoyl-spermine, CCS) that, in the form of micelles 
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Natural products such as pinanamine derivatives also exhibit good anti-influenza activities. In 
particular, the most promising is compound 35 that is active as inhibitor of A/M2 wild type 
and A/M2-S31N mutant channels, and in the case of the S31N mutant displays improved 






TCN032, that is an antibody targeting the IAV M2 protein, is in clinical trial. It has been 
developed by Theraclone Sciences and specifically binds to the conserved ectodomain of M2, 
which is exposed on the surface of infected cells; in doing so, it prevents virus budding and 
thus acts via a very different mechanism from the M2 ion channel inhibitors. TCN032 has 
been evaluated in a phase II study and found to be safe and effective at reducing symptoms 





3.2.3. M1 protein inhibitors  
Mopyridone 36, a compound which was identified from a screening of a series of tetrahydro-
2(1H)-pyrimidinone derivatives by Galabov and colleagues, has a large spectrum anti-
influenza activity on different A and B viral strains in vitro and in vivo. Very importantly, this 
compound is the first anti-flu agent that has been shown to have M1 protein as a target
245
, 
with a low acute toxicity in mice
246
. Starting from a screening on a library of more than 
70,000 commercially available small molecules, Mosier and co-workers found some 
compounds that act as inhibitors of M1 protein. In particular, the lead compound 37 acts as 
“wedge”, avidly binding to M1-M1 interface and weakening M1-M1 self-association. It was 
seen that it reduces the thickness of the M1 layer in mature virions and inhibits in ovo 
propagation of multiple IAV strains including H1N1, H3N2 and H5N1. These findings 
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More recently, Ai and co-workers
 
proved that some compounds belonging to the Traditional 
Chinese Medicine, such as Corydalis Rhizoma, Mori Folium, Forsythiae Fructus, Salvia, 
Lonicerae Japonicae Flos, Menthae Herba, have efficacy in the treatment of influenza, acting 





3.2.4. NA inhibitors  
Neuraminidase inhibitors (NAIs) act by preventing the release of the new viral particles and, 
although the emergence of NAI resistance could be a relevant clinical concern, they constitute 
the only class of antivirals recommended for the control of influenza epidemics and eventual 
pandemics, being active against all IAV subtypes and the two main IBV lineages. The two 
major NAI are zanamivir (Relenza
®
) and oseltamivir (Tamiflu
®
), that are analogues of the 
enzymatic transition state. In fact, the study of the crystal structure between the enzyme and 
the sialic acid, led to the identification of the mechanism of hydrolysis that was the starting 
point for the development of analogues of the transition state. 
In the 1970s Meindl and colleagues synthesized the 2-deoxy-2,3-dehydro-N-
trifluoroacetylneuraminic acid (FANA)
249
 and the 2-deoxy-2,3-dehydro-N-acetilneuraminic 
acid, Neu5Ac2en (DANA)
250
 which are analogues of the sialic acid. In the 1990s, Holzer and 
co-workers modified the structure of DANA, introducing a guanidino group in C4, and 
obtained zanamivir 38, that is able to bind NA more efficiently than the previous compounds, 
by forming a new interaction between amino acids Glu119 and Glu227
251
. In particular, 
zanamivir is a slow-binding inhibitor with a high affinity for NA. It is effective against 
influenza A/Singapore/1/57 and B/Victoria/102/85 virus with IC50 values of 14 nM and 5 nM, 
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respectively, in MDCK assays. In 1999, the FDA and EMA approved zanamivir as the first 
NA inhibitor agent, although for its very low oral bioavailability (2-3%) it must be 
administered via inhalation. Based on the structure of zanamivir and on studies of its three-
dimensional conformation
252
, Kim and collaborators
253
 synthesized oseltamivir 39, which is 
an ethyl ester prodrug that requires hydrolysis to be converted to the active form (oseltamivir 
carboxylate, GS-4071). It shows IC50 values in the range 0.3-1.5 nM against representative 
N3-N9 NAs and it has enhanced oral bioavailability, because of the esterification of the acid 
function and the bulky lipophilic side chain. In 1999, oseltamivir, as phosphate, was the first 
NA inhibitor for oral administration approved by FDA and then by EMA, and, by now, it is 
the most popular NA inhibitor in the clinic. It is important to underline that, although in the 
past there was a rapid rise in oseltamivir resistance among H1N1 IAVs
254
, in the last years 




                                 
 
Another NAI is peramivir 40 (Rapivab
®
, BCX 1812); this pentacyclic derivative was 
developed with the aim of obtaining a compound able to interact, through its side chains, with 
the lipophilic regions of NA. In vivo and in vitro studies demonstrated that it has activity 
against both IAV and IBV
256
. In 2009, peramivir was approved by the FDA for the 
emergency treatment of hospitalized patients infected by H1N1
257,258
. The emergency use 
authorization for peramivir expired in June 2010, and on December 2014 the FDA approved 
its intravenous administration to treat influenza infection in adults
259
. In 2016 the drug was 
also approved by EMA
260
. The clinical efficacy of peramivir was assessed by randomized 
controlled trials, in which it was administered by intravenous or intramuscular injection in 
adults and today further clinical trials are ongoing
188,189,261
. The newest NAI drug is 
laninamivir 41 (R-125489). It is a long-term NA inhibitor that shows potent NA inhibitory 
activity against eleven strains of H1N1 viruses, fifteen strains of H3N2 and twenty three 
strains of IBV with IC50 values in the range 1.29-5.97 nM, 7.09-38.80 nM and 10.40-31.40 
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nM, respectively, in enzymatic assays. Laninamivir octanoate (CS-8958), the prodrug of 
laninamivir, is approved in Japan since 2010, and appears to be effective for patients with 
oseltamivir resistance
262-264
. To date, laninamivir octanoate is in phase III clinical trial
265
. Its 





                               
 
The recent progress in researching NA inhibitors has mainly focused on the structure 
modification/optimization of zanamivir and oseltamivir. Compound 42 (A-315675) is a potent 
NA inhibitor discovered by Abbott researchers, who demonstrated that the basic group, 
previously deemed necessary for the interaction with the amino acid residues Glu119, Glu227 






Starting from this knowledge, Hanessian and co-workers synthesized a series of analogues of 
GS-4071, in which the basic amino group is replaced by a hydrophobic vinyl group. Among 
these molecules, compound 43 is the most active, having a Ki value in the nanomolar range 
(Ki = 45 nM). Its co-crystal X-ray structure with NA confirmed the binding mode in which the 
vinyl group projects into the region occupied by the amino group that is present in oseltamivir 
carboxylate, highlighting the importance of hydrophobic interactions for NA inhibition
268
. It 
is important to underline that the introduction of a hydrophobic substituent could be 
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advantageous also in terms of drug pharmacokinetics: in fact, the zwitterionic character of 





A series of triazole substituted carbocycles, synthesized by Mohan and collaborators, is active 
as NAI. For example, compound 44 has a Ki value of 72 nM against virus-like particles, 
possessing an IAV N1 activity
269
. The same researchers also discovered a series of N-
substituted oseltamivir analogs (general structure 45). It was seen that derivatives containing 
relatively small N-guanidine substituents (N-methyl and N-hydroxyl) display enhanced 
inhibition against NA derived from oseltamivir-resistant and wild-type strains, showing IC50 
values in the low nanomolar range
270,271
. The spirolactam 46 has an in vitro potency that can 
be comparable to that of compound 45; it is noteworthy that, although the spiro-fused ring in 
place of the guanidine group alters the strong hydrogen-bond network, it does not affect the 





                              
 
In 2012, Cheng and co-workers synthesized a series of oseltamivir analogs: oseltamivir 
phosphonic acid (tamiphosphor, 47a), its monoethyl ester (47b), guanidine tamiphosphor 
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(48a) and its monoethyl ester (48b), as potent NAIs. They inhibit the replication of influenza 
viruses, including the oseltamivir-resistant H275Y strain, at low nanomolar to picomolar 
levels. These compounds, when orally administered at 1 mg/kg or higher doses, significantly 
protect mice from infection with otherwise lethal doses of influenza viruses. These 
compounds are stable in simulated gastric fluid, liver microsomes and human blood, and are 
largely free from binding to plasma proteins. Pharmacokinetic properties of these inhibitors 




                       
 
In 2013, Kim and co-workers designed a series of covalent NA inhibitors (represented by 
compound 49) by introducing the strong electronegative fluorine atom in the core-ring of 
zanamivir and oseltamivir. These compounds form transient covalent intermediates with 
Tyr406 located in the catalytic domain of NA, thereby gaining potent broad-spectrum 
inhibitory activity against drug-resistant strains. They show good antiviral activity in vitro and 
high efficacy as enzyme inhibitors. For example, compound 49 has IC50 values of 1 and 10 
nM against B/Perth/211/01 and A/Fukui/45/01 H3N2, respectively, in PRA. Furthermore, 
they show good inhibition of NAs from zanamivir- or oseltamivir-resistant influenza virus 
strains, indicating an altered resistance profile, and they function well in controlling influenza 
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Schade and collaborators synthesized other oseltamivir analogs, in particular, oseltamivir 
amidine 50 and its bifunctional prodrug amidoxime ethyl ester 51. Compound 50 has a 
potency comparable to that of oseltamivir against different wild-type IAV strains, but 
additionally shows efficacy (IC50 = 14.5 nM) against oseltamivir-resistant influenza 
A/Berlin/55/08, H275Y mutant. Docking experiments revealed that the compound is able to 
make additional interactions in the NA active site, to a similar extent as guanidine-containing 
NAIs. Amidoxime prodrug 51 exhibits an in vivo pharmacokinetic profile that is competitive 
with oseltamivir, with comparable oral bioavailabilities (31% versus 36%). A possible asset 
of this molecule can be seen in its prolonged plasma half-life (111 minutes versus 44 minutes 
for oseltamivir) that means a retardation effect that could be beneficial for the required dosing 
regimen. In general, the amidine-based oseltamivir derivatives exhibit excellent in vitro 
properties, have a good pharmacokinetic profile, are stable under various physiologically 





                       
 
Previously, also dimeric (or tethered) zanamivir conjugates were synthesized in order to 
achieve multivalent binding. Some of these derivatives showed to be highly potent NA 
inhibitors, with broad-spectrum activity
276-278
. Among dimeric derivatives of zanamivir, the 
viral NA inhibitor BTA938, containing a fourteen-carbon linker bridging two zanamivir 
moieties, has high antiviral activity as demonstrated by visual and colorimetric determination 
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of the inhibition of CPE plus PRA. The EC50 values are in the low nanomolar range, with 
BTA938 exhibiting higher potency than zanamivir, oseltamivir and laninamivir for the 
majority of viruses tested. Moreover, it was demonstrated that single-dose BTA938 protects 
mice from pandemic H1N1 virus infection and is equivalent to multiple doses of zanamivir 
for an oseltamivir-resistant strain (H275Y)
279
. 
In the field of NAIs having a different structure than that of zanamivir and oseltamivir, we 
have to remind pyrrolidine and benzoic acid derivatives, dextran sulphate and AV5080. Some 
pyrrolidine derivatives were found to be effective against IAVs and IBVs acting as NAIs. For 
example, compound 52 shows an IC50 of 0.2 μM against NA A/Tokyo and 8 μM against NA 






With the aim to find novel potent NA inhibitors, benzoic acid derivatives (as example, 
structures 53 and 54) have been developed; some of these compounds have antiviral activity 




                           
 
The negatively charged sulphated polysaccharide dextran sulphate (DS), 55, was considered 
an inhibitor of the HA-dependent attachment of the virus to the cell
284,285
, while more recently 
it seems that is mainly involved in the late stage NA-dependent of the viral infection. The 
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suppression of NA activity and virus release depend on both DS’s negative charge and on the 
characteristics of NA, but it is not yet clear which amino acid(s) of NA are responsible for 
DS’s suppressive effect, and the mechanism by which DS suppresses viral replication
286
. 
Studies on recombinant viruses having mutation(s) on NA gene show that DS severely 
suppresses oseltamivir-resistant recombinant virus H274Y in PRA, highlighting the 







AV5080, 56, has a subnanomolar activity against influenza virus NA in vitro, with IC50s of 
0.03 nM and 0.07 nM against NA of A/Duck/Minnesota/1525/1981 H5N1 and 
A/Perth/265/2009 H1N1 in NA enzyme based assays, respectively. It is highly potent also 






Also some natural products and their derivatives have been found to possess anti-influenza 
activities acting on NA. Ginkgetin-sialic acid conjugates (compound 57) show potent anti-
influenza virus activities in vivo, significantly improving the survival rate of mice infected 
with the A/PR/8/34 (H1N1) strain
289
, while the flavanone 58 and the flavonoid 59 show 
potent NA inhibition (IC50 ranges 1.4-20 μM against NA)
290,291
. Nagai and co-workers 
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showed that isoscutellarein 60 and its derivatives are active in the low micromolar range in 
cellular assays against influenza A/Guizhou/54/89 H3N2 MDCK cell-based CPE assay and in 
animal models, acting as NA inhibitors
292,293
. Also compounds extracted from Ferula assa-
foetida have great potency against IAV (H1N1) (IC50 = 0.26-0.86 μg/mL). The most potent 
molecule is compound 61
294
. 
                                  
 
                                              
 
In order to develop new anti-influenza virus drugs, several derivatives of resveratrol, a 
molecule that has an antiviral effect due to is ability to inhibit the protein kinase C (PKC) 
activity and its dependent pathways
295
, have been extracted, isolated or synthesized by Li and 
co-workers. Using several biological assays and computer aided studies, they demonstrated 
that the resveratrol related compounds have significant inhibitory effects on influenza H1N1 
virus NA. In particular, compound 62 not only exhibits high inhibitory activity on NA, but 
also possesses anti-influenza virus activity in MDCK cells, which means that its mechanism 
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3.2.5. NP inhibitors  
As previously reported, NP has multiple functions in the virus: among them, it is involved in 
replication and in the formation of specificity to the host. NPs are the major components of 
vRNP and within the vRNP complex oligomerize via two interaction forces. One comprises 
an intra-strand interaction through which the tail loop (residues 402-428) is inserted into the 
neighboring NP tail loop pocket
297
, while the other comprises an inter-strand interaction 
between two NP strands with opposite polarity. The mechanism underlying the interaction 
between the two NP strands is still not clear; however, it is known that two dimer interfaces, 
the helix-turn-helix motif (residues 149-167) and the C-terminal region (residues 482-498), of 
NP are involved in this process
298
. For these reasons, it is an interesting anti-influenza target 
and some potential inhibitors of NP have been recently discovered. In 2010, Kao and co-
workers found a small molecule, nucleozin, 63, which can trigger the aggregation process of 
NP, blocking its nuclear accumulation. It inhibits the infection caused by H1N1, H3N2 and 
H5N1 strains, with EC50s of 0.07 μM, 0.16 μM and 0.33 μM in MDCK cell-based PRA, 
respectively
299
. In the same year, an anti-influenza screening against a large compound library 
together with a high-throughput virus yield reduction methodology resulted in the 
identification of several classes of unique compounds, which appear to act on different 
targets. One of the identified compound, structure 64, is an analog of the nucleozin that 
inhibits influenza RdRp interacting with NP
300
. A year later these findings, Shen and co-
workers reported a rational approach to target influenza virus with a new mechanism of 
disruption of NP-NP interaction. Based on the crystal structures, they predicted that mutations 
of amino acids in positions 339 (glutamic acid to alanine, E339A) and 416 (arginine to 
alanine, R416A), and the tail loop deletion (Δ402-428) would perturb NP-NP interactions, 
and in turn the ability of NP to interact with RdRp productively. Analyses by analytical 
ultracentrifugation indicated that these three NP-mutants existed as monomers in the free 
form as opposed to trimers for wild-type NP, and that their ability to bind RNA was 
significantly perturbed. Moreover, a luciferase-based reporter assay showed that the three 
mutants were unable to support the RdRp activity. Having demonstrated the importance of the 
salt bridge between Glu339 and Arg416 for viral survival, the same researchers performed a 
virtual screening to target this interaction. This study led to identifying some small molecules 
able to disrupt the formation of NP trimers and inhibit replication of wild-type and nucleozin-
resistant virus strains, even though with less activity than nucleozin and its analogs, 
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previously described. Among these newly identified molecules, the most active is compound 









Cheng and collaborators replaced the isoxazole ring of nucleozin with a triazole to obtain a 
series of compounds, among which derivative 66 has IC50 values in the low micromolar range 







In 2016, the crystal structure of NP-nucleozin complex at 3 Å resolution showed the binding 
sites of nucleozin at NP for the first time. The complex structure reveals how NP and 
nucleozin interact with each other. The mechanism of action proposed is that nucleozin could 
link two NP molecules into dimeric subunits, and then further induce the formation of large 
aggregates
303
. After a screening of a library of 50,000 compounds using cell-based infection 
assays, the antiviral compound 67 was identified. It shows potent antiviral activity in vitro 
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against many different subtypes of IAV (e.g. IC50 value of 0.40 µM against 
A/California/7/2009 virus (H1N1)) and partially protects mice from a lethal dose of 
A/WSN/1933 (H1N1) virus, although in vivo data show that it is less effective than 
oseltamivir phosphate. The mechanism of action of 67 is the inhibition of vRNP activity, 
causing the NP to accumulate in the cell nucleus; in silico docking analysis revealed that it 






Small molecules such as cycloheximide 68, the eukaryote protein synthesis inhibitor, and 
naproxen 69, the known inhibitor of inducible cyclooxygenase type 2 (COX-2), are effective 
against the functional polymerization of the NP monomers. In particular, naproxen inhibits 
NP-RNA association required for NP function, and for this reason it is a promising lead 
compound for the development of novel antivirals against IAVs
305,306
. A licensed antiviral 
drug named ingavirin 70, approved in Russia for the treatment of IAV and IBV infections, 
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3.2.6. NS1 inhibitors 
The non-structural protein 1 (NS1) of the influenza virus is a small, multifunctional protein, 
formed by two domains joined by a flexible linker region, that is encoded by all strains of 
IAVs and is highly conserved
308-310
. NS1 has different essential roles in viral replication and 
evasion of the cellular innate immune response. It binds in a non-sequence specific manner to 
viral RNA protecting it from degradation
311
 and it interacts with the tripartite motif-containing 
protein 25 (TRIM25), preventing the activation of retinoic acid-inducible gene I (RIG-I), 
thereby suppressing the production of cellular interferon
125,312,313
. It is also able to bind to 
cleavage and polyadenylation specificity factor (CPSF30), blocking the maturation of the host 
RNAs, which leads to the reduction of host proteins
308,314-316
. Twu et al. found that the 
binding between NS1 protein of IAVs and CPSF30 is mediated by the second and third zinc 
fingers (F2F3) of CPSF30; in particular, the viral replication is inhibited when the binding 
process is blocked by a fragment containing the F2F3 binding motif. This indicates that the 
CPSF30 binding site in the NS1 protein could be a potential target for antiviral therapies 
against the IAV
317
. In 2012, Jablonski et al. showed that NSC125044, 71, and a series of 
derived compounds, such as 72, are able to display inhibitory activity against NS1 protein in a 




                      
 
 
3.2.7. RdRp inhibitors 
RdRp of influenza virus has been highly conserved among all strains and subtypes during 
evolution
319
. During the early stages of infection, RdRp synthesizes mRNA using vRNA as a 
template, while during the advanced stage of infection, it becomes responsible for the 
catalytic synthesis of cRNA and new vRNA
131
. Playing a critical role during the life cycle of 
the virus, RdRp has become a promising target for the development of anti-influenza drugs in 
recent years
132
. Based on the mechanism of the interactions between inhibitor and 
polymerase, compounds targeting RdRp can be subdivided into four subtypes: PA 
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3.2.7.1. PA endonuclease inhibitors  
A promising target in viral RdRp is the conserved residues inside of the catalytic site of N-
terminal domain of PA (PA-N). As previously said, PA-N has the catalytic domain for the 





) and several residues that are conserved among IAVs and IBVs, and are 
important for the catalysis or metal ion coordination. Moreover, this catalytic center is 
surrounded by several hydrophobic pockets that are well suited for drug design. Hence, PA 
inhibitor design is currently focused on chemical scaffolds bearing coplanar oxygens with the 
right geometry to coordinate the divalent metal ion(s), and also, suitable hydrophobic 
elements
320
. In the literature, there are several PA inhibitors with inhibitory activity in 
enzymatic assays on the viral polymerase or isolated PA-N. The first class of PA inhibitors 
was reported by Merck (Kenilworth, NJ, USA) in the mid-1990s; these molecules have a 4-
substituted 2,4-dioxobutanoic scaffold and exhibited IC50s ranging from 0.2 to 29.0 μM. In 







Quinoline derivatives bearing a hydroxamic acid moiety were identified as selective inhibitors 
of RdRp by a high-throughput in vitro transcription assay. The hit compound 74 inhibits the 
capped RNA-dependent transcription of IAV and IBV with a similar potency (IC50 of 40 and 
50 μM, respectively). SAR of 74 and its analogs indicates that the phenolic hydroxyl group, 
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the hydroxamic acid moiety and the nitrogen of quinoline are essential for the activity. 
Interestingly, the incorporation of the hydroxamic acid portion into a cyclic ring system led to 
two potent inhibitors, 75 and 76. However, apparent toxicity observed in cell cultures 




                              
 
The fungal metabolite flutimide, 77, bearing a 2,6 diketo-piperazine scaffold, has an 
interesting antiviral activity: it inhibits IAV PR/8/34 RdRp (IC50 = 5.5 μM) in a cap-
dependent transcription assay and IAV infection of MDCK cells (EC50 = 5.9 μM) without 
apparent toxicity (CC50 ≥ 100 μM)
324
. Starting from this interesting activity, several 
derivatives of flutimide have been designed and synthesized by introducing different aromatic 
groups at 3 and 5 positions, which led to several more potent inhibitors (general structure 78), 
but with overt cytotoxicity to cells at > 10 µM concentrations and unacceptable selectivity 
index values in cell culture
325,326
. 
                
 
During studies for the identification of a pharmacophore model useful in the development of 
more potent PA-N inhibitors, Parkes and co-workers identified a series of potent inhibitors of 
the endonuclease of both IAV and IBV. Unfortunately, these derivatives show unacceptable 
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The antiviral activity of (-)-epigallocatechin gallate (EGCG) 80 against influenza virus was 
reported for the first time in 1993. This compound, present in green tea, affects viral 
infectivity in cell culture and agglutinates influenza viruses, preventing their absorbing to 
MDCK cells
197
. Moreover, green tea extracts including EGCG exert an inhibitory effect on 
the acidification of endosomes and lysosomes, resulting in inhibition of influenza virus 
growth in tissue culture
328
. EGCG and other related polyphenolic compounds are able to 
inhibit viral NA
329
, and the replication of influenza virus, but also, show significant protective 
effects against oxidative stress through exhibiting antioxidant activity
330
. In 2009, a study 
demonstrated that green tea cathechins are active as antivirals because they are able to inhibit 






Using biological screening on thalidomide analogs, in particular, a PA endonuclease 
inhibition assay, a PB2 pathogenicity-determinant domain-binding assay, and an anti-IAV 
assay, Iwai and co-workers found that some phenethylphenylphthalimide analogs (for 
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The same researchers identified three families of phytochemicals, namely marchantins, 
plagiochins and perrottetins (represented by marchantin A 82, plagiochin A 83 and perrottetin 
F 84) as inhibitors of influenza endonuclease, by the use of a PA endonuclease inhibition 
assay and an anti-IAV assay. These compounds have a 3,4-dihydroxyphenethyl group in 




                 
 
In 2013, Shoji and colleagues screened a series of fullerene derivatives using an in vitro PA 
endonuclease inhibition assay, identifying some inhibitors of the endonuclease activity of the 
PA-N domain or full-length PA protein. In silico docking simulation analyses suggest that 
fullerenes can bind to the active pocket of PA endonuclease. Among them, compound 85 is 
the most promising, having IC50 values of 20 µM and 31 µM against A/PR8/34 (H1N1) and 
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In the same year, molecules having the hydroxypyridinone scaffold were synthesized and 
biologically evaluated, providing useful scaffolds for the development of endonuclease 
inhibitors that could block the cap snatching associated with IAV replication. Two of the most 
potent compounds of this series, 86 and 87, show good IC50 values of 11 and 23 nM, 






Also the hydroxyquinolinone scaffold was found to be promising for the synthesis of new PA 
inhibitors. This development led to two potent inhibitors 88 and 89, having both of them IC50 
values of 0.5 μM with regard to their ability to inhibit the endonuclease activity as measured 
by a high-throughput fluorescence assay. These compounds, analogously to compounds 86 
and 87, are substituted by a p-fluorophenyl group
336
. The same researchers synthesized also a 
series of substituted hydroxypyrimidinones among which the most active are compounds 90 
and 91, showing good inhibition activity with IC50 values of 0.58 μM and 0.15 μM, 
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In 2014, using an in silico screening on a library of 450,000 compounds, Chen and colleagues 
identified molecules 92 and 93, bearing four oxygenated functional groups, as potent antiviral 
agents against PA-N endonuclease (IC50s of 6 µM and 14 µM against H1N1 endonuclease) 




                 
 
With the aim of identifying the essential pharmacophoric motif that could be involved in 
functional sequestration of the metal ions and consequently in the inhibition of PA subunit, 
Carcelli and collaborators proposed the 2,3-dihydroxy benzamide scaffold as a versatile 
platform for designing influenza PA endonuclease inhibitors. Compound 94 is the most active 
of this series. Its corresponding magnesium complex has an IC50 of 18 µM in a PA 
endonuclease inhibition assay, while the uncomplexed ligand has an IC50 of 33 µM, 
suggesting that the effective inhibitor of the activity of the enzyme is the metal complex and 
not the free ligand
339
. In 2015, the continuation of this project led to the identification of a 
series of salicylaldehyde thiosemicarbazone derivatives that seem to be promising PA 
inhibitors. In particular, thiosemicarbazone 95, with two hydroxy groups in position 2 and 3 
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The same researchers identified also β-diketo-acid containing molecules as promising lead 
compounds for the development of new potent inhibitors of the PA catalytic activity. Among 
others, they synthesized and biologically evaluated some piperidine compounds 96 (analogs 






Also trihydroxy-phenyl bearing compounds have provided a useful scaffold for the 
development of endonuclease inhibitors; for example, compounds 97 and 98 inhibit the PA-N 
endonuclease activity in a FRET-based endonuclease assay with IC50 values of 9.7 and 8.3 
µM, respectively, and show inhibition activities in cell culture (EC50 = 11.76 and 14.42 µM, 
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Pala and co-workers identified a series of indole carboxamidic compounds with an interesting 
PA inhibitory activity. Among them, 99 and 100 have IC50 values in the low micromolar 
range in an enzymatic plasmid-based endonuclease assay with influenza virus PA-N. Both 
molecules also show antiviral activity in cell-based assays and have potency comparable to 




             
 
Credille and co-workers identified pyromeconic acid and its analogs as efficient PA-N 
endonuclease inhibitors, by using a fragment-based drug discovery campaign. They 
synthesized a series of 6-substituted pyromeconic acid derivatives to increase antiviral 
activity; among them, the most active compound is the tertiary amine 101, with an IC50 of 
0.94 μM in a PA endonuclease inhibition assay. Subsequently, they substituted the pyrone 
ring with a pyridinone one, to tighten the metal binding and increase the ligand basicity. A 
library of N-substituted pyridinones was synthesized and biologically tested. Compound 102, 
containing a tetrazole group at the 4-position of phenyl ring, shows an IC50 value of 36 nM. 
Then, the researchers decided to merge the most potent inhibitors substituted at the 6-position 
of the pyrone ring with the most potent inhibitors substituted at the 1-position of pyridinone 
ring. This approach led to compound 103, which has an IC50 value of 14 nM in a PA 
endonuclease inhibition assay and displays potency against IAV H1N1 in MDCK cells (EC50 




CHAPTER 3. Therapeutic treatments 
PhD Thesis in Pharmaceutical, Food and Cosmetic Sciences 
Ilaria Giacchello 
73 
                               
 
ANA-0, 104, was identified by Yuan and colleagues as a potent endonuclease inhibitor using 
a screening approach that integrated the fluorescence resonance energy transfer based 
endonuclease inhibitory assay with the DNA gel-based endonuclease inhibitory assay. ANA-0 
inhibits the replication of multiple subtypes of IAV, including H1N1, H3N2, H5N1, H7N7, 
H7N9 and H9N2, in cell cultures. It has been seen that the combination of zanamivir and 
ANA-0 has a synergistic anti-influenza effect in vitro and its intranasal administration has a 






While I am writing this thesis, Alios Biopharma, Inc. is testing AL-794 as endonuclease 
inhibitor in clinical stage evaluation. AL-794 is currently in clinical phase I
345
, although 
recently a study (NCT03411421) to assess the safety, tolerability and pharmacokinetics of 
repeated dosing regimens of AL-794 in healthy volunteers was closed as the data received did 
not support the continuation. The structure of this molecule is not disclosed. The prodrug S-
033188 (baloxavir marboxil) 105, that has been developed by Shionogi (Osaka, Japan) in 
collaboration with F. Hoffmann-La Roche Ltd., has demonstrated safety and acceptable 
pharmacokinetics in clinical stage evaluation. Moreover, this drug demonstrated efficacy in a 
wide range of influenza viruses, including oseltamivir-resistant strains (e.g. H7N9, H5N1). A 
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phase III study (NCT02954354, CAPSTONE-1) showed that patients treated with S-033188 
have significantly greater reductions from baseline in both viral titer and RNA content than 
those treated with oseltamivir or placebo and that S-033188 is generally well tolerated, with 
overall incidence of treatment-emergent adverse events lower compared with oseltamivir
346
. 
Very recently (October 2018), the FDA approved baloxavir marboxil (Xofluza
™
) for the 
treatment of acute, uncomplicated influenza in people twelve years old or older. Roche 
announced that Xofluza
™
 will be further studied in a phase III development programme 
including pediatric populations, post-exposure prophylaxis and severely ill hospitalized 
people with influenza, as well as the assessment of its potential in reducing transmission in 
otherwise healthy people.  
 
 
3.2.7.2. PB1 inhibitors  
The PB1 inhibitors are very promising in anti-influenza drug development because of their 
low cytotoxicity, high resistance barrier and broad coverage of diverse RNA viruses
19
. 
Ribavirin 106 and favipiravir 107 (also named T-705 or Avigan) are RdRp inhibitors both 
containing a purine pseudo base, but have a different mechanism for their antiviral and 
mutagenic effects on influenza virus. Ribavirin is a guanosine analogue that was approved in 
1986 as a broad-spectrum antiviral drug
347-349
. Its anti-influenza effect is based on IMP 
(inosine monophosphate) dehydrogenase inhibition, which results in fast and profound GTP 
depletion and an imbalance in the nucleotide pools. In particular, ribavirin causes an increase 
in both cytosine-to-uracile and guanine-to-adenine transitions and is misincorporated as 
triphosphate into replicating genomes by the viral RdRp
350
. Favipiravir is a nucleobase 
mimetic discovered by Toyama Chemical Co., Ltd. It acts as a potent and GTP-competitive 
inhibitor of the viral polymerase. It is transformed by cellular enzymes into its active form, 
favipiravir-ribofuranosyl-5'-triphosphate (RTP). This form is recognized by RdRp and 
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misincorporated into nascent RNA as a purine, which results in chain termination during 
RNA synthesis. Favipiravir is active against a broad range of influenza viruses, including IAV 
H1N1, H5N1 and H7N9, inhibits influenza strains resistant to current antiviral drugs, and 
shows a synergistic effect in combination with oseltamivir
351
. One of the major concerns for 
favipiravir is its potential teratogenicity, and this is the reason behind the conditional approval 
of the drug in Japan. Favipiravir pharmacokinetic and efficacy is being tested in several 
clinical trials (phase II and phase III) in Japan and in USA
352
. In conclusion, in infected cells, 
viral RNA synthesis is completely inhibited by favipiravir or ribavirin at concentrations > 50 
µM, whereas exposure to lower drug concentrations induces formation of non-infectious 
particles and accumulation of random point mutations in the viral genome. This mutagenic 













 are reported to have anti-influenza activities against IAV and 
IBV. For example, as a pyrimidine analogue, 2'-deoxy-2'-fluorocytidine (2’-FdC), 108, 
inhibits the polymerase complex of various IAV and IBV strains in vitro and in vivo, with 
IC50 values ranging from 0.13 µM to 4.60 µM
356
. Although these nucleoside analogues show 
strong inhibitory activities, the clinical application is limited because their therapeutic 





Among the PB1 non-nucleoside inhibitors, compound 109 was the first identified influenza 
inhibitor that was proved to act on the PB1 subunit
300
. Optimization of this compound could 
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result in the development of new interesting anti-influenza agents. ASN2, 110, was first 
reported as an activator of the host innate immune response which can restore the interferon 
response to influenza-infected cells. However, the PB1 mutant Y499H, showing resistance to 
ASN2 in a mini-genome assay, suggested that the PB1 subunit should be the direct target. 
ASN2 shows potent inhibitory activity against IAV and IBV in vitro against several viral 




                      
 
 
3.2.7.3. PB2 Cap-binding inhibitors  
The natural ligand of the PB2 domain is the m7GpppN cap (where m7G is 7-
methylguanosine, p is a phosphate group and N is the first transcribed nucleotide), so 
compounds containing a 7-methylguanine group or its analogs could compete with the natural 
ligand for the PB2 cap-binding domain (PB2-CBD). Pautus and co-workers first identified 7-
alkylguanine derivatives as inhibitors of this domain, and further modifications, in order to 
mimic the negative charges of the triphosphate group of m7GTP with carboxylate groups, led 
to the synthesis of active compounds, among which compound 111, that has an IC50 of 0.6 
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Among the PB2 cap-binding inhibitors, there is the azaindole based inhibitor VX-787, 112, 
known also as pimodivir or JNJ63623872. It was discovered by Vertex Pharmaceuticals and 
is being developed by Janssen Pharmaceuticals
359
. VX-787 is a first-in-class, specific, oral 
polymerase inhibitor which is under phase II development for the treatment of IAV 
infections
360,361
. It displays potent antiviral activity against a wide range of IAV strains 
including amantadine- and NAI-resistant strains, with EC50s in the nanomolar range in 
cellular assays
359,362
. The X-ray structure demonstrates that VX-787 is able to occupy the 
m7GTP binding pocket in the PB2 cap-binding domain of IAVs
165
. Moreover, more recently, 
it was found that VX-787 inhibits IAV replication but does not alter cellular antiviral 
responses
363
. Several VX-787 analogs were synthesized and biologically evaluated, including 




                    
 
Cap-3 and Cap-7 (structures 114 and 115, respectively), reported by Roch et al., are active as 





                   
 
Recently, Liu and co-workers identified compound D715-2441, 116, by screening a library of 
compounds in a cell-based MTT assay. D715-2441 possesses antiviral activity against 
multiple subtypes of IAV strains, including H1N1, H5N1, H7N9, H3N2, the clinical isolate 
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690 (H3), and oseltamivir-resistant strains with the H274Y NA mutation, and suppresses the 
early steps of the virus replication cycle. Mechanistic studies indicate that D715-2441 inhibits 







3.2.7.4. RdRp disrupting compounds  
As reported before, the three subunits of the RdRp bind each other non-covalently in a set of 
interactions that are essential for the polymerase function. An attractive strategy for 
developing RdRp inhibitors appears to interrupt the interactions among the three units. 
Compounds that act with this mechanism of action are called protein-protein interaction 
inhibitors (PPI inhibitors) because of their interference or inhibition of the protein-protein 
interaction in the RdRp assembly. Among the interactions between the three different 
subunits of the RdRp, the PA-PB1 is probably the most interesting one for the development of 
new inhibitors. In fact, PA and PB1 directly interact to form a stable complex which binds to 
the vRNA promoter; this interaction has been characterized and is known to occur between 
the C-terminal region of PA (PA-C) and the N-terminal region of PB1 (PB1-N). Moreover, 
the interface of PA-PB1 interaction contains several hydrophobic pockets that are important 
for small-molecule drug design
132,367
. A more detailed description of this interaction and its 
importance as a target for the development of new promising antiviral drugs will be cited in 
the project section of this thesis. 
In 2007, Ghanem et al. identified a 25 amino acid peptide (amino acid sequence 
ADVNPTLLFLKVPAQNAISTTFPYT) derived from IAV PB1-N, corresponding to the PA-
binding domain, that could inhibit RdRp activity by disrupting the PA-PB1 interaction (IC50 
value of 1.8 nM). This is the first example of small peptides inhibiting the PA-PB1 complex 
formation
368
. The same research group found smaller peptide inhibitors by generating several 
truncated fragments of IAV PB1-N. These peptides show good IC50 values for IAVs and 
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. Anthracene derivative 117 (AL18), an inhibitor of cytomegalovirus 
DNA polymerase, was also serendipitously identified as a blocker of the connection between 
RdRp subunits. It shows an interesting activity as disruptor of the interaction between PA and 
PB1 subunits (IC50 = 20.3 μM) both on IAV (A/PR/8/34) with an EC50 of 14.5 μM and on 
IBV (B/Lee/40) having an EC50 of 8.3 µM
371
. Other two PA-PB1 PPI inhibitors, 
benzbromarone, 118, and diclazuril, 119, were identified by a Japanese group with an in silico 
screening of a database of about 4,000 drugs
372
. These two compounds are already in clinic 
for other uses and they can represent a good starting point for further development as well as 
good alternatives in case of an outbreak of an influenza virus resistant to current drugs. 
 
                             
 
More recently, the identification of small molecules and peptides acting as PA-PB1 inhibitors 
has been mainly based on high-throughput screening (HTS) and structure-based virtual 
screening (SBVS). Benzofurazan derivatives, a new class of PA-PB1 PPI inhibitors, were 
identified by HTS using a biochemical ELISA-based screening approach followed by PRA on 
MDCK cells infected with the virus A/WSN/33 (H1N1). In particular, compound 120 and its 
analogue 121 show promising antiviral activity against IAV (H1N1), with IC50s in the low 
micromolar range. Also a series of thioaryl derivatives, for example compound 122, shows 
antiviral activity comparable to 120, as well as improved cytotoxic profile
373
. Additional 
chemical structure modifications led to the identification of more potent compounds, among 
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Using an in silico screening and then testing the selected compounds for their ability to inhibit 
the interaction between PB1 and PA in vitro with an ELISA-based assay and in cells, 
Muratore et al. identified several compounds acting as effective inhibitors of the polymerase 
PA-PB1 interaction. In particular, the most promising molecules turned out to be compounds 




                 
 
During subsequent SAR studies on the chemical structure of compound 125, the thiophene-3-
carboxamide moiety, which emerged as a favourable scaffold in the design of RdRp 
inhibitors, was preserved. I will describe in more detail molecules 117, 123, 124 and 125 in 
Chapter 4., Paragraph 4.1. 
The substitution of the pyrazolo[1,5-a]pyrimidine with a triazolo[1,5-a]pyrimidine led to 
compound 126, which is a three-fold more potent PA-PB1 inhibitor, with an IC50 value of 7.5 
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Among cycloheptathiophene-3-carboxamide derivatives, compounds 127 and 128 emerged as 





                          
 
In 2015, Massari et al. during an optimization study on dihydrotriazolopyrimidine, 
synthesized some derivatives active as PA-PB1 interaction. Among them, the hybrid molecule 
129, obtained by combining the triazolopyrimidine and the previously explored 
cycloheptathiophene scaffold, turned out to be a potent PA-PB1 PPI inhibitor with an IC50 of 






In 2016, Yuan and colleagues identified ANA-1, 130, as a novel compound which could be 
developed as an anti-influenza drug. It was found to be a strong inhibitor of viral polymerase 
activity and a potent antiviral agent against infections of multiple subtypes of IAV, including 
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H1N1, H3N2, H5N1, H7N7, H7N9 and H9N2 subtypes. Molecule 130 shows EC50 values 






Very recently, by screening of an in house library, Shibasaki and co-workers identified 
MZ7465, 131, a salcomine derivative, as a potent inhibitor of influenza virus propagation. 
Treatment with MZ7465 of infected cells decreases both viral protein and RNA synthesis and 
experimental results suggest that MZ7465 inhibits viral polymerase complex activity. 







3.3. Agents targeting host sites  
Another strategy to fight against influenza viruses is to target host sites that are essential for 
viral replication. Influenza virus exploits a number of cellular signaling pathways during the 
course of its replication, rendering them potential targets for new therapeutic interventions. It 
is important to underline that a viral inhibitor that targets host factors, rather than viral 
mechanisms, may be effective against multiple virus strains and subtypes, and be less likely to 
elicit viral drug resistance. There are several cellular sites that could be targeted; below I will 
mention only the main ones with the most promising relative molecules. 
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3.3.1. V-ATPase inhibitors 
Endosomal acidification plays a major role in facilitating the fusion between viral and 
endosomal membranes, and the vacuolar ATPase (v-ATPase) is a regulating factor on viral 
replication. The inhibition of v-ATPase activity reduces the influenza viral infection by 
preventing the pH-dependent membrane fusion between endosomes and virions. Some 
adamantane drugs tested for the treatment of Parkinson’s disease, among which, for example, 
norakin, 132, has shown inhibitory activity against IAV and IBV acting as v-ATPase 
inhibitors
381-383
. The natural compound diphyllin, 133, seems to be a promising v-ATPase 
inhibitor for several influenza virus strains. The results of cell-based assays show that it alters 
cellular susceptibility to influenza viruses through the inhibition of endosomal acidification, 
thus interfering with downstream virus replication, including that of known drug-resistant 
strains. Moreover, combinatorial treatment of diphyllin with oseltamivir or amantadine 








Numerous studies have reported that the viral infection is often associated with redox changes 
characteristic of oxidative stress and emerging evidence has demonstrated that oxidative 
stress is an important contributor to infectious diseases and, among them, to influenza
385,386
. 
Indeed, during both in vivo and in vitro experimental models a shift towards a pro-oxidant 
state, a decrease in glutathione (GSH) levels, and a general oxidative stress have been 
observed
387,388
. It was noted that an exogenous administration of molecules able to increase 
cellular GSH concentration inhibits the replication of several viruses, including the influenza 
virus, through different mechanisms
389
. Cai et al. demonstrated that, when added 
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extracellularly, GSH has a dose-dependent anti-influenza effect in cultured cells. Moreover, 
the addition of GSH to the drinking water of influenza infected mice inhibits viral titer in the 
trachea and lungs
390
. These data strongly suggest that reducing conditions within the host cell 
could interfere with disulfide bond formation, thus preventing the correct folding and 
maturation of HA and consequently its transport and insertion into the cell membrane
391
. 
Moreover, oxidative stress is one of the most important causes of tissue injury, inflammation 
and apoptosis related to influenza virus infection
392
. 
A part from GSH, among anti-oxidant compounds, there are tocopherols. They are radical 
scavengers that deliver an hydrogen atom to quench free radicals, minimizing their damaging 
effect. Among them, there is α-tocopherol 134 that, alone or in combination, could normalize 






There are still other small-molecule antioxidants that work on influenza viruses. For example, 
the terpenophenol (+)-S-bakuchiol, 135, that produces an anti-influenza effect through 
influencing oxidative stress response of host cells
397
 or flavonoids biochanin A and baicalein 
(136a and 136b, respectively) that inhibit highly pathogenic avian H5N1 IAV replication by 




                     
 
Interestingly, it seems that also NADPH oxidases family is involved in oxidative stress related 
to viral infection. NADPH oxidases are enzymes whose function is to generate ROS. They are 
divided in multiple isoforms, which primarily are distinguished by their membrane-spanning 
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catalytic “NOX” or dual oxidase “DUOX” subunit that it uses to transfer electrons from 
NADPH to molecular oxygen. In particular, NOX1 and NOX2 oxidases appear to have 
opposing roles in the regulation of inflammation caused by IAV. NOX 1 oxidase seems to 
suppress influenza virus-induced lung inflammation and oxidative stress
399
, while NOX2 
might promote the respiratory symptoms of the IAV infection and impede the clearance of the 
virus. For this reason, NOX2 could be a promising novel pharmacologic target against IAV 





3.3.3. Protease inhibitors  
Protease inhibitors are a class of influenza virus inhibitors; among them, it is important to 
mention the sialidase DAS181 (Fludase). It is a recombinant protein designed to remove sialic 
acid from respiratory epithelium and thereby prevent the attachment of influenza virus or 
other viruses that use sialic acid as a receptor. The protein, which is delivered via inhalation, 
consists of a heparin binding sequence that anchors the protein on respiratory epithelial cells 
and a sialidase derived from Actinomyces viscosus which cleaves sialic acid linkages from 
surrounding glycans
402
. Fludase is effective against both IAV and IVB and protects mice 
when it is administered either as prophylaxis or up to 48 h post-viral infection. Results of 
phase II trials indicate that the drug is well tolerated and significantly reduces viral load and 
viral shedding when administered over three days. One of the major concerns for using a 
protein therapy is the development of antibodies which would prohibit the subsequent use of 
the drug; neutralizing antibodies to Fludase have been observed, particularly when the drug is 
given for long periods and so its use must be limited to a once-off treatment
188,189,403,404
. 
Currently, Fludase is being developed by the USA start-up biopharmaceutical company 
NexBio Research Pvt. Ltd.
405
. The serine protease inhibitor aprotinin (Trasylol), a monomeric 
globular polypeptide derived from bovine lung tissue, can be considered as a promising drug 
against the influenza virus. It was seen that aprotinin inhibits HA cleavage and replication of 
IAV H1N1 in all host systems, including human tracheo-bronchial epithelium, not inducing 
any apparent toxic side effects in these hosts. Other serine protease inhibitors, such as 
camostat, 137, and leupeptin, 138, show antiviral activity acting as suppressors of virus HA 
cleavage. They limit the reproduction of influenza viruses or target a number of host 
mediators of inflammation, by down regulating their levels in virus-infected hosts
406
. 
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However, aprotinin is a protein with unfavorable pharmacokinetics whereas camostat is a 
covalent binder; both are non-specific protease inhibitors with potential side-effects. To 
achieve agents with superior potency and safety, other ways were explored. One of these 
ways was to develop specific inhibitors of the relevant airway proteases, particularly the 
transmembrane serine protease 2 (TMPRSS2). Among these inhibitors, usually containing 
either a 4-amidinobenzylamide or a sulfonylated 3-amidinophenylalanylamide, the best 
inhibitor turned out to be compound 139, with a Ki value of 0.9 nM. Interestingly, it produced 
clear inhibition of HA0 cleavage and virus replication in cultured human airway epithelial 
cells 3 (Calu-3), which endogenously express HA0-activating proteases like TMPRSS2. An 
entirely different approach to find more potent and safe protease inhibitors that has recently 






VL-01 (ViroLogik GmbH) is an inhibitor of the 20S and 26S proteasome with antiviral 
properties against influenza virus in vitro and in vivo, having the ability to reduce influenza 
virus induced cytokines and chemokines. In particular, it reduces influenza virus replication in 
human lung adenocarcinoma epithelial cells (A549) as demonstrated with three different 
influenza virus strains, A/PuertoRico/8/34 (H1N1) (EC50 value of 1.7 µM), 
A/Regensburg/D6/09 (H1N1) (EC50 value of 2.4 µM) and A/Mallard/Bavaria/1/2006 (H5N1) 
(EC50 value of 0.8 µM). In in vivo experiments in mice VL01-aerosol-treatment results in no 
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toxic side effects, decreases progeny virus titers in the lung and enhances survival of mice 
after infection with IAV A/Puerto Rico/8/34 (H1N1) up to 50%. Furthermore, treatment of 
mice with VL-01 reduces the cytokine release of different types of interleukin, CC-





3.3.4. Pathway inhibitors 
The intracellular signaling pathways are interesting targets for the development of new anti-
influenza strategies. Among the most interesting, there are Raf/MEK/ERK, NF-κB and 




Figure 17. Involvement of cellular Raf/MEK/ERK, NF-κB, PI3K/Akt/mTOR and PKC pathways during the 
replication of influenza virus. Adapted from: Antiviral Research., 98, 457-468 (2013).   
 
The Ras-dependent Raf/MEK/ERK signaling pathway belongs to the family of so-called 
mitogen-activated protein kinase (MAPK) cascades and it is used by almost all growth factors 
and cytokines that act through receptor tyrosine kinases, cytokine receptors or G-protein-
coupled receptors. This pathway is involved in several cellular responses, such as cell 
proliferation, survival, differentiation, motility and angiogenesis
410
. Since the activation of the 
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Raf/MEK/ERK signaling pathway is essential for efficient influenza virus replication and 
virus titers are enhanced in cells that have this pathway activated, its inhibition might interfere 
with virus replication. Through the activation of the Raf/MEK/ERK signaling pathway, 
influenza virus performs the efficient export of RNPs from the nucleus into the cytoplasm, 
and so the inhibition of this cascade leads to nuclear retention of the viral RNP complexes in 
late stages of the replication cycle
44,48,411
. PD0325901, PD184352 (CI-1040) and selumetinib 
(ARRY-142886) are examples of MEK inhibitors
412
. In particular, recently, it was 
demonstrated that PD184352, 140, significantly reduces virus titers in vitro, holding viral 
RNP complexes in the cell nucleus, and it is able to reduce virus lung titers in vivo. 







Another important influenza virus-induced signaling mediator and potential target for the 
development of new antiviral drugs is the nuclear factor kappa-light-chain-enhancer of 
activated B cells (NF-κB). It controls the expression of a variety of genes involved in 
physiological responses, such as immune and acute phase inflammatory responses, cell 
adhesion, differentiation, oxidative stress responses, apoptosis and antiviral responses
414
. 
During virus infection, NF-κB is involved in the activation of caspases, leading to enhanced 
nuclear export of viral RNPs into the cytoplasm and to the regulation of viral RNA 
synthesis
415
. In 2007, Leban and co-workers found a new class of NF-kB pathway signaling 
inhibitors by virtual screening, medicinal chemistry studies and QSAR analysis; among this 
class, compound 141 possesses activity in the nanomolar range in a cell-based NF-κB reporter 
gene assay
416
. As an efficient and quite selective inhibitor of the NF-κB-activating kinase 
(IKK), acetylsalicylic acid (ASA) 142, aspirin, functions as an antiviral agent against 
influenza virus. It inhibits the replication of several influenza viruses in MDCK or A549 cells, 
in a concentration range that is not toxic for host cells, while in animal studies the aerosol 
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reduces virus titers in the lung and significantly promotes the survival of lethally infected 
mice. In contrast to the neuraminidase-inhibitor oseltamivir or the M2 ion-channel blocker 
amantadine, ASA does not lead to the generation of resistant virus variants in multipassaging 
experiments in cell culture
417
. DL-Lysine acetylsalicylate glycine (BAY 81-8781, LASAG), a 
water soluble form of acetylsalicylic acid, has antiviral properties against influenza virus. It 
was demonstrated that BAY 81-8781 is able to control influenza infection of highly 
pathogenic avian influenza virus strains in vitro and, in the mouse infection model, its 
inhalation resulted in reduced lung virus titers and protection of mice from lethal infection. 
Moreover, the treatment of mice infected with influenza virus started as late as 48 h after 




                             
 
SC75741, 143, is another nanomolar NF-κB inhibitor active against several viral strains in 
A549 and MDCK cells. It is able to protect mice from lethal influenza virus infection with an 
activity comparable to that of oseltamivir, at concentrations that do not cause adverse 
effects
419
. Mode of action studies revealed that it inhibits the caspase mediated nuclear export 
of RNPs
420
. Since the classical virus-induced activation of the NF-κB pathway requires 
proteasomal degradation of the inhibitor of NF-κB, it was hypothesized that inhibition of 
proteasomal inhibitor of NF-κB degradation should impair IAV replication. It was chosen the 
specific proteasome inhibitor PS-341 144 (bortezomib; Velcade
®
) and, as expected, PS-341 
treatment of infected A549 cells in a concentration range that was not toxic resulted in a 
significant reduction of progeny virus titers. However, the proposed suppression of NF-κB-
signaling was not observed in vitro. Rather, PS-341 treatment resulted in an induction of the 
inhibitor of NF-κB degradation and activation of NF-κB. This coincides with enhanced 
expression of antiviral genes, such as interleukin-6 and, most importantly, MxA, which is a 
strong interferon (IFN)-induced suppressor of influenza virus replication. This suggests that 
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Silymarin is a complex mixture of four flavonolignan isomers, namely silybin 145 (the major 
and most active compound), isosilybin, silydianin and silychristin, which are extracted from 
milk thistle seeds. Songa and colleagues demonstrated that silymarin possesses strong 
antiviral activity (about 98%) against influenza A/PR/8/34 virus in MCDK cells at the 
concentration of 100 μg/mL, and antiviral activity of about 45% at the concentration of 10 
μg/mL
422
. Silymarin acts against the elevated autophagy induced by IAV infection, by 
inhibiting IKK pathways together with oxidative stress, activation of extracellular signal-
regulated kinase (ERK)/p38 and mitogen-activated protein kinase (MAPK), as well as 
expression of autophagic genes. All of these components have been reported to be related to 






Among the hybrid compounds able to inhibit both virus NA and NF-kB signaling pathway, 
derivatives with a pyridinyl-quinazolinone scaffold are worth mentioning; in particular, 
compound 146 has the most potent anti-IAV (H1N1) activity in vitro with an IC50 of 51.6 µM 
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The PI3K/AKT/mTOR pathway is another signaling pathway that is activated by influenza 
virus. It is required for virus uptake and, at a later stage, for localization of RNP 
complexes
425,426
. Moreover, it supports virus replication by inhibiting premature cellular 
apoptosis
427
. Among mTOR inhibitors, the macrolide compound everolimus (RAD001), 147, 
and sirolimus (also known as rapamycin), 148, protect from infection of multiple subtypes of 
the influenza virus in vitro and in vivo. Although its antiviral activity, they have consistent 




                        
 
The inhibitors targeting PKC, a family of serine/threonine kinases involved in cell signaling, 
could be promising antiviral agents. The already mentioned resveratrol, 149, have an antiviral 
effect related to the inhibition of PKC activity and its dependent pathways
295
. In 2008, 
through the use of a high-throughput screening of biologically active compounds, Hoffamann 
and collaborators showed that influenza virus growth can be modulated both positively and 
negatively by chemical manipulation of Na
+
 transport or PKC activity. In fact, it was proved 
that the treatment with the commercially available PKC inhibitor rottlerin, 150, at a 
concentration of 12.5 µM significantly reduces influenza virus replication in A549 cells, 
while activation of PKC enhances virus production
431
. 
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More recently, it was found that the kynurenine metabolic pathway is an interesting host site 
to be targeted for the fight against influenza virus. It might provide potential avenues toward 
development of anti-influenza strategies via immunomodulatory mechanisms, and in general, 
it should be taken into account for the development of novel antiviral and antibacterial drugs. 
The kynurenine pathway is responsible for the degradation of almost all the ingested 
tryptophan not used for protein synthesis. This pathway constitutes the starting point for the 
synthesis of nicotinamide adenine dinucleotide (NAD) in mammals, and its dysregulation can 
lead to alterations in the immune system activation and accumulation of neurotoxic 
compounds. Kainov et al. found that the kynurenine pathway is altered in influenza-infected 
mice
432
 and, more recently, this metabolic pathway received increasing attention and it was 
confirmed as interesting for the development of anti-influenza agents
433
. 
Today, most of the signaling inhibitors are licensed or under clinical evaluation as anticancer 
drugs. One important point in their development as antivirals is to establish if they are suitable 
from a safety point of view. There are several differences between the use as anticancer drugs 
and as antivirals; the duration of treatment is an example: cancer therapy usually lasts at least 
two or three months, while anti-influenza treatment usually only five days. This drastic 
difference may have an impact on the incidence of adverse events and their severity. Another 
point that has to be taken into consideration is the drug dosage: the amount of the compound 
could be reduced when treating influenza, which would presumably reduce the frequency and 
severity of side effects. One way to reduce the dosage could be to combine a signaling 
inhibitor with a direct-acting antiviral, such as oseltamivir. For example, studies show that the 
association between MEK inhibitors and oseltamivir resulted in strong anti-influenza activity 
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3.3.5. Phospholipase inhibitors  
Phospholipases are enzymes that hydrolyse phospholipids into fatty acids and other lipophilic 
substances. They are divided into four major classes, termed A, B, C and D, which are 
distinguished by the type of reaction catalysed. In particular, phospholipase D (PLD), divided 
in two predominant isoenzymes PLD1 and PLD2, is involved in the formation of phosphatidic 
acid, an important messenger in cellular signaling and metabolic pathways
435
. In 2014, using 
novel synthetic compounds and biochemical approaches, the up-regulation of PLD activity 
during influenza infection was demonstrated, and evidence that PLD inhibition delays virus 
entry, allowing for a more robust innate antiviral response to be mounted in the infected host 
cell and leading to a significant reduction in viral titer. Consequently, PLD turned out to be a 
targetable host restriction factor for influenza viruses that facilitates rapid endosomal 
trafficking and escape from innate immune detection in the host cell
436
. Moreover, it was 
demonstrated that the human PLD2 inhibitor ML395, 151, possesses an interesting antiviral 







3.3.6. vRNPs inhibitors and gene therapy  
As the nuclear export of influenza virus vRNPs has been demonstrated to be mediated by host 
exportin 1 (XPO1)
438,439
, the development of inhibitors of XPO1 to interrupt this process and 
then hinder the replication cycle of the virus could be interesting. Studies performed by 
Perwitasari and co-workers showed that verdinexor, 152, a selective inhibitor of XPO1, is 
able to inhibit the replication process of several IAV and IBV strains in vitro and in vivo in a 
selective and potent way
440
. In particular, it was showed that verdinexor reduces influenza 
virus shedding and pro-inflammatory cytokines expression in bronchoalveolar lavage fluid 
and reduces inflammatory cell infiltration into the bronchoalveolar space in influenza infected 
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Gene therapy consists of modulating (up-regulating or down-regulating) genes and/or their 
products involved in the response to influenza. MicroRNAs (miRNAs) are small non-coding 
RNA molecules (about 22 nucleotides) that are able to perform RNA silencing or RNA 
interference and can regulate the expression of the viral genes in the post-transcriptional 
phase. Since host miRNAs are able to down-regulate the expression of viral genes, miRNA 
modulation could be a promising approach in influenza treatment, despite the difficulties of 
delivering these types of RNA to cells efficiently
442
. Also small interfering RNAs (siRNAs) 
(about 19-26 nucleotides) are mediators of RNA interference, since they induce sequence-
specific degradation of homologous mRNA
443-445
. Long non-coding RNAs (lncRNAs) are 
able to modulate various biological processes
446
. Ouyang et al. found that the negative 
regulator of antiviral (NRAV), a type of the IncRNA, is able to act as a negative regulator of 
antiviral response and is down-regulated during influenza infection. In particular, NRAV 






3.3.7. Immunomodulatory agents  
Inflammatory changes and other immune reactions associated with acute IAV infection may 
influence the mortality caused by influenza and can be countered by immunomodulatory 
agents. Among natural molecules, licorice triterpenoid derivatives, in particular, glycyrrhizic 
acid (or glycyrrhizin), 153, and glycyrrhetinic acid, 154, have proved to be effective to 
interfere with the early phases of influenza virus infection. In particular, these molecules act 
through the stimulation of interferon-gamma (γ-INF) production by T cells, 
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immunomodulation, anti-inflammation and reduction of virus uptake by host cells. Moreover, 
glycyrrhizic acid shows an improvement in survival time of mice after viral infection, 
suggesting that licorice triterpenoid derivatives may be beneficial for the treatment of 




              
 
Systemic corticosteroids are widely prescribed in patients with influenza in an attempt to halt 
disease progression and to improve clinical outcomes, based on the findings that marked 
elevation of pro-inflammatory cytokine levels was associated with a high mortality rate in 
severe influenza virus infections due to IAVs
452-454
. 
Except for a small number of studies
455-457
, the majority of observational studies
458-462
 have 
shown that, when administered in high dose, corticosteroids may increase the risk of mortality 
and morbidity, while, to date, the role of low dose systemic corticosteroid requires further 
evaluation
463
. Statins, among which atorvastatin, 155, are competitive inhibitors of the 
enzyme 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase (HMGCR), and commonly 
prescribed for treatment of hypercholesterolemia. Statins have anti-inflammatory and 
immunomodulatory effect (e.g. repressing the induction of major histocompatibility complex 
II (MHC-II) by interferon (IFN)-γ and subsequent T-lymphocyte activation)
464,465
 and for this 
reason could be used for the treatment of influenza
466
. There are currently no published 
human data based on randomized control trials on the acute use of statins in the management 
of severe influenza. An on-going study (NCT02056340) is evaluating atorvastatin vs placebo, 
in addition to standard care, for decreasing inflammatory markers in acute influenza. 
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Macrolide antibiotics have anti-inflammatory effects in addition to their anti-bacterial 
properties; in vitro, they show to down regulate pro-inflammatory cytokines/chemokines, 
inhibit signal transduction and adhesion molecules expression, and regulate inflammatory cell 
functions. Yeganeh and co-workers found that macrolide bafilomycin A1, 156, has disparate 
concentration-dependent effects on subcellular organelles and suppresses IAV replication. 
During this study, it has been seen that bafilomycin A1, at the very low concentration of 0.1 
nM, is able to retain the capacity to significantly impair IAV nuclear accumulation as well as 
IAV replication and release, and it does not exhibit cytotoxic effects or induce apoptotic cell 
death, based on morphological and fluorescence-activated cell sorting  (FACS) analyses
467
. 
The concanamycins are a family of macrolide antibiotics isolated from Streptomyces 
diastatochromogenes. Guinea and colleagues proved that concanamycin A, 157, is able to 
inhibit an early step of influenza virus infection at 5 nM and to completely block it at 10 nM 
in MDCK cells. The target of concanamycin A seems to be an early event in virus infection, 
although not related to virus binding to receptors or internalization. In fact, it has been seen 
that radioactive influenza virus is internalized after binding with the same kinetics and to the 
same extent in the absence or in the presence of the antibiotic, and the binding takes place 
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Other macrolides that have antiviral activities are erythromycin, clarithromycin, and 
azithromycin. The triple combination of oseltamivir, clarithromycin, and naproxen for severe 
influenza was demonstrated to be effective in one randomized control trial, but these findings 
have to be confirmed. Moreover, it is necessary to perform more studies to assess macrolide 
efficacy against influenza virus infection
463
. Apart from its clinically useful lipid-lowering 
activity, the peroxisome proliferator-activated receptor (PPAR) agonists can be useful in the 
treatment of influenza infection. There is evidence that the PPAR-α-agonist gemfibrozil, 158, 
can inhibit production of pro-inflammatory cytokines
469
, while several studies based on the 
mice model showed some anti-inflammatory effects of PPAR-γ-agonists against influenza 
virus infection, with survival advantage
470-472
. The use of PPAR agonists as anti-inflammatory 
drugs for treatment of severe influenza in the animal model should be further explored, but 




Pamidronate, 159, is a bisphosphonate used for treatment of hypercalcaemia and Paget's 
disease. It exhibited protective effects against influenza infection caused by IAV H1N1 and 
H5N1 viruses in both in vitro and in vivo models, and this effect seems to be partly mediated 
by IFN-γ
473
. Unfortunately, given the potential side effects (e.g. ocular inflammation, renal 
failure, electrolyte imbalance etc.), pamidronate-based therapy would not be a high priority 




Mycophenolic acid, 160a, or its prodrug mycophenolate mofetil (MMF), 160b, are widely 
used as immunomodulatory agents in transplant recipients and other patients with 
autoimmune diseases
474,475
. PRA showed that 160a has antiviral activity against multiple 
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clinical isolates of IAV (H1N1, H3N2, H7N9) and IBV (IC50 < 1 μM)
476
. Moreover, it was 
seen that the protective mechanism of 160b against A (H5N1) virus infection is due to 
inhibition of cellular inosine monophosphate dehydrogenase (IMPDH) with a consequent 
diminution of viral mRNA and protein expression. Furthermore, after treatment with MMF, 
expression levels of some interferon (e.g. IFN-β) and interleukin (e.g. IL-1β, IL-6) are 
substantially down regulated in MDCK cells
477
. However, more work is needed to understand 




Type I interferons (e.g. IFN-α/β) and type III interferons (IFN-λ) are important mediators of 
the innate immune response against influenza viruses
478
; their expression increases in 
response to influenza virus infection, resulting in viral restriction and activation of the 
adaptive immune response
479
. In IFN-α receptor knock-out mice, it was seen that type I IFNs 
are responsible for direct resolution of viral load and limitation of acute lung injury through 
suppression of immunopathology caused by IAV via IL-10 production
480
. Moreover, it was 
seen that low-dose IFN-α protected mice against A (H5N1) and A (H1N1) viral infection in 
vitro and in mice
481
. A study has shown that the association of IFN-λ1 with antiviral agents 
with different mechanisms of action (e.g. oseltamivir) exert a significantly greater synergistic 
effect against seasonal influenza viruses, highlighting that the use of this type of combination 
may be a potential therapy for treating infections
482
. Passive immunotherapy in the form of 
convalescent plasma or immune IVIG may be useful as an adjunct therapy for severe 
influenza, and definitive studies are on-going. The presumed functional component of both 
immune plasma and IVIG is the IgG fraction. The efficacy of other agents with potential 
immunomodulating effects, such as anti-C5a antibodies, human mesenchymal stromal cells 
(MSC), mesalazine, chloroquine etc. deserves more investigation. However, unfortunately, at 
the moment there are no immunomodulatory agents that have been conclusively proven to be 
of benefit in severe influenza
463
. 
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CHAPTER 4. Discussion. Synthesis of hybrid 3-cyano-
diphenylpyridine derivatives, pyrimidine and pyridine compounds 
as inhibitors of influenza virus RdRp PA-PB1 interaction. 
 
4.1. Previous work  
As previously said, influenza virus RdRp is essential for viral replication. In particular, the 
interaction between the C-terminal part of PA (PA-C) and the N-terminal part of PB1 (PB1-
N) is an attractive drug target for the discovery of novel anti-influenza agents. The interaction 
between PA-C and PB1-N is an innovative promising target for several reasons: first of all, it 
has a high degree of conservation among virus strains, which suggests that its inhibitors may 
be active against many viral subtypes and less prone to drug-resistance. Moreover, this 
interaction involves few amino acids and so it could be inhibited by small molecules
483
. The 
interaction between PA and PB1 subunits was structurally identified by crystallographic 
studies. He and collaborators used an IAV subtype (A/goose/Guangdong/1/96, H5N1) to 
clone PA from residues 257-716 and PB1 from residues 2-25
484
, while Obayashi and co-
workers used a human IAV subtype (A/Puerto Rico/8/1934, H1N1) to clone PA from residues 
239-716 and PB1 from 1-81
485
. The structures were determined with a resolution of 2.9 Å 
(PDB code: 3CM8) and 2.3 Å (PDB code: 2ZNL), respectively. It is worth to mention that, in 
2014 Pflug et al. published the X-ray structure of IAV H17N10 RdRp (PDB code: 4WSB), 
that comprises the whole PA in complex with PB1, PB2 and a viral RNA promoter
143
. I have 
previously described the RdRp structure that comes out from this study. In addition, studies 
on the crystal structure of PA in the absence of PB1 showed structural changes compared with 
the same structure when PB1 peptides were present, indicating plasticity of the PA-PB1 
binding interface that may be exploited in the development of novel therapeutics
486
. Liu and 
Yao analyzed and compared the two X-ray structures of PA-C bound to PB1-N (PDB code: 
3CM8 and 2ZNL) and found that only some loops of the PA portion far from the PA-PB1 
binding site are different from each other and are unable to influence the function of the PA-
PB1 binding surface. Starting from one of the two X-ray crystal structure (3CM8), they 
performed an 8 ns molecular dynamics (MD) simulation with the aim to describe the 
interaction features of the protein-protein complex. They found that the intramolecular van 
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der Waals interplays and the non-polar interactions are mainly responsible for the binding of 
PA-PB1, while polar interactions do not contribute significantly to PA-PB1 interaction. 
Through the pair interaction analysis and virtual alanine scanning, the authors identified the 
hot spots for PA and PB1. Residues Trp706, Phe710, Phe411, Asn412, Gln408, Gln670, 
Leu666, Leu640 and residues 619-623 contribute to PA binding to PB1. For PB1 binding to 




As already previously discussed, in the last years the growing interest around this new 
promising target led to the identification of a number of small molecules able to disrupt PA-
PB1 interaction. My research doctorate activity was focused on the synthesis and biological 
evaluation of novel anti-influenza agents acting as PPI inhibitors, in particular, disrupting the 
PA-PB1 interaction. My work in this field is the continuation of the project developed in 
collaboration with the University of Siena and the University of Padua. The research started 
from the identification of a benzofurazan hit compound 120, having micromolar potency in 
the inhibition of viral replication (IC50 = 5 μM). In particular, this study was performed by 
employing an ELISA-based high-throughput screening method using fluorescence 
polarization, and allowed to quickly screen a library of about 15,000 small molecules for 
antiviral activity against influenza virus strain A/WSN/33 (H1N1). In order to explore the 
chemical space around the hit structure, a library of 70 compounds was synthesized. These 







Employing a homology model built using the IAV H1N1 sequence and the two PA−PB1 
complexes templates 2ZNL and 3CM8, docking studies were performed to better understand 
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the interactions responsible for the antiviral activity. Results suggested that the residues 
Trp706, Gln408, and Lys643 are crucial for the binding of the benzofurazan derivatives to the 
PB1 binding pocket on PA, and therefore could be targeted for the design of novel PA-PB1 
interaction inhibitors. In particular, it was seen that Trp706 is involved in a π-stacking 
interaction with the molecules, Gln408 establishes an H-bond interaction with the oxygen 
atom of the furazan group and Lys643, with its amino group in the lateral chain, interacts 
electrostatically with the nitro group of the compounds
374
. As an example, the binding mode 
of benzofurazan derivative 123 is shown in Figure 18. 
 
                     
 
Figure 18. Binding mode of compound 123 to the PB1-binding pocket on PA. Carbon atoms of the compound 
are colored in pink and the amino acids responsible for the key interactions are highlighted. 
 
It is important to underline that, similar interactions were also found for other identified PA-
PB1 inhibitors 117 (AL18) and 124, previously described. As it is possible to see from Figure 
19., the analysis of FLAP docking poses of compounds 117 and 124 showed that they are 
docked in the same binding region. Seven poses out of ten showed that the aromatic moiety of 
compound 117 is involved in a π-π stacking with Trp706 and several hydrogen bonds are 
formed between the molecule and residues Gly408, Lys643 and Asn412. Regarding 
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Figure 19. FLAP best pose for 117 (on the left) and compound 124 (on the right) in  IAV PA. Flexibility of the 
Lys643 side chain was considered. 
 
Despite their good antiviral activity, benzofurazan derivatives were found to be unsuitable for 
further development because of their poor selectivity index. So, on the basis of the 
information acquired, a computational approach was used to find new scaffolds able to disrupt 
the PA-PB1 interaction. A molecular dynamic simulation was performed to identify the “hot 
spots” responsible for the interaction at the protein-protein surface. As a result, in accordance 
with previous results published by Wunderlich et al.
369
, amino acids Met1, Val3, Asn4, Pro5, 
Leu7, Leu8, Phe9 and Leu10 of PB1 were recognized as important for the interaction with 
residues on PA. Furthermore, several stable hydrogen bonds were identified at the interface, 
in particular, between amino acids Asn412, Gln408, Trp706, Arg673 and Gln670 of PA-C 
and Asp2, Val3, Asn4, Leu10 and Pro13 of PB1-N, respectively.  
Starting from the information obtained from molecular dynamic experiments, a high-
throughput docking approach was used to screen the Asinex database (703,200 molecules) in 
search of good candidates able to inhibit the PA-PB1 interaction. This screening was 
performed employing the same docking programs (Glide4, version 5.5 and GOLD
488
) and the 
same homology model previously described. But, since in 2014, after the publication of the 
manuscript by Pagano et al. regarding benzofurazan derivatives
374
, a more detailed X-ray 
structure of viral RdRp was published
143
, a comparison between the PA-C X-ray structure and 
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that build with the homology model was performed. As a result, it was seen that the two 
structures had 71.21% identity in sequence alignment and they superposed very well (RMSD 
1.09 Å), especially in the PB1-binding site region (RMSD of 0.537 Å), thus validating the 
reliability of the homology model. Since biological evaluations were performed on the IAV 
H1N1 strain and the homology model was assessed of good quality, it was used this for the 
docking simulations. As a result of the high-throughput screening on Asinex database, 115 
compounds were selected, according to the overall match between the binding modes 
proposed by the docking program and the predicted score values. Then, an ELISA protocol
489
 
was used as a biochemical method to test the virtual screening hits. From this study, 
compounds possessing a 3-cyano-4,6-diphenylpyridine nucleus were identified as weak 
inhibitors of the PA-PB1 interaction, being endowed with IC50 ranging from 80 to 180 μM. In 
particular, derivative 161, having an IC50 of 80 µM and an CC50 of 150 µM, seemed to be the 




To further extend this study, ten derivatives endowed of the same 3-cyano-4,6-
diphenylpyridine scaffold, were searched on commercial databases, bought and tested. 
Among them, molecules 162 and 163 emerged as promising compounds for further 
development, with IC50s of 30-80 μM in ELISA assay and a low cytotoxicity in preliminary 
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Remarkably, comparing the binding orientation of compound 162 with the pose previously 
identified for nitrobenzofurazan inhibitor 120, some common interactions were identified: an 
hydrogen bond with Gln408, an electrostatic interaction with Lys643 and hydrophobic 




Figure 20. Comparison of the binding orientation of compound 162 (in orange) with the pose of benzofurazan 
derivative 120 (in grey). The common interactions are highlighted. 
 
For a better understanding of the underlying SAR, starting from the 3-cyano-4,6-
diphenylpyridine scaffold, a series of derivatives was synthesized by performing modification 
or replacement of molecule portions. 
From SAR studies it was possible to obtain important information: 
- The importance of the sulfur atom in the C2 side chain. When it is removed or 
substituted with CH2, O, NH or CH=CH, a decrease of the activity is observed, 
probably due to different geometry properties of these atoms that do not allow the 
small molecule to assume a suitable conformation for correct binding. This results in a 
bad docking pose and explains the inactivity of these molecules. 
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- The optimal length of the C2 lateral chain seems to be that with only one methylene 
group. 
- The presence of a hydrophilic group at the end of the C2 side chain causes loss of the 
antiviral activity. 
- The two phenyl rings directly attached to the pyridine ring appear to be essential. 
- The removal of the cyano moiety does not affect the activity. 
- The substitution of the pyridine ring with a pyrimidine one does not affect antiviral 
activity, but seems to be responsible for a lower ability to dissociate the PA-PB1 
complex. 
In order to rationalize the SARs, all the synthesized compounds were evaluated by means of 
docking simulation within the PB1-binding site of PA, in order to produce their putative 
binding poses. Docking studies were carried out employing the homology model previously 
described and two widely used programs (Glide, version 6.2 and GOLD
488
). Then, the 
obtained binding poses of the compounds were compared. Moreover, the PA-compound 
complexes for one representative derivative for each class of compounds (168 for 
cyanopyridine, 169 for pyridine and 170 for pyrimidine) were further investigated by means 
of MD using Schrödinger Desmond, version 3.7 (Figure 21.). 
 
 
Figure 21. Structures of the molecules representative of the three major classes of compounds analyzed by MD 
studies: 3-cyanopyridine (164), pyridine (165) and pyrimidine (166). 
 
In particular, after an extensive equilibration, a 14 ns MD simulation was performed for each 
complex starting from the most representative docking pose and, for a more detailed analysis 
of the stability of the PA-ligand complexes, the interactions between the protein and the small 
molecules were investigated on the whole 14 ns simulation time. Occupancy percentages 
were also calculated (Table 1.). 
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Table 1. Ligand interaction occupancies for 164, 165, and 166 in complex with PA. 
                                                                       Occupancy (%)
















Val621(O) NH bbHB 25.10 98.36 24.97 
Gln408(HE) O scHB 22.04 97.05 14.68 
Lys643(NZ) CN or S I 56.35 6.38 25.88 
Lys643(HZ) O scHB 0.00 0.00 15.78 
Lys643 4-phenyl Pcat 74.54 31.30 3.54 
Lys643 N pyrimid. WB NA NA 46.09 
Trp706 Pyridine Hyd 35.41 65.90 50.72 
Phe411 3-Me-phenyl Hyd 16.80 15.63 27.31 
Phe 411 3-Me-phenyl PP 30.29 1.23 33.20 
Cys415 3-Me-phenyl Hyd 5.93 6.72 3.60 
Pro620 6-phenyl Hyd 4.15 0.24 0.00 
Val628 6-phenyl Hyd 3.22 0.79 3.05 
Leu666 4-phenyl Hyd 2.88 2.47 0.79 
Phe707 4-phenyl Hyd 23.69 12.61 30.02 
Phe710 4-phenyl Hyd 46.97 24.16 19.01 
Phe710 4-phenyl PP 25.77 29.66 17.75 
His713 4-phenyl PP 10.04 14.20 0.00 
 
a 
Only for hydrogen bonds and ionic contacts, the interacting atom is reported in brackets using the following 
abbreviations: O = backbone oxygen; HE = hydrogen of the side chain amide; NZ = nitrogen of the side chain 
amine; HZ = hydrogen side chain. 
b 
Type of interaction between the protein and the ligand. Abbreviations used: 
bbHB = hydrogen bond with residue backbone; scHB = hydrogen bond with residue side chain; I = ionic 
interaction; Pcat = π-cation interaction; Hyd = hydrophobic interaction; PP = π-π stacking; WB = water bridge.  
c 
Percentage of trajectory frames in which the interaction was recorded. NA = not applicable. 
 
From MD simulations it was possible to deduce that hydrogen bonds and ionic interactions 
are the most stable contacts between PA and the ligand, with occupancy higher than 60%, 
whereas in general, hydrophobic interactions are weaker. An exception is the hydrophobic 
interaction with Trp706 which is stable and important, particularly for compound 165 
(65.90% occupancy) and for compound 166 (50.72% occupancy). The ionic contact between 
Lys643 side chain amine group and the compounds is much more important in the complex 
between the protein and 164, where the interaction involves the CN group of the small 
molecule. Differently, weak ionic contacts occur between Lys643 and the sulfur atom of 165 
and 166. Lys643 side chain amine is involved in a π-cation contact with the phenyl moiety in 
C4 position of the core structure of the ligands which appears to be more stable for compound 
164, and is also involved in a water-bridge contact with one nitrogen of the pyrimidine of 
compound 166. It is worth to note that this last type of interaction is not possible for 
CHAPTER 4. Discussion. Synthesis of hybrid 3-cyano-diphenylpyridine derivatives, pyrimidine and 
pyridine compounds as inhibitors of influenza virus RdRp PA-PB1 interaction. 
PhD Thesis in Pharmaceutical, Food and Cosmetic Sciences 
Ilaria Giacchello 
107 
compounds 164 or 165. Remarkably, hydrogen bonds between the amide portion of 
compound 165 and Val621 backbone oxygen and Gln408 side chain amide hydrogen present 
occupancy values close to 100%, while the same interactions in the other PA-compound 
complexes are weaker. From the visualization of the trajectories, a change of conformation of 
compounds 164 and 166 was observed. In particular, in the PA-compound 164 trajectory, the 
interaction between the CN group and Lys643 occurred during the whole duration of the 
simulation, while the hydrogen bonds with Val621 and Gln408 broke after approximately 4 
ns. A shift of the pyridine core of 164 weakened the interaction of Trp706, placed the phenyl 
ring in C4 position in a more suitable area for the π-cation contact with Lys643, and enhanced 
the hydrophobic interactions with the areas II and III, explaining the higher occupancy values 
for these contacts (Lys643 π-cation contact and Phe707 and Phe710 hydrophobic interactions, 
in particular). Furthermore, the methyl-substituted phenyl ring lacks the constraints given by 
the hydrogen bonds involving the amide moiety of the ligands, and is able to give weak T-
shaped π-π stacking with Phe411 in the hydrophobic area I. Regarding the PA-compound 166 
trajectory, a shift of the central aromatic ring occurred after approximately 3.7 ns, similar to 
what was observed for the system containing molecule 164. Also in this case, the change in 
the binding mode weakened the interaction with Trp706, increased the hydrophobic 
interactions with the areas II and III and allowed the establishment of a weak T-shaped π-π 
stacking with Phe411. However, in this simulation Lys643 did not give a π-cation interaction 
with the phenyl moiety, but it interacted with compound 166 through a direct hydrogen bond 
(with the carbonyl oxygen) and a water bridge (with the pyrimidine nitrogen), mainly after the 
compound repositioning. Thus, in the case of 166, the water molecule has the same role of the 
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Figure 22. Superposition of the PA-compound 164 and PA-compound 166 complexes extracted after 4 ns of 
simulation. Carbon atoms of compound 164 are colored in blue; while the ones of compound 166 are in pink. 
The same color is used for protein carbon atoms. The water molecule is represented in sticks. Hydrogen bonds 
are indicated in red.  
 
So, to summarize, from docking and MD studies it was seen that:  
- The two hydrogen bonds between the amide portion of the ligands and residues 
Gln408 and Val621 seem to be important for the interaction between PA and the 
ligands, especially for pyridine derivatives. 
- When present in the ligand, a third hydrogen bond occurs between the CN nitrogen of 
the compound and Lys643 amine side chain. 
- The three phenyl rings are accommodated in three hydrophobic areas of PA indicated 
as I (Val 621, Phe411 and Cys415), II (Pro620, Val628 and His713) and III (Phe658, 
Leu666, Phe707 and Phe710). 
- A hydrophobic interaction involves Trp706 and the pyridine or pyrimidine ring of the 
ligand. 
- In the case of pyrimidine derivatives, a water bridge between the nitrogen group in the 
ring and Lys643 mimics the interaction that in cyanopyridine derivatives involves the 
CN group. 
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4.2. Synthesis of hybrid 3-cyano-diphenylpyridine derivatives 
 
4.2.1. Background 
The overlap of PB1-N in the X-ray crystallography structure of PA
143
 with the docking pose 
of the promising cyanopyridine compound 161 revealed that the cyano-pyridine core fits very 
well with a central region of PB1-N, but fails in establishing crucial interactions which are 
instead made with PA by the three terminal amino acids methionine-aspartate-valine (Met1-
Asp2-Val3) of PB1-N peptide, highlighting the need to explore the C2 side chain of the 
cyanopyridine derivatives to find more potent RdRp PPI inhibitors (Figure 23.). 
 
               
 
Figure 23. Superimposition of the crystallographic poses of PB1-N and the docking pose of compound 161. 
PB1-N is showed as grey cartoon and the last three amino acids (Met1-Asp2-Val3) are represented by sticks. 
The three amino acids of PA (Gln408, Asn412 and Ile621) that interact with the C2 chain are represented by 
green sticks and labelled. The three protein regions I, II and III are highlighted. 
 
Starting from this knowledge, I decided to synthesize a library of RdRp PPI inhibitors 
characterized by a hybrid structure constituted by the promising 3-cyano-4,6-diphenylpyridine 
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4.2.1.1. Project: synthesis of hybrid 3-cyano-diphenylpyridine derivatives bearing the 
three final amino acids of PB1 in the C2 side chain 
With the aim to enhance the ability of 3-cyano-diphenylpyridine compounds to completely 
displace PB1 and increase their affinity toward the target protein PA, I decided to synthesize 
hybrid derivatives combining the cyanopyridine core linked to the last three amino acids of 
PB1-N (Met-Asp-Val). The rational design was performed choosing the cyano-pyridine ring 
of compound 161 as the nucleus to which specific amino acids were added on the C2 side 
chain. Since the majority of the previously described virtual screening hits were characterized 
by a p-methyl group substituent on the C4 phenyl ring, this was maintained. 
I synthesized the adducts with valine, valine-aspartate and valine-aspartate-methionine methyl 
esters (compounds 167a, 168a and 169, respectively). I decided to introduce amino acids as 
esters because they are more permeable through membranes than the correspondent free 
acids
492,493
. Moreover, to confirm the hypothesis that the methyl ester derivatives could be 
hydrolyzed in cell, giving the corresponding free acids, I synthesized mono-amino acid and 




Figure 24. Structures of the synthesized hybrid compounds 167a,b, 168a,b and 169.  
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The first part of the synthetic work has been devoted to the set-up of a fast and high yielding 
procedure for the preparation of the 3-cyano-4,6-diphenylpyridine nucleus. Starting materials 
were acetophenone and p-tolualdehyde which were reacted via base catalyzed Claisen-
Schmidt-condensation reaction, affording the chalcone derivative 170
494-496
. This acts as 
Michael acceptor, and the dihydropyridine derivative 171 was obtained through a Hantzch 
type cyclization of 170 with cyanothioacetamide using sodium methoxide (MeONa) as a 
base
497
. Compound 171 was aromatized with 2,3-dichloro-5,6-dicyano-p-benzoquinone 
(DDQ), affording 2-mercapto derivative 172
498
. Then, a nucleophilic substitution with 2-
bromoacetic acid was carried out in dimethylformamide (DMF) using potassium hydroxide 
(KOH) as base, affording the cyanopyridinic core 173 (Scheme 1.). 
 
Scheme 1. Synthesis of the key intermediate 173. 
 
 
In order to obtain the mono-amino acid derivative 167a, I performed the coupling reaction 
between intermediate 173 and L-Val methyl ester, using 1-ethyl-3-(3-dimethylaminopropyl) 





, and dry N,N-diisopropylethylamine (DIPEA) in anhydrous DMF. 
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Methyl ester 167a was hydrolyzed in mild basic conditions, using 1 N sodium hydroxide 
(NaOH) solution, to get the free carboxylic derivative 167b (Scheme 2.). 
 
Scheme 2. Synthesis of mono-amino acid adducts 167a,b. 
 
 
The synthetic route to obtain the diamino acid adduct 168a is shown in Scheme 3. The L-Val-
L-Asp dipeptide 168a was synthesized in solution phase through the previous described 
amidation procedure, using L-Val amino acid protected with fluorenylmethyloxycarbonyl 
(Fmoc) group and L-Asp methyl ester. Dipeptide 174 was subjected to the cleavage of the 
Fmoc protecting group with sodium azide (NaN3). The free amine 175 was then coupled with 
acid derivative 173, furnishing the diamino acid adduct 168a. Eventually, the ester functions 
of 168a were hydrolyzed using the same basic conditions described before, affording the 
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Scheme 3. Synthesis of diamino acid adducts 168a,b. 
 
 
The synthesis of the tri-amino acid adduct 169 required the preparation of the tripeptide Val-
Asp-Met, that was performed in solid phase through the Fmoc strategy. MW-SPPS 
(microwave solid phase peptide synthesis) was conducted by using an automated peptide 
synthesizer that was charged with a Wang resin bearing the last amino acid of the tripeptide, 
L-Met, covalently linked. Prior to use, the resin was swallowed for 2 h in DMF. In addition to 
resin and solvents (DMF and CH2Cl2), the instrument was also charged with the other two 
Fmoc-protected amino acids (Fmoc-L-Asp-(OtBu) and Fmoc-L-Val), the coupling activators 
HOBt and 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate 
(HBTU), DIPEA and a deprotection solution (20% piperidine in DMF). At the end of the 
deprotection and coupling cycles, the resin-bounded tripeptide 176 was obtained. 
The cleavage of the resin was performed using a solution of trifluoroacetic acid (TFA), water 
and triisopropylsilane (TIPS) as scavengers for the reactive species produced during the 
process, and dithiothreithol (DTT) to avoid L-Met oxidation. Under these acid conditions the 
tertbutyl ester in the L-Asp lateral chain was hydrolyzed, furnishing the resin-free tripeptide 
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177 that was used directly in the next step. The methyl esterification of dicarboxylic functions 
of 177, accomplished by the treatment with a methanolic solution of freshly distilled thionyl 
chloride (SOCl2), was necessary to avoid side reactions in next steps. The reaction was carried 
out at room temperature and with controlled equivalents of SOCl2, in order to prevent the 
acid-catalyzed racemization of the L-Met stereocenter. The obtained tripeptide 178 was then 
deprotected from the Fmoc group with NaN3, furnishing the free amine 179. Intermediate 179 
was coupled with carboxylic core 173, using the amidation procedure previously described 
(EDC, HOBt and dry DIPEA in anhydrous DMF), affording the final tri-amino acid adduct 
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Scheme 4. Synthesis of tri-amino acid adduct 169. 
 
 
4.2.1.1.2. Biology: in vitro evaluation 
Amino acid derivatives 167a,b, 168a,b and 169 and intermediate 173 were tested as inhibitors 
of the PA-PB1 interaction. The in vitro biological evaluation of these compounds was 
conducted through enzyme-linked immunosorbent assays (ELISA) and plaque reduction 
assays (PRA) in Madin-Darby canine kidney (MDCK) cells infected with IAV (A/PR/8/34 
strain). In particular, the ELISA PA-PB1 interaction assay can measure the physical inhibition 
between the two subunits, providing IC50 values. This assay was performed using the PB1(1-
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, as a positive control for inhibition. The PRA evaluates the block of the viral 
replication providing EC50 values and includes oseltamivir carboxylic acid (OSV), the active 
form of oseltamivir (NA inhibitor), and ribavirin (RBV), as positive controls. Cytotoxicity, 
which is evaluated by measuring CC50 values, was assessed both in MDCK cell lines and in 
human embryonic kidney 293 cells expressing a mutant version of the SV40 large T antigen 
(HEK 293 T), by MTT assays. Moreover, to confirm the mechanism of action of these 
molecules, the ability of the most interesting compounds to inhibit IAV RdRp enzymatic 
activity in a cellular context was assessed by minireplicon assays in transfected HEK 293 T 
cells, using RBV
500
 as a reference drug, since it acts as RNA synthesis inhibitor thanks to its 
guanosine-like structure (Table 2.). 
From biological tests, compound 169 turned out to be a weak inhibitor, while more interesting 
activity profiles have been revealed for compounds 167a and 168a. Experimental data show a 
relevant discordance between the low PA-PB1 interaction inhibition and the good 
intracellular activity, but minireplicon assays confirm the on-target activity, suggesting a 
possible enzymatic hydrolysis in the cell. In fact, the biological data of free-acid derivatives 
167b and 168b seem to confirm that they are the actual responsible for the antiviral activity.  
It is worth to mention that the good results of valine adducts 167a,b are in agreement with 
experimental data previously reported by Wunderlich et al.
369
, which revealed Val3 on the 
PB1 peptide as one of the most important residues for the interaction with PA, exhibiting the 
lowest binding free energy. This suggests that its displacement could inhibit the RdRp 
heterodimerization. The intermediate 173 was also tested and it showed an interesting activity 
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Table 2. Biological results of the synthesized compounds 167a,b, 168a,b, 169 and 173 
Compound 
CC50 
























167a 210 ± 8  >250 52 ± 2 167 ± 20 41 ± 16 
167b >250 250 50 ± 7 76 ± 16 77 ± 14 
168a >250 >250 49 ± 8 143 ± 17 59 ± 18 
168b >250 ND 100 77 ± 9 ND 
169 >250 ND >100 68 ± 14 ND 
173 >250 218 ± 21 65 ± 11 56 ± 5 43 ± 14 
PB1(1-15) -
Tat peptide 
>250 >250 49.7 ± 5.1 31.7 ± 10.8 15.5 ± 2.6 
OSV >250 >250 0.015 ± 0.006 ND ND 
RBV >250 >250 12.8 ± 2.1 ND 23.8 ± 4.5 
 
ND: not determined. 
a
Activity of the compounds in the ELISA PA-PB1 interaction assay. Values represent the 
compound concentration (in µM) that reduces the interaction between PA and PB1 by 50% (IC50). 
b
Antiviral 
activity of the compounds in plaque reduction assays against the IAV A/PR/8/34 strain. Values represent the 
compound concentration (in µM) that inhibits 50% of plaque formation (EC50). 
c
Cytotoxicity of the compounds 
exhibited in MTT assays. Values represent the compound concentration (in µM) that causes a 50% decrease in 
cell viability (CC50). The CC50 were assessed in MDCK and HEK 293 T cells. 
d
The EC50 values represent the 
compound concentration that reduces by 50% the activity of IAV RNA polymerase in HEK 293 T cells. 
e
All 
values represent the means ± SD of data derived from at least three independent experiments in duplicate. 
Reference compounds are PB1(1-15)-Tat peptide, oseltamivir carboxylic acid (OSV) and ribavirin (RBV). 
 
4.2.1.1.3. Molecular modeling 
Using the GOLD program (GoldScore function)
501
, molecular docking studies on the 
synthesized compounds within the PB1-binding site of PA using the crystallographic structure 
4WSB
143
 were performed. In particular, studies were carried out to investigate the possible 
binding mode of molecules 167a,b, 168a,b, 169 and intermediate 173 within the PB1 binding 
site of PA. The 3-cyano-4,6-diphenylpyridine scaffold binds in a hydrophobic cleft of PA, 
which is known to accommodate the binding partner PB1
144
, while the peptide chain occupies 
a narrow and more solvent-exposed pocket where it establishes a network of H-bond 
interactions with key PA residues, including Gln408, Asn412, Ile621 and Glu623. Only few 
compounds are able to contact Lys635 and Glu416. Notably, all compounds show to fit the 
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Figure 25. Possible binding mode of the synthesized hybrid derivatives 167a,b, 168a,b, 169 and intermediate 
173. The crystallographic structure of PA in complex with PB1 (PDB: 4WSB) is shown as yellow lines. Ligands 
are shown as cyan sticks. Polar interactions are highlighted by grey dashed lines. Only residues within 4 Å from 
the ligands are shown; non-polar H atoms are omitted. 
 
Moreover, in order to confirm the initial hypothesis, the superposition of the docking pose of 
169 binding mode with the PB1-N fragment was performed. These studies demonstrated that 
derivative 169 is able to maintain the crucial interactions with PA and show a good overlap of 
the tripeptide region with PB1-N (Figure 26.).  
 
                                  
Figure 26. Superposition of docking poses of compound 169 and PB1-N. Ligand is showed as cyan sticks, PA 
residues are represented by green sticks while PB1-N in grey. Key interactions are highlighted. 
 
 
167a 167b 168a 
168b 169 173 
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In recent years, the viral polymerase has proved to be an important target for drug design. In 
particular, the development of small molecules able to interfere with the correct assembly of 
RdRp complex, through the inhibition of the interaction between PA and PB1, is an attractive 
goal. Starting from a rational drug design, I synthesized hybrid compounds characterized by a 
3-cyano-4,6-diphenylpyridine nucleus and the three last same amino acids of PB1-N (Met-
Asp-Val) in the C2 side chain. The biological data results highlighted a major anti-flu activity 
(EC50 in PRA) of 167a and 168a, not correlated to the low enzymatic inhibition (IC50 in 
ELISA). To better investigate this discrepancy, minireplicon experiments were performed, 
confirming the PA-PB1 interaction disruption as the main target of the compounds. Moreover, 
the hypothesis that these methyl ester derivatives could be hydrolyzed in cells was confirmed 
by the biological results of the free acid derivatives 167b and 168b, which showed a better 
IC50 when compared to that of 167a and 168a. In summary, the synthesis of these hybrid 
compounds allowed to explore the potential antiviral activity of this new class of 3-
cyanopyridine derivatives and to acquire information to guide the subsequent syntheses of 
new hybrid compounds as potential IAV RdRp PPI inhibitors.  
 
4.2.1.2. Project: synthesis of 3-cyano-4,6-diphenylpyridine derivatives bearing different 
L-amino acids methyl esters in the C2 side chain 
Encouraged by the previously described findings, I decided to investigate the effects of the 
introduction of other amino acids on the interaction between PA and PB1 subunit of RdRp, 
through the addition of different L-amino acids as methyl esters in the C2 side chain of the 3-
cyano-4,6-diphenylpyridine nucleus, synthesizing a small library of derivatives 180a-g 
(Figure 27.)
483
. L-leucine (L-Leu) (180a) and L-isoleucine (L-Ile) (180b) have been chosen 
as good hydrophobic replacement of valine, while other residues have been selected as 
representatives of all the existing classes of amino acids, to investigate the possible 
interactions of their different functions. L-histidine (L-His) (180c) and L-arginine (L-Arg) 
(180d) bear a positive charge at physiological pH, L-phenylalanine (L-Phe) (180e) and L-
tyrosine (L-Tyr) (180f) are characterized by aromatic lateral chains that can interact with the 
hydrophobic protein region I. Finally, L-glutamate (L-Glu) (180g), if hydrolyzed, bears 
negative charges that could enhance the affinity of the ligand towards the protein. 
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Figure 27. Synthesized L-mono-amino acid hybrid compounds 180a-g. 
 
4.2.1.2.1. Chemistry 
To synthesize the mono-amino acid adducts 180a-g, I used the amidation procedure 
previously described (EDC, HOBt, dry DIPEA in anhydrous DMF) to react together 
intermediate 173 and the opportune L-amino acid methyl ester (Scheme 5.). 
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4.2.1.2.2. Biology: in vitro evaluation  
Derivatives 180a-g were tested as inhibitors of the PA-PB1 interaction. As for the previously 
described hybrid molecules, the in vitro biological evaluation was conducted through ELISA 
assay (IC50 values) and PRA (EC50 values) in MDCK cells infected with IAV (A/PR/8/34 
strain), while cytotoxicity was assessed both in MDCK and HEK 293 T cell lines by MTT 
assays. For the most interesting compounds the ability to inhibit IAV RdRp enzymatic 
activity in a cellular context was assessed by minireplicon assays in transfected HEK 293 T 
cells. As before, PB1(1-15)-Tat peptide, OSV and RBV were used as positive controls.  
The results of the biological tests on the synthesized compounds are promising: apart from 
180c, none of the tested compounds are cytotoxic in MDCK and HEK 293 T cells (CC50 > 
200 µM), and many of them are endowed with good antiviral activity as disruptor of the PA-
PB1 interaction. The most promising derivative is compound 180b that has a good antiviral 
activity in infected cells (EC50 = 39 ± 2 µM in PRA) and likely acts by inhibiting the PA-PB1 
PPI, as suggested by both the ELISA (IC50 = 36 ± 3 µM) and the minireplicon assays (EC50 = 
53 ± 16 µM). It is worth to underline that, although the small difference in the side chain 
between derivatives 180b and 180a, this latest appears to have a low ability to disrupt the PA-
PB1 interaction (IC50 = 149 ± 15 µM) and to inhibit the activity in infected cells (EC50 = 97 ± 
9 µM). Regarding the other amino acid derivatives, compounds 180c,d and 180f have good 
activities in the ELISA experiments but, unfortunately, 180c is cytotoxic (CC50 =  152 ± 28 
µM in MDCK cells), while 180d and 180f does not retain the antiviral activity in cells (EC50 
> 100 µM). A particular case is the one of the phenylalanine derivative 180e that seems not to 
have affinity with PA (IC50 > 200 µM), but in infected cells is active, perhaps after the ester 
hydrolysis or through an off-target mechanism of action. At the end, the glutamate derivative 
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Table 3. Biological results of the synthesized compounds 180a-g. 
Compound 
CC50 
























180a  215 ± 28   ND 97 ± 9 149 ± 15 ND 
180b >250 229 ± 12 39 ± 2 36 ± 3 53 ± 16 
180c 152 ± 13 ND 80 ± 6 32 ± 7 ND 
180d >250 ND >100 48 ± 8 ND 
180e 240 ± 18 ND   68 ± 10 >200 ND 
180f >250 ND >100 18 ± 5 ND 
180g >250 ND >100 187 ± 14 ND 
PB1(1-15)-Tat 
peptide 
>250 >250 49.7 ± 5.1 31.7 ± 10.8 15.5 ± 2.6 
OSV >250 >250 0.015 ± 0.006 ND ND 
RBV >250 >250 12.8 ± 2.1 ND 23.8 ± 4.5 
 
ND: not determined. 
a
Activity of the compounds in the ELISA PA-PB1 interaction assay. Values represent the 
compound concentration (in µM) that reduces the interaction between PA and PB1 by 50% (IC50). 
b
Antiviral 
activity of the compounds in plaque reduction assays against the IAV A/PR/8/34 strain. Values represent the 
compound concentration (in µM) that inhibits 50% of plaque formation (EC50). 
c
Cytotoxicity of the compounds 
exhibited in MTT assays. Values represent the compound concentration (in µM) that causes a 50% decrease in 
cell viability (CC50). The CC50 were assessed in MDCK and HEK 293 T cells. 
d
EC50 values represent the 
compound concentration that reduces by 50% the activity of IAV RNA polymerase in HEK 293 T cells. 
e
All 
values represent the means ± SD of data derived from at least three independent experiments in duplicate. 
Reference compounds are PB1(1-15)-Tat peptide, OSV and RBV. 
 
4.2.1.2.3. Molecular modeling 
Similarly to what was done for the previously described hybrid compounds, molecular 
docking studies on the synthesized compounds 180a-g within the PB1-binding site of PA, 
using the crystallographic structure 4WSB, were carried out to investigate their possible 
binding mode. These studies were performed using the GOLD program (GoldScore 
function)
501
, and confirmed that the 3-cyano-4,6-diphenylpyridine scaffold binds in a PA 
hydrophobic cleft which is known to accommodate PB1, while the peptide chain occupies a 
narrow and more solvent-exposed pocket where it establishes a network of H-bond 
interactions with key PA residues. All synthesized compounds 180a-g show to fit the PB1 site 
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Figure 28. Possible binding mode of the synthesized mono-amino acid derivatives 180a-g. The crystallographic 
structure of PA in complex with PB1 (PDB: 4WSB) is shown as yellow lines. Ligands are shown as cyan sticks. 
Polar interactions are highlighted by grey dashed lines. Only residues within 4 Å from the ligands are shown; 
non-polar H atoms are omitted. 
 
Therefore, to identify the possible molecular determinants responsible for the strong 
inhibition in the ELISA assay, MD investigations on the docking-based complexes between 
PA and compounds 180e and 180f were carried out (Figure 29.). These two molecules differ 
each other only for the OH phenol group in 180f that is missing in 180e, but were notably 
different in the ELISA experiment, as 180e is inactive up to 200 µM concentration, while 
180f is a potent PA-PB1 inhibitor. Thus, they represent a suitable model system to challenge 
MD simulations. In particular, the representative docking complexes of 180e and 180f were 
solvated in a box of water molecules and were energy minimized, heated and equilibrated in 
density
502,503
 before running 250 ns of unrestrained MD simulations. Cluster analysis 
performed on the whole MD production trajectories coupled with visual inspection, clearly 
indicate that 180f is stable in the PB1 binding site, with a conformation that is highly 
consistent to that identified by molecular docking. The nitrile group of 180f establishes a H-
bond interaction with the side chain of Lys643, the two phenyl rings of the 3-cyano-4,6 
diphenylpyridine scaffold are included in a hydrophobic cleft bounded by Pro625, Phe658, 
180a 180b 180c 180d 
180e 180f 180g 
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Leu666, Trp706, Phe707, and Phe710. The peptide moiety overlaps with the crystallographic 
pose of the PB1-N
144 
and establishes a network of H-bonds. The amide bond contacts Glu623 
and Gln408 (bridged by a water molecule), that, as previously said, are crucial residues for the 
binding of PA-PB1 inhibitors. The L-Tyr side chain of 180f is accommodated in a 
hydrophobic sub-pocket of PA, where it interacts with Asn412 (bridged by a water molecule), 
Ser415 and Lys635. It is worth mentioning that these three H-bonds are established by the OH 
phenol group of 180f, which is missing in 180e. Different from the docking pose, the peptide 
moiety of 180e bends back towards the hydrophobic cleft of PA, thus assuming an 
unfavorable placement. Moreover, in this conformation, 180e is unable to establish most of 
H-bond interactions with PA key residues, with the only exception of a single H-bond to 
Lys635. So, to conclude, the different binding conformation and interaction network between 





Figure 29. Binding pose of 180f (panel A) and 180e (panel B) extrapolated from the most representative cluster 
of MD frames. The protein is shown as green cartoon, residues within 4 Å from the ligand are shown as lines, 
residues H-bonded to the ligand are shown as sticks and are labelled. Non-polar H atoms are omitted. Bridged 
water molecules are shown as red spheres, while the bulky solvent is omitted. 180e is shown as white sticks, 
180f as cyan sticks. H-bond interactions are highlighted by grey dashed lines. 
 
4.2.1.2.4. Conclusions 
The synthesis of the small library of hybrid derivatives 180a-g was planned to better explore 
the chemical space around the C2 side chain of the 3-cyano-4,6-diphenylpyridine core and to 
try to find more potent IAV RdRp PPI inhibitors. Interestingly, the modulation in C2 of the 
starting chemical structure led to an increase in the on-target activity. In particular, the best 
results were achieved with the isoleucine derivative 180b, which exhibited a good biological 
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profile with no cytotoxic behavior. Moreover, modeling simulations added further insights 
into the inhibition mechanism of these compounds.  
 
 
4.2.1.3. Project: synthesis of 3-cyano-4,6-diphenylpyridine hybrid derivatives endowed 
with an L- or D- amino acid as benzyl or methyl ester in the C2 side chain  
With the aim to further explore the mono-aminoacidic peptidomimetic side chain in C2 
position of the 3-cyano-4,6-diphenylpyridine core, I synthesized derivatives 181a-e (Figure 
30.). I introduced in C2 the same amino acids that were present in the most promising 
derivatives previously described 181a-g, exploring the effect of different conformations (D or 




Figure 30. Synthesized D or L- mono-amino acid hybrid compounds 181a-e. 
 
4.2.1.3.1. Chemistry 
The synthesis of derivatives 181a-e was performed using the condensation reaction 
previously described (EDC, HOBt, dry DIPEA in anhydrous DMF) between intermediate 173 
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Scheme 6. Synthesis of mono-amino acid methyl or benzyl ester hybrid derivatives 181a-e. 
 
 
4.2.1.3.2. Biology: in vitro evaluation 
Derivatives 181a-e were tested as inhibitors of the PA-PB1 interaction through ELISA assay. 
Their antiviral activity was measured with PRA in MDCK cells infected with IAV virus 
(A/PR/8/34 strain), while cytotoxicity was assessed in MDCK by MTT assays. PB1(1-15)-Tat 
peptide, OSV and RBV were used as positive controls. In Table 4. the biological data are 
reported. All the synthesized compounds are not cytotoxic but, unfortunately, the majority of 
them do not have a promising antiviral activity in cell (EC50 >100) and also the IC50 values 
are not so good as expected. An exception is the L-Val benzyl ester adduct 181a, that has a 
promising antiviral activity in cell (EC50 = 69.5 µM) together with a good ability to disrupt 
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181a >250 69.5 42 
181b >250 >100 153.3 ± 50.3 
181c >250 >100 181.7 ± 14.4 
181d >250 >100 161.7 ± 20.8 
181e >250 >100 98.3 ± 22.5 
PB1(1-15)-Tat peptide >250 49.7 ± 5.1 31.7 ± 10.8 
OSV >250 0.015 ± 0.006 ND 
RBV >250 12.8 ± 2.1 ND 
 
a
Activity of the compounds in the ELISA PA-PB1 interaction assay. Values represent the compound 
concentration (in µM) that reduces the interaction between PA and PB1 by 50% (IC50). 
b
Antiviral activity of the 
compounds in plaque reduction assays against the IAV A/PR/8/34 strain. Values represent the compound 
concentration (in µM) that inhibits 50% of plaque formation (EC50). 
c
Cytotoxicity of the compounds exhibited in 
MTT assays. Values represent the compound concentration (in µM) that causes a 50% decrease in cell viability 
(CC50). The CC50 were assessed in MDCK cells. 
d
All values represent the means ± SD of data derived from at 




Despite overall the antiviral activity and the ability as RdRp PPI inhibitors of these 
compounds were not as good as expected, this small library of mono-amino acid hybrid 
derivatives 181a-e allowed to extend SAR evaluations and to add to the previous knowledge 
important information in the way to find new hybrid antiviral compounds. In fact, from the 
comparison of the biological results of the three synthesized small library of hybrid 
compounds is possible to make some important SAR evaluations. For example, in the case of 
valine derivatives, it is possible to say that 167a and 181a, bearing L-Val as amino acid, have 
better antiviral activity than 181b and 181c, bearing D-Val. This is probably due to the fact 
that the L conformation allows the compound to better enter the cell than the D conformation. 
Regarding the ability to disrupt the PA-PB1 interaction, the most promising result is that of L-
Val benzyl ester adduct 181a. For L-Leu derivatives, it is possible to say that the methyl and 
benzyl ester, 180a and 181d respectively, have comparable ability to disrupt the PA-PB1 
interaction, while in the case of L-Ile derivatives, the benzyl ester 181e get worse the antiviral 
activity in cell and inhibition of the PA-PB1 interaction than methyl ester 180b. However, 
more studies are needed to go deeper in this class of hybrid compounds and to better 
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understand for example, why, despite the small difference in the lateral chain, L-Val benzyl 
ester shows a better ability to disrupt the PA-PB1 interaction than the methyl ester derivative, 
while for compound having L-Ile as amino acid in the lateral chain is the contrary.  
 
 
4.3. Synthesis of a library of phenyl pyrimidine derivatives 
 
4.3.1. Background 
Since SAR studies seem to show that the cyano group is not essential for the antiviral activity, 
and considering that it is often related to potential cytotoxicity, it was decided to remove the 
CN group in C3 position of the pyridine derivatives and to include the nitrogen atom in the 
ring. For this reason, two representative pyrimidine derivatives 166 and 182 were synthesized 
and tested (Figure 31.). The biological results on these molecules were quite promising: 166 
had a good cytotoxicity profile (CC50 > 250 µM both in HEK 293T and MDCK cells), but an 
IC50 > 200 µM. On the other hand, 182 had a good antiviral activity as disruptor of PA-PB1 
interaction (IC50 = 165 ± 18 µM), although the cytotoxicity values were not so good (CC50 of 




              
Figure 31. Structure of the two previously synthesized pyrimidine compounds 166 and 182. 
 
As previously said, another confirmation of the possibility of removing the CN group without 
affecting the key interactions between the compounds and PA subunit, came from MD 
simulation. In fact, this study suggested that the lack of the ionic contact between the CN 
group and Lys643 side chain amine is compensated by the fact that the nitrogen in the 
pyrimidine core is able to establish a water bridge that mimics the CN group. Interestingly, 
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this water molecule overlapped very well with the CN nitrogen of the 3-cyanopyridine 
derivatives, when the structures of PA-compound 164 and PA-compound 166 were extracted 
after 4 ns of MD simulation and were superposed (see Figure 22.)
491
.                                                                                                                                 
 
4.3.2. Project 
Starting from these promising results, I decided to synthesize a library of phenyl pyrimidine 
derivatives 183a-n (Figure 32.). Following a rational design process, I maintained in C2 the 
2-mercapto-N-(m-tolyl)acetamide chain that was present in the promising compound 161, and 
I explored the effect of different aromatic substituents in C4 and C6 of the pyrimidine ring. I 
introduced as substituents the phenyl group unsubstituted or p-substituted with halogens (Cl 
and F) and the 1-naphtyl group, with the aim of extending the hydrophobic interactions of the 
molecule. Furthermore, I inserted the thiophenolic ring to investigate the effect of a more 
flexible aromatic substituent on the activity. Finally, in compound 183n I decided to introduce 
an aromatic amide to explore possible new interactions with the PA key residues. Moreover, 
all of these aromatic substituents allowed to explore thoroughly the two hydrophobic areas II 
and III of the PA subunit.  
 
Figure 32. Synthesized library of pyrimidine compounds 183a-n. 
 
4.3.3. Chemistry 
Derivatives 183a-i were synthesized starting from a Suzuki reaction between 2,4,6-
trichloropyrimidine and the opportune phenyl boronic acid, in the presence of the catalysts 
palladium acetate (Pd(OAc)2) and triphenylphosphine (PPh3) and an aqueous solution of 
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sodium carbonate (Na2CO3) in tetrahydrofuran (THF), to obtain the key intermediates 184a-c. 
The reaction was carried out following published Suzuki reaction procedures
504,505 
with some 
modifications, as reported in the experimental section. From derivatives 184a-c with another 
Suzuki reaction, using 1-naphthalene boronic acid or the appropriate phenylboronic acid in 
dimethoxyethane (DME) or THF, I obtained compounds 185a-c and 185g-i, respectively. The 
reaction between intermediates 184a-c and thiophenol led to molecules 185d-f. To introduce 
the thiophenolic moiety, I used two different procedures, NaOH in water and acetone or 
sodium hydride (NaH) in anhydrous DMF, depending on the starting material. With an 
aromatic nucleophilic substitution reaction
491
 using 2-mercapto-N-(m-tolyl)acetamide, 
anhydrous potassium carbonate (K2CO3), in anhydrous acetonitrile (MeCN), under nitrogen 
atmosphere at room temperature for 5 h, I introduced the C2 lateral chain, obtaining the 
desired final compounds 183a-i (Scheme 7.). 
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Scheme 7. Synthesis of pyrimidine derivatives 183a-i. 
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Starting from 2,4,6-trichloropyrimidine, with a Suzuki reaction using two equivalents of the 
opportune phenylboronic acid
504,505
, I obtained intermediates 186a,b. The following aromatic 
nucleophilic substitution reaction with 2-mercapto-N-(m-tolyl)acetamide previously described 
led to the final compounds 183l,m (Scheme 8.). 
 
Scheme 8. Synthesis of pyrimidine derivatives 183l,m. 
 
 
For the synthesis of compound 183n, I started from a Suzuki reaction between 2,6-dichloro-4-
carboxylic acid and phenylboronic acid to get intermediate 187. The following condensation 
reaction with aniline in the presence of EDC and HOBt in anhydrous DMF, gave amide 188 
and then, the aromatic nucleophilc substitution reaction in the same condition previously 
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Scheme 9. Synthesis of pyrimidine derivative 183n. 
 
 
4.3.4. Biology: in vitro evaluation 
Pyrimidine derivatives 183a-n were tested as PA-PB1 PPI inhibitors. The in vitro biological 
evaluation of these compounds was conducted through ELISA assay on PA-PB1 complex and 
PRA in MDCK cells infected with IAV (A/PR/8/34 strain). Cytotoxicity was assessed in 
MDCK cell line by MTT assays. PB1(1-15)-Tat peptide, OSV and RBV were used as positive 
controls. In Table 5. all the biological data are reported. Derivatives 183a-c, bearing the 1-
naphtyl substituent, are not cytotoxic but are not able to inhibit the interaction between PA 
and PB1 subunits; their antiviral activity in cell is probably due to an off-target mechanism of 
action. Compound 183d shows a good ability to disrupt the PA-PB1 interaction but, 
unfortunately, its CC50 value is too low. Compounds 183e,f and amide 183n, unfortunately, 
have a cytotoxic behavior in MDCK cells and not such a good ability as PPI inhibitors. The 
most promising derivatives are compounds 183g-i, endowed with phenyl groups in positions 
4 and 6 of the pyrimidine ring. They are not cytotoxic (CC50s > 200 µM), are able to inhibit 
the interaction between PA and PB1 (IC50s between 86 and 125 µM) and to retain the antiviral 
activity in cell (EC50s between 2.8 and 45 µM). 
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183a    >250 21.1 ± 8 >200 
183b >250 >100 >200 
183c >250 14.9 ± 1.6 >200 
183d 73.3 4.6 ± 0.4 28.8 ± 1.5 
183e 16 ± 4 33 ± 4 >200 
183f 48 ± 2 16 ± 2 159 ± 29.7 
183g >250 45 ± 2 86 ± 5.3 
183h >250 2.8 ± 0.6 90 ± 30 
183i 206 ± 12 30 ± 1 125 ± 37.7 
183l >250 >100 70.8 ± 19.5 
183m >250 62.5 ± 4.3 137.5 ± 35 
183n 46.3 13 ± 10.5 125.7 ± 36.7 
PB1(1-15)-Tat peptide >250 49.7 ± 5.1 31.7 ± 10.8 
OSV >250 0.015 ± 0.006 ND 
RBV >250 12.8 ± 2.1 ND 
 
a
Activity of the compounds in the ELISA PA-PB1 interaction assay. Values represent the compound 
concentration (in µM) that reduces the interaction between PA and PB1 by 50% (IC50). 
b
Antiviral activity of the 
compounds in plaque reduction assays against the IAV A/PR/8/34 strain. Values represent the compound 
concentration (in µM) that inhibits 50% of plaque formation (EC50). 
c
Cytotoxicity of the compounds exhibited in 
MTT assays. Values represent the compound concentration (in µM) that causes a 50% decrease in cell viability 
(CC50). The CC50 were assessed in MDCK cells. 
d
All values represent the means ± SD of data derived from at 




In the field of the research and development of new RdRp PPI inhibitors, starting from 
previously done SAR studies and from the promising results from MD simulations, I 
synthesized a library of pyrimidine compounds 183a-n. I decided to remove the CN group in 
C3 of the previously synthesized 3-cyanopyridine compounds, to maintain the 2-mercapto-N-
(m-tolyl)acetamide chain in C2 and to explore different aromatic substituents in C4 and C6. 
Biological data results highlighted a major activity as RdRp PA-PB1 inhibitors for pyrimidine 
derivatives 183g-i endowed with small aromatic groups (phenyl groups), that probably can 
accommodate better in the two hydrophobic areas II and III of the PA subunit than the bulkier 
naphtyl group or the too flexible thiophenol. This new library of pyrimidine compounds 
allowed to extend SAR evaluations and to get further insights into this new promising class of 
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antiviral molecules, exploring the effect of different aromatic substituents in C4 and C6 
positions of the pyrimidine core. Moreover, it was possible to find promising IAV RdRp PPI 
inhibitors which will be a good starting point for further development. In this regard, 
molecular modeling studies to understand better the biological behavior of this new class of 
compounds are in progress. 
 
 
4.4. Synthesis of pyridine derivatives  
4.4.1. Background 
During the previously described screening work, it was synthesized also one representative 
pyridine derivative 165. This molecule showed good biological results, having a promising 
antiviral activity (EC50 = 7.3 µM), a good action as disruptor of the PA-PB1 interaction (IC50 
= 52.6 µM) and a not cytotoxic behavior (CC50 > 250 µM). For these reasons it was decided 
to get through the mechanism of action, performing the MD simulation on this molecule. As 
previously said, from this study it was seen that, although the lack of one of the nitrogen 
atoms and consequently of the interaction with Lys643 of PA subunit seen for the 
cyanopyridine and pyrimidine scaffold, stronger interactions with critical residues (Val621, 
Gln408 and Trp706, in particular) seems to be responsible for the good biological profile as 




                                                                                                           
                                                                                                           
 
Figure 33. Binding pose of 3-cyanopyridine compound 164 (orange sticks) and pyridine compound 165 (cyan 
sticks) in PA from docking studies. 
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With the aim to better explore the behavior of pyridine compounds as RdRp PA-PB1 
inhibitors, I decided to try to synthesize some pyridine derivatives 189a-g, maintaining, as 
done for the previously described pyrimidine library, the 2-mercapto-N-(m-tolyl)acetamide 
chain in C2 and exploring the effect of different substituents in C4 and C6 positions. 
Unfortunately, the last nucleophilic substitution for the introduction of the lateral acetamidic 
chain in C2 did not work in all cases, and for this reason I was only able to obtain pyridine 
derivatives 189a,b (Figure 34.). 
 
 
Figure 34. A. Pyridine derivatives planned to be synthesized 189a-g. B. Obtained pyridine compounds 189a,b. 
 
4.4.3. Chemistry 
Derivatives 189a,b were synthesized starting from a Suzuki reaction between 2,6-dichloro-4-
iodopyridine and the opportune phenyl boronic acid, in the presence of the catalysts Pd(OAc)2 
and PPh3 and an aqueous solution of Na2CO3 in THF, to obtain the key intermediates 190a-c. 
The reaction between 190a-c and thiophenol, using NaH in anhydrous DMF, led to molecules 
191a-c, while with a Suzuki reaction on intermediates 190a,b I introduced the 1-naphthalene 
moiety, obtaining compounds 191d,e. An Ullman-type reaction of aromatic nucleophilic 
substitution between intermediates 191a-e and 2-mercapto-N-(m-tolyl)acetamide, in the 
presence of anhydrous K2CO3, copper iodide (CuI) and L-proline in anhydrous DME under 
nitrogen atmosphere at reflux for 30 h
491
, gave the desired final compounds 189a,b. 
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Unfortunately, this reaction did not work for all the substrates, despite an increase in reaction 
time or different ratio of reagent equivalents (Scheme 10.). 
 
Scheme 10. Synthesis of pyridine compounds 189a,b and attempts to obtain 189c-e. 
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The attempts to obtain final compounds 189f,g started from 2,6-dichloropyridine-4-carboxylic 
acid. To prepare intermediate 193a, I performed the condensation between 2,6-
dichloropyridine-4-carboxylic acid and aniline to get amide 192a followed by the reaction 
with thiophenol; while to obtain intermediate 193b, I introduced the phenyl group using a 
Suzuki reaction followed by the reaction with aniline in the presence of EDC, HOBt in 
anhydrous DMF. Unfortunately, the last aromatic nucleophilic substitution with 2-mercapto-
N-(m-tolyl)acetamide on intermediates 193a,b did not work (Scheme 11.). 
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4.4.4. Biology: in vitro evaluation 
Pyridine derivatives 189a,b were tested as inhibitors of the PA-PB1 interaction. As for the 
previously synthesized series, the in vitro biological evaluation was conducted through 
ELISA assay and PRA in MDCK cells infected with IAV (A/PR/8/34 strain), while 
cytotoxicity was assessed in MDCK cell line by MTT assay. PB1(1-15)-Tat peptide, OSV and 
RBV were used as positive controls. Pyridine derivatives 189a,b are not cytotoxic and have a 
good antiviral activity that, especially in the case of compound 189b, seems to be strongly 
related to the ability to disrupt the interaction between PA and PB1 subunits (Table 6.). 
 

















189a >250 32.3 ± 3.2 141.3 ± 43.9 
189b >250 62.9 ± 25.2 87 ± 15.7 
PB1(1-15)-Tat peptide >250 49.7 ± 5.1 31.7 ± 10.8 
OSV >250 0.015 ± 0.006 ND 
RBV >250 12.8 ± 2.1 ND 
a
Activity of the compounds in the ELISA PA-PB1 interaction assay. Values represent the compound 
concentration (in µM) that reduces the interaction between PA and PB1 by 50% (IC50). 
b
Antiviral activity of the 
compounds in plaque reduction assays against the IAV A/PR/8/34 strain. Values represent the compound 
concentration (in µM) that inhibits 50% of plaque formation (EC50). 
c
Cytotoxicity of the compounds exhibited in 
MTT assays. Values represent the compound concentration (in µM) that causes a 50% decrease in cell viability 
(CC50). The CC50 were assessed in MDCK cells. 
d
All values represent the means ± SD of data derived from at 




With the aim to find other inhibitors of the interaction between PA and PB1 subunit of the 
RdRp and to extend SAR evaluations, I decided to try to synthesize some pyridine 
compounds. I maintained the 2-mercapto-N-(m-tolyl)acetamide chain in C2, as done for the 
previously described library of pyrimidine derivatives, exploring the effect of different 
substituents in C4 and C6 positions of the pyridine core. Despite several attempts, I was able 
to obtain only molecules 189a,b. The promising biological results highlight the pyridine 
scaffold as a promising starting point to develop other potential IAV RdRp PPI inhibitors and 
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for this reason molecular modeling studies to understand better the biological behavior of this 
new class of compounds are in progress.  
All modeling studies shown up to now have been developed in collaboration with the 
University of Siena, while biological tests have been performed in collaboration with the 
University of Padua. 
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CHAPTER 5. Discussion. Synthesis of substituted pyrazolo[3,4-
b]pyridines as potent A1 adenosine antagonists. 
 
5.1. Introduction 
Adenosine 194 is an endogenous neuromodulator which mediates its effects by interacting 
with four G-protein-coupled receptor subtypes named A1, A2A, A2B and A3. These receptors 
are distributed in a wide variety of tissues, including the central nervous system (CNS), 







The adenosine extracellular baseline physiological level is in the range 20-300 nM
508
 and is 
due to different biological processes: its extracellular production and its intracellular 
formation and transport. The extracellular production relies on the hydrolysis of adenosine 
triphosphate or diphosphate (ATP or ADP). This process is controlled by a two-step 
enzymatic reaction: the first is the conversion of ATP or ADP to adenosine monophosphate 
(AMP), thanks to the ectonucleoside triphosphate diphosphohydrolase 1 (ENTPD1) enzyme, 
the second is the hydrolysis of AMP thanks to the ecto-5’-nucleotidase (NT5E) enzyme. The 
formation of intracellular adenosine raises when the consumption of ATP exceeds its 
synthesis, leading to an increase of the AMP levels. Then, using different types of transport, 




 or through endocytosis
511 
adenosine can go out of 
the cell.
 
Normally, the physiological intracellular levels of adenosine are not high, while the 
increase of these levels is associated with pathologies. Many studies showed that some 
pathophysiological states are associated with changes of adenosine levels, making the search 
for adenosine receptor agonist or antagonist an interesting target in medicinal chemistry
512
. 
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Moreover, studies done on knock-out mice for ENTPD1 and NT5E genes and for Adora 
genes, which encode for adenosine receptors, seems to demonstrate that a long-term treatment 
with adenosine receptors (ARs) antagonists could be tolerated without serious 
consequences
513-517
. For these reasons, many ARs antagonist have been developed in the last 
decades, in particular, the A1 receptor subtype seems to be an interesting target
518
. A1AR is 
the more preserved receptor subtype among different species
519 
and is widely expressed in 
many parts of the body. A1AR activation inhibits the activity of adenylate cyclase, activates 
potassium channels, blocks calcium transient (T) channels and increases the intracellular 
levels of calcium and, due to the phospholipase C (PLC) activation, of inositol-1,4,5-
triphosphate (IP3). In particular, an excessive stimulation of  A1ARs is related to different 
pathologies, such as various forms of dementia, including Alzheimer’s disease, depression, 




Comparison of compounds belonging to different classes of antagonists highlighted that, 
despite differences in the structure, the adenosine receptor ligands show some common 
features: in general, the structures are planar, aromatic or π-electron rich and nitrogen-
containing heterocycles. The heterocycles are often 6:5 or 6:6 fused bicycles or 6:6:5 fused 
tricycles, substituted with hydrophobic moieties. Moreover, antagonists lack the ribose 
moiety, which is essential for agonist activity. Starting from caffeine and theophylline, which 
are prototypic adenosine receptor antagonists but non selective and of moderate potency
524
, 
several xanthine derivatives have been obtained. For example, compound 195a (DPCPX) and 
its analogue derivative 195b, that has a F18 on the propyl chain in N3, are potent A1ARs 
antagonists. Compound 195a is a highly potent and selective A1ARs antagonist in a rat model, 
while for human (h) A1ARs it is ten-fold less potent with a consequent reduction of selectivity 
versus the other receptor subtypes
525
. Derivative 195b is active as A1ARs antagonist both in 
vivo and in vitro with Ki values of 0.63, 1.37 and 1.26 nM in mouse, pig and human, 
respectively. This molecule, bearing a F18 atom, can be used as radio tracer because, as a 
result of its intravenous injection, it is able to accumulate in different regions of the brain, 
including the thalamus, the striated body, the cortex and the cerebellum
526
. 
Xanthine derivatives having a nitroxide group in C3 or C8 can be used as probes for electron 
paramagnetic resonance (EPR) to study adenosine receptors. Among them, compound 196 
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has a Ki value of 5.5 nM for A1ARs, 1600-fold selectivity vs A2A, more than 200-fold vs A2B, 




                              
 
Starting from the promising lead compound naxyfilline (BG9719)
528
, 197, norbornyl-
substituted lactone xanthine derivatives were developed. Among them, compound 198 shows 
high A1 binding affinity and selectivity with a Ki for hA1ARs of 6 nM and, similarly to 
BG9719, in vivo activity in rat diuresis model. Unfortunately, the poor water solubility of 
these compounds and the finding of more active molecules led to an interruption of the 




                     
 
Starting from rolofylline (KW-3902)
 530,531
, 199, Müller and coworkers synthesized a series of 
derivatives. Compound 200 has a Ki of 0.12 nM for A1ARs in rat and 0.7 nM for hA1AR 
together with a high selectivity for hA1 receptors (>>200-fold versus the other receptor 
subtypes). Compound 201, which was obtained blocking the propyl substituent in C3 position 
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With the aim to enhance water solubility, Biogen, Inc. synthesized other xanthine derivatives 
introducing more polar substituents. One of the obtained compounds is tonapofylline 
(BG9928), 202, a selective hA1ARs antagonist with a Ki of 7.4 nM and a high oral 
bioavailability in different species
533
. Unfortunately, a phase IIb clinical study showed that 






Another interesting class of A1ARs and A2AARs antagonists were synthesized from the 
cyclization of the correspondent xanthine derivatives with substituted benzylamines. With the 
variation of the substituent in N9, the affinity for A1 receptor subtype was enhanced; for 








On the other hand, many structurally different non-xanthine derivatives have been synthesized 
and studied as A1AR antagonists: they are fused polycyclic or monocyclic compounds. 
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Regarding 6:5-fused heterocyclic compounds, Novellino and co-workers synthesized a series 
of N-alkyl or N-aryl imidazo-triazine amines among which the most active A1 antagonist 






Purine derivatives are interesting A1ARs antagonists; for example, compounds 205a,b have 
Ki values of 12 nM and 22 nM, respectively, in bovine cortical membranes. Moreover, 







Among A1ARs antagonists, there are also 8-azaadenine derivatives: compound 206 has a Ki 
value of 26 nM for A1ARs in bovine cortical membranes, good water solubility (1.2 mg/nL) 
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In the class of the 2,6,8-trisubstituted purine derivatives, compound 207a (LUF5962) is a 
potent and selective A1AR antagonist (Ki = 0.29 nM for hA1ARs)
538
 and also the 1-
deazapurine analog 207b (LUF5816) shows a similar ability to act as A1ARs antagonist (Ki = 






SLV320, 208, a 7-deazaadenine derivative synthesized by Solvay Pharmaceuticals (today 
Abbott), is a potent and selective A1ARs antagonist, having a Ki value of 1.0 nM for hA1ARs. 
This molecule was tested in a phase II clinical trial in patients affected by congestive cardiac 
failure with renal disfunction
540
. Unfortunately, the studies on this molecule were stopped due 






Maemoto and colleagues synthesized a library of pyrazolo[1,5-a]pyridine derivatives as 
A1ARs antagonists. Among them, compound 209 (FR194921) is a potent and selective 
A1ARs antagonist, being endowed of a Ki = 2.90 nM and of no affinity for A2A and A3 
adenosine receptors. Moreover, pharmacokinetic studies in rats showed that it can be orally 







C in the methyl group of the piperidine ring, can be used for cerebral imaging in 




CHAPTER 5. Discussion. Synthesis of substituted pyrazolo[3,4-b]pyridines as potent A1 adenosine 
antagonists 





Tieno[3,4-d]pyridazines, that were found by chance during a study for the identification of 
new allosteric modulators of adenosine receptors, are potent A1ARs antagonists. In particular, 






Among 6:6-fused heterocycles, it has long been known that amino-substituted pyrido[2,3-
d]pyrimidindiones bind to A1ARs and A2ARs
545
; the most active compound having this 




Appropriately substituted 1,8-naphthyridine derivatives seems to be promising A1ARs 
antagonists. The most interesting is compound 212, having a Ki value of 0.15 and 300 nM in 
bovine cortical membranes and human striatal membranes, respectively, associated with a 
good selectivity for A1ARs
546,547
. 
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Among tricyclic compounds, there are pyrimido[4,5-b]indole derivatives. Molecules 213a,b 






Other important classes are that of triazine[4,3-a]benzimydazolones, such as compound 214 
which has a high selectivity and a Ki of 18 nM for bovine (b) A1ARs
549
 and 1,2,4-triazole[4,3-





                                
 
Starting from the structure of BG9928, tricyclic imidazoline derivatives were developed by 
Vu and co-workers. In particular, imidazoline compound 216 shows the most promising 
A1ARs antagonist activity (Ki = 22 nM for hA1ARs) with good selectivity over the other three 
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Synthesis, biological tests and therapeutic applications of a series of arylidenopyrimidine 
were patented for their interesting activity both on A1 and A2A receptors and their possible 
applications for the treatment of neurodegenerative disorders and other problems related to 
Parkinson’s disease. The most active compound is derivative 217, with a Ki value of 1.8 and 






Among monocyclic compounds active as A1ARs antagonists, 1,2,4-thiadiazole-benzamidic 
compounds LUF5437, 218, and VUF5472, 219, have Ki values of 7 and 20 nM, respectively, 




                      
 
Also thiazolic derivatives are potent and selective A1ARs derivatives: for example, compound 
220 has a Ki value of 18 nM for A1ARs in rat cortical membranes
557
. In 2009, the synthesis 
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2,6-Diphenyl-4-amidopyrimidine and 4,6-diphenyl-2-amidopyrimidine are two important 
classes of A1ARs antagonists. LUF5740, 221, and LUF5735, 222, are endowed with a Ki of 






The development of new ligands of the adenosine receptors is not easy because it is necessary 
to take into account some peculiar characteristics of the adenosine signal: the fact that 
adenosine and its receptors are present ubiquitously and consequently the action on these 
receptors could be responsible for a wide range of physiological and physiopathological 
functions
 
and the fact that the signal itself is very complex and so it should be possible to have 
several side effects. 
 
5.2. Background 
In this context, the research group where I worked synthesized a wide library of 4-
aminopyrazolo[3,4-b]pyridine-5-carboxylic acid esters 223, introducing various substituents 
at the N1, C4 and C5 positions of the central scaffold
560-563
. Many of these compounds turned 
out to be active as A1AR antagonists both on bovine and human receptors; some of them were 
also characterized by a good selectivity towards A1AR. The antagonistic action was 
demonstrated by monitoring the conversion, catalyzed by adenylate cyclase, of [R32P]-ATP to 
[R32P]-cAMP. In particular, the ability of the antagonists to block the inhibition of adenylate 
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cyclase induced by the A1 adenosinic agonist N6-cyclohexyl-adenosine (CHA) and therefore 




The most potent and selective compounds turned out to be those that had in N1 the 2-chloro-
2-phenylethyl chain. In particular, compound 223a, having a phenyl ethylamine chain in C4 




Starting from these promising results, a second generation of A1ARs antagonists was 
synthesized, maintaining the 2-chloro-2-phenylethyl chain in N1 and exploring different 
substituents in C4 and C5. The most active compounds of this series were derivatives 223b 
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Moreover, the racemic mixture of compound 223b was separated into the correspondent 
enantiomers. Enantiomer R turned out to be seven times more active than enantiomer S, with 
Ki values of 3.5 and 24 nM for bA1AR and of 31 and 435 nM for hA1AR, respectively. 
Thanks to the synthesis of a small library of analogs, it was noticed that the introduction of 
halogens (F, Cl, Br) in the para position on the phenyl group on the N1 lateral chain, 
determined the maintenance of the affinity for bA1ARs, while caused a strong diminution of 
the affinity for hA1ARs. For example, derivative 223d showed a Ki value of 8.0 nM for 




To investigate the binding interaction of these compounds, a model of the bA1AR was 
generated using the crystal structure of bovine rhodopsin (1L9H, 2.6 Å resolution)
564
 as the 
template. The bA1AR model was built applying a homology modeling procedure, which takes 
into account the flexibility of the receptor, considering a large number of its conformations. In 
particular, the sequence alignment was studied on several adenosine receptors and was guided 
by the highly conserved amino acid residues, including asparagine N1.50, the LA-AD (L2.46, 
A2.47, A2.49, and D2.50) and D/ERY (D/E3.49, R3.50 and Y3.51) motif, the highly 
conserved tryptophan W4.50, the two prolines P4.59 and P6.50, and the NPXXY motif in the 
transmembrane domain (TM) 7 (N7.49, P7.50, and Y7.53)
565
. On the basis of this alignment, 
the bA1AR model was built, subjected to a Modeller program
566
 and then, refined by means of 
a 2-ns MD simulation. In particular, the binding site of the ligands, defined by taking into 
account interaction of retinal in the X-ray structures and the major mutagenesis data, was 
individuated in the region between TM3, TM5, and TM6
567
. The hypothetical binding site 
was then subjected to a simulated annealing protocol by means of the Modeller program to 
obtain 500 conformations of the receptor that were then clustered and 42 representative 
conformations were extracted. Both R and S enantiomers of compound 223b were docked 
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into the 42 receptor models using the GOLD software
501
. Docking results were filtered on the 
basis of the interaction of the two enantiomers with L3.33(88), T3.36(91), Q3.37(92), and 
H6.52(251), which are the main residues that a mutagenesis study
567
 suggested to be 
important. From this study, it was seen that the pyrazolo-pyridine scaffold of the R-223b 
enantiomer interacted with T3.36(91), the ester chain formed a hydrogen bond with 
Q3.37(92), the 2-chloro-2-phenylethyl group interacted with H6.52(251) and the p-
methoxyphenyl substituent was stabilized by the lipophilic interaction with L3.33(88). The S 
enantiomer showed a disposition very similar to that observed for the R enantiomer with only 
a slightly different disposition of the 2-chloro-2-phenylethyl side chain. The two ligand-
receptor complexes were then subjected to 1.3 ns of MD simulation in a fully hydrated 
phospholipid bilayer environment. From MD simulation it was possible to see that the 
pyrazolo-pyridine nucleus of R-223b interacted with a lipophilic cleft delimited by 
F5.43(185), V5.47(189), L6.51(250) and W6.48(247). The hydrogen bond with T3.36(91) 
was maintained. The ester chain interacted with Q3.37(92) and formed an intramolecular 
hydrogen bond with the amino group at C4. The terminal methyl substituent of the ester chain 
was inserted in a cleft limited by L3.33(88), M5.38(180), V5.39(181), N5.42(184) and F5.43 
(185). The p-methoxyphenyl substituent at C4 showed lipophilic interactions with A3.29(84), 
L3.33(88), I167, M177, and V5.39(181), and the methoxy group formed a hydrogen bond 
with N147. Finally, the 2-chloro-2-phenylethyl mainly interacted with V5.47(189), 
F5.43(185) and H6.52(251). Compound S-223b displayed a very similar disposition of the 
central scaffold. The ester and p-methoxyphenyl substituents showed all the above described 
interactions, whereas the 2-chloro-2-phenylethyl moiety had a different disposition, 
interacting with L248 and H251, and lacking the lipophilic interactions with V5.47(189) and 
F5.43(185). The lacking of these latest lipophilic interactions should be the explanation of the 
fact that enantiomer S turned out to be seven times less active than enantiomer R (Figure 
35.). 
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Figure 35. Minimized structures of the average of the last 800 ps of the MD simulation of R-223b (A) 
and S-223b (B). Carbon atoms of enantiomer R are coloured in green, while the ones of enantiomer S 
are coloured in light blue. Aminoacid residues are represented with grey sticks. 
 
The most promising bA1AR antagonists were also tested for their affinity toward the hA1AR. 
From the analysis of the bovine/human A1AR affinity profile of new and previously 
synthesized compounds, the 2-chloro-2-phenylethyl substituent seemed to be allocated in a 
more flexible or larger cavity in the bA1AR which also allowed the interaction of para-
substituted phenyl rings. Similarly, various substituents on the ester chain are tolerated by 
bovine receptor, while restricted steric characteristics are required for high hA1AR affinity. 
Moreover, the difference in affinity toward hA1AR shown by the two enantiomers is much 
larger than that shown towards bA1AR, in agreement with a hypothesized larger cavity for the 
latter
563
. These observations, combined with computational studies previously carried out by 
other research groups
547
, confirmed the hypothesis that bA1AR and hA1AR could be 
characterized by a different dimension of their binding site. In particular, hA1AR seem to 
contain a binding pocket smaller than that of bA1AR. 
 
5.3. Project 
Starting from the results previously described, I decided to synthesize two small libraries of 4-
aminopyrazolo[3,4-b]pyridine-5-carboxylic acid ester derivatives. These two series of 
compounds have in C5 of the pyrazolo-pyridine scaffold the ethyl ester chain, while in C6 
there are different substituents. Compounds 224a-g are characterized by a 2-chloropropyl 
chain in N1, while 225a-g have the bulkier 2-phenylpropyl chain. Since, as already said, 
A B 
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previous studies indicated that hA1AR contains a binding pocket smaller than that of bovine 
receptors, the aim of my work was that of obtaining more potent and selective antagonists for 




Figure 37. General structure of the synthesized library of 4-aminopyrazolo[3,4-b]pyridine-5-carboxylic acid 
ester derivatives 224a-g and 225a-g. 
 
5.4. Chemistry 
The synthesis of these two library of compounds was obtained using a synthetic procedure 
previously published
563,568
. The reaction of hydrazine monohydrate with methyloxirane at 
reflux for 15 min
 
(Method A) or with 1-bromo-2-phenylpropane in absolute EtOH at reflux 
for 24 h (Method B), gave 1-hydrazino-propan-2-ole (226a) or 1-hydrazino-2-phenypropane 
(226b), respectively. Then, intermediates 226a,b were treated with ethyl(ethoxymethylene) 
cyanoacetate in absolute EtOH at reflux, to give the pyrazolo derivatives 227a,b. The ester 
group of these intermediates was hydrolyzed using NaOH, giving compounds 228a,b; then, in 
order to obtain intermediates 229a,b, the carboxylic group was eliminated by thermal 
decarboxylation at 150 °C, without solvents. The successive reaction with diethyl 
ethoxymethylenemalonate at 120 °C for 2 h gave compounds 230a,b. The pyrazolo[3,4-
b]pyridine scaffold was obtained treating intermediates 230a,b with phosphorous(V) 
oxychloride (POCl3) at reflux for 18 h, giving compounds 231a,b. Finally, a reaction of these 
last molecules with appropriate amines in anhydrous toluene at room temperature for 48 h 
(Method C) gave the desired compounds 224a-f and 225a-g,  while the reaction with aniline 
in absolute EtOH at reflux for 5 h (Method D) allowed to get compound 224g. (Scheme 12.). 
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5.5. Biology: in vitro evaluation 
Compounds 224a-g and 225a-g were tested for their affinity towards hA1ARs stably 
expressed in chinese hamster ovary (CHO) cells and towards bA1ARs in cortical bovine 
membranes. In details, the activity was evaluated measuring the capacity of compounds to 
displace the radio ligand [
3
H]DPCPX from A1ARs. Compounds were dissolved in 
dimethylsulfoxide (DMSO) and diluted in a buffer solution so that the DMSO did not exceed 
2% and tested at concentration of 100 and 10 nM; for molecules that showed interesting 
percentage of binding inhibition at 10 nM, a dose-response plot was built, so obtaining IC50 











or % of inhibition 
bA1AR 
Ki (nM) 
224a C4H9 52.3 ± 8.4 ND
a 
224b CH2C6H5 387.6 ± 35.9 654.2  ± 59 
224c CH2CH2C6H4-2F 764.6 ± 29 ND 
224d CH2CH2C6H4-3F 383.9 ± 37.1 ND 
224e CH2CH2C6H4-4F 851.4 ± 22.9 ND 
224f CH2CH2C6H4-4OCH3 678.1 ± 71 ND 
224g C6H5 57 ND 
 
225a CH2CH2C6H5 231.9 ± 0.2 5.65 ± 0.62 
225b CH2CH2C6H4-4Cl 61 ND 
225c CH2CH2C6H4-2F 37 3.71 ± 0.36 
225d CH2CH2C6H4-3F 59 27.4 ± 2.63 
225e CH2CH2C6H4-4F 4195 ± 2.15 2.43 ± 0.26 
225f CH2CH2C6H4-4OCH3 57 2.05 ± 0.07 
225g CH2CH2C6H4-4CH3 62 ND 
 
a ND = not determined 
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Tests showed that compounds 224a-g, with the less bulky 2-chloropropyl chain in N1, are 
endowed with improved activity on hA1AR. In particular, the most active compound is 224a, 
having in C4 a butilammine chain, less bulky and more flexible than other substituents in 
224b-g. On the other hand, compounds 225a-g, having in N1 a 2-phenylpropyl chain, showed 
good affinity for bA1ARs and, as expected, they are less active on hA1AR. Among this series 
of derivatives, the most active compound is 225f, which has a 4-methoxy-phenylethylammine 
chain in C4, having a Ki value of 2.05 ± 0.07 nM for bA1ARs. It is worth to mention that the 
biological results on the synthesized compounds that were tested both on bA1AR and hA1AR 
confirmed the hypothesis of a smaller binding site for hA1AR. For example, compound 224b 
shows more affinity for hA1AR than for bA1AR (387.6 vs 654 nM) or compound 224e has a 
Ki value of 851.4 nM for hA1ARs while its analog 225e has a Ki of 4.2 µM for the same 




Because of A1AR stimulation plays a central role in a lot of pathologies, the discovery of 
human A1 selective antagonists is very significant. With this work it was possible to enrich 
our library of A1 antagonists belonging to the class of pyrazolo[3,4-b]pyridines, to extend 
SAR evaluations and, importantly, to confirm that the binding site of the hA1AR is smaller 
than that of the bA1AR. In the complex, the synthesized compounds represent a step forward 
in the research for active compounds on A1AR, a field that was not so much explored but that 
could lead to interesting results in therapy thanks to a modulatory effect on target tissues. 
Docking studies and biological tests have been developed in collaboration with the University 
of Pisa. 
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CHAPTER 6. Discussion. Enantioselective Pd-catalyzed C-H 
activation reactions and related topics. 
 
6.1. Introduction 
During the third year of my PhD, I spent three months at the Department of Organic 
Chemistry at the University of Basel, within the research group of Prof. Dr. Olivier Baudoin. 
The research of this group is focused on the development of step-economical transition-metal-
catalyzed methods for the functionalization of non-activated C-H bonds, employing catalysis 
by palladium(0) complexes. Transition-metal catalysis has recently emerged as a powerful 
tool to functionalize otherwise unreactive C-H bonds. Moreover, using this type of reaction it 
is possible to create a variety of carbon-carbon and carbon-heteroatom bonds. In this context, 
several groups have synthesized fused carbocycles and heterocycles by intramolecular Pd(0)-
catalyzed reactions, and recently the attention has been directed toward the development of 
asymmetric versions of these reactions
570
. The literature on this topic is very broad; below I 
will mention just a few examples. Regarding the C(sp
3
)-H activation, interesting examples 
were reported by the groups of Kündig, Kagan and Cramer. They showed the highly 
enantioselective synthesis of fused indolines through the activation of methyl or methylene C-
H bonds using chiral N-heterocyclic carbene (232) or phosphine (233 and 234) ligands
571-573
, 
while Cramer and co-workers described the enantioselective arylation of cyclopropane C-H 
bonds using chiral phosphoramidites 235
574
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Scheme 13. Some enantioselective Pd(0)-catalyzed C(sp
3
)-H activation reactions and the 







In the field of C(sp
3
)-H activation, Baudoin and co-workers performed the diastereo and 
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Scheme 14. Diastereo and enantioselective synthesis of fused cyclopentanes performed by 
Baudoin and co-workers. 




)-H activation reactions, Cramer and co-workers demonstrated a mild 
intramolecular direct arylation of vinyl triflates for the synthesis of indanes with quaternary 
stereocentres. This reaction proceeds with excellent enantioselectivities at room temperature, 
thanks to the use of tailored taddol-based phosphoramidite ligands (237) in combination with 
highly polar solvents
576
. Other examples of C(sp
2
)-H arylation are reactions furnishing P-
chiral phosphorous compounds in good yields and stereoselectivities, using taddol-based 
phosphoramidite ligands (238 and 239), described in 2015 by Liu and collaborators and Lin 
and co-workers
577,578
 (Scheme 15.). 
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Scheme 15. Some enantioselective Pd(0)-catalyzed C(sp
2
)-H activation reactions and the 
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More recently, He and collaborators developed a Pd-catalyzed intramolecular C-H cyclization 
reaction for the enantioselective construction of indole-based atropoisomers, using a modified 
taddol-phosphoramidite ligand 240
579
, while Cramer et al. showed enantioselective Pd(0)-
catalyzed C−H functionalizations of ketene aminal phosphates at room temperature. These 
reactions provided isoindoline scaffolds with high enantioselectivity, thanks to the use of an 




Very recently, the same group of researchers developed a Pd(0)-catalyzed C-H 
functionalization method for the synthesis of chiral 1H-isoindoles bearing quaternary 
stereogenic centres, by using phosphordiamidite ligands 242. This procedure allowed to 
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Scheme 16. Some more recently published enantioselective Pd(0)-catalyzed C(sp
2
)-H 
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Pd(0)-catalyzed C-H activation as well as C-C coupling reactions, proceed through a catalytic 
cycle that starts from an oxidative addition, continues with the C-H activation and finishes 
with a reductive elimination by which the product is formed and the Pd(0) species replaced. 
The enantiodetermining step of this cycle is usually the C-H activation, when the ancillary 
ligand and the base performing the C-H bond cleavage are all coordinated to the palladium 
center in the transition state. In particular, a simplified general catalytic cycle for 
intramolecular C(sp
3
)-H arylation from various aryl and heteroaryl chlorides is proposed in 
Figure 37. The oxidative addition of the aryl chloride A to Pd
0
/trialkylphosphine (PR3) 
followed by exchange of the chlorine ligand for carbonate (Y=O
-
) or pivalate (Y = tBu) gives 
rise to Pd(II) complex C. From complex C, the base-induced concerted demetalation-
deprotonation (CMD) mechanism effects the intramolecular C-H bond cleavage to furnish 





Figure 37. General intramolecular Pd(0)-catalyzed C(sp
3
)-H arylation mechanism. [Pd] = Pd-PR3 complex; Y = 
tBu or O
-
; Z = no atom, CR2, N-R, O, or C=O. Adapted from: J. Am. Chem. Soc., 132 (31), 10706-10716 (2010). 
 
Apart from a palladium source, Pd(0)-catalyzed reactions need a ligand and a base to be 
performed. In particular, their enantioselective version relies on the use of a chiral ancillary 
ligand and/or a chiral base. Until now, phosphine, phosphoramidite, phosphonite and N-
heterocyclic carbene have been used as chiral ancillary ligands, while carboxylate and 
phosphate as chiral bases
570
. 
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In the context of enantioselective Pd(0)-catalyzed reactions, it would be very interesting to 
use a bifunctional molecule in which both ancillary ligand and base are present. Such a 
bifunctional ligand would possess a more organized structure, compared to the corresponding 
bimolecular system, and might be applicable to several types of asymmetric C-H activation 
reactions operating by a similar mechanism. Baudoin and co-workers are working on this 
topic
583
. In particular, they are interested in the development of a bifunctional molecule that 
can act as ligand and as base at the same time, to use it in enantioselective Pd(0)-catalyzed C-
H activation reactions. This compound will be described in details in the following section. 
The model reaction for the optimization of the catalyst transforms the substrate into a 
fluoradene derivative. Fluoradenes seem to be key intermediates for the synthesis of 
buckybowls that can be considered as fragments of fullerenes, having five- and six-membered 
rings and a curved surface. Buckybowls are interesting compounds for their several possible 




So, to summarize, the work of Baudoin and collaborators has demonstrated that starting from 
an achiral precursor 243 and using an enantioselective C-H arylation reaction with appropriate 
conditions, ligand and base, it is possible to obtain fluoradene derivatives 244. From the 
obtained fluoradenes, with a second transition-metal catalyzed cyclization, it should be 
possible to obtain interesting enantioenriched buckybowl systems 245 (Scheme 17.).  
 
Scheme 17. General outlook of the synthesis of enantioenriched fluoradene derivatives 244 
and their possible application to obtain buckybowl systems 245. 
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In this context, the work that I have done during my three-months internship within Baudoin’s 
group is related to different aspects linked to C-H activation reactions, and could be divided 
into three main topics:  
- Synthesis of the key intermediate to get the binaphtyl bifunctional ligand 
- Enantio and racemic C-H activation reactions 
- Attempts to obtain new substrates 
 
6.3. Project: synthesis of the key intermediate to get the binaphtyl bifunctional ligand  
As previously said, the enantioselective C-H activation reactions to obtain enantioenriched 
fluoradene derivatives need, in addition to a palladium source, in particular, 
tris(dibenzylideneacetone)dipalladium(0)-chloroform adduct (Pd2(dba)3·CHCl3), a chiral 
ligand 246. Moreover, the chiral ligand is a phosphine-carboxylate ligand having a binaphthyl 
scaffold which incorporates both the phosphine and the carboxylic acid moiety. Through 
optimization studies of the aryl groups on the phosphine it was established that the best 
enantioselectivity on the catalysis (enantiomeric ratio (e.r.) of 85:15 by chiral HPLC analysis) 
is achieved when they are substituted with two methyl group in the meta positions; other 
interesting aspects yet to be deeply investigated are the possible effect of different groups on 
the binaphtyl scaffold (R) (by now, methyl and phenyl substituents have been introduced) and 
the optimal length of the linker (n) (Figure 39.).  
 
                                  
Figure 39. General structure of the phosphine-carboxylate bifunctional ligand 246 and the proposed mechanism 
of action during CMD step. 
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6.3.1. Chemistry  
Starting from the opportune in-house binaphtyl derivative, obtained from the commercially 
available binol through some methylation and bromination/debromination steps, I synthesized 
compound 247, which will be useful as starting material to get the opportune chiral ligand. I 
stopped my reaction route at intermediate 247 because, before going on, it was necessary to 
establish the optimal length of the carboxylic lateral chain. I started from a Suzuki reaction on 
the binaphtyl derivative using phenylboronic acid in the presence of barium hydroxide 
octahydrate (Ba(OH)2·8H2O) and tetrakis(triphenylphosphine)palladium(0) ((Pd(PPh3)4) in 
order to introduce the phenyl moiety on the binaphtyl scaffold, obtaining intermediate 248. 
The treatment of compound 248 with boron tribromide (BBr3) followed by the reaction to 
introduce the triflate group, allowed to obtain first compound 249, and then intermediate 250. 
With a palladium-catalyzed reaction, using Pd(OAc)2, 1,4-bis(diphenylphosphino)butane 
(Dppb) and DIPEA, I introduced the phosphine moiety and, after the treatment of 
intermediate 251 with 3 M NaOH, I obtained the desired final compound 247 (Scheme 18.). 
Some of the previously described reactions were carried out following published 
procedures
586
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Scheme 18. Synthetic route to obtain compound 247. 
 
 
6.4. Project: enantio and racemic C-H activation reactions 
Starting from two in-house substrates, I performed some C-H activation reactions. I 
synthesized racemic and enantioenriched derivatives of both compounds 252 and 253 using 
two different procedures (Figure 40.). I obtained derivative 252 in racemic and 
enantioenriched form (e.r. 77:23 by chiral HPLC analysis), while, unfortunately, compound 
253 turned out to be unstable on silica, probably due to the cleavage of the methoxy group 
(seen from GS-MS) favored by the presence of the oxygen in the ring, and so no further 
analyses were possible.  
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For the synthesis of racemic compounds 252a and 253a, I used tricyclohexylphosphine 
tetrafluoroborate (PCy3·HBF4) and palladium acetate (Pd(OAc)2) as catalysts, cesium pivalate 
(C5H9O2Cs), Cs2CO3 and 4 Å molecular sieves (MS) in anhydrous xylenes at reflux for 16 h. 
To obtain enantiomeric compounds 252b and 253b, I used Pd2(dba)3·CHCl3 adduct, the 
bifunctional ligand 250a, Cs2CO3 and 4 Å MS in anhydrous and degassed DME at 140 °C for 
24 h (Scheme 19.). For compound 252b, e.r. was 77:23, while, unfortunately, compound 
253b turned out to be unstable on silica, and was lost during purification, probably for the 
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6.5. Project: attempts to synthesize new substrates 
Until now, the substrates for the Pd-catalyzed C-H activation reactions have been 




Figure 41. The three main substrates used for C-H activation reaction until now. 
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To explore better this type of reactivity, it would be interesting to try the enantioselective 
reactions on benzylic position. It is worth to underline that this time the C-H activation should 
take place on C(sp
3
) and not on C(sp
2
) as before. The second part of my research work was 
devoted to try to develop a high-yield route for the synthesis of new substrates 254b, 255b 




Figure 42. New compounds to be synthesized as substrates for C-H activation reactions 
 
6.5.1. Chemistry 
Unfortunately, despite many attempts, I had some problems to get the desired final products 
(see Schemes 20-23 below). For the synthesis of compound 254b, after the first step, I was 
not able to hydrolyze the stable immine which I obtained; the route for the synthesis of 
compound 255b allowed to obtain in high yield an intermediate different from the desired 
one, while in the case of the synthesis of substrate 256b, the problematic step was the final 
cyclization. Since in the literature there is an example of this type of reaction with a substrate 
having four hydroxyl groups instead of two, I decided to plan another synthetic route to try to 
obtain substrate 256c (Scheme 23.), which, for the purpose to try C-H activation reactions, is 
equivalent to substrate 256b, but unfortunately, also in this case, the final step did not work. 
In more detail, the attempt to obtain the final compound 254b started with a Friedel-Crafts 
reaction between m-toluidine and o-tolunitrile using boron trichloride (BCl3) and aluminum 
chloride (AlCl3) in anhydrous toluene, in order to get the stable immine 257
587
. At this point, 
despite many different conditions tried (hydrolysis under different acidic conditions), I did not 
obtain the desired intermediate; also the attempt to do a Pd-catalyzed hydrogenolysis did not 
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Scheme 20. Attempt to obtain substrate 254b.  
 
 
The attempt to obtain the final compound 255b started from a Diels-Alder reaction between 
dimethylfuran and maleic anhydride followed by treatment of the endoxide 258 with 
concentrated H2SO4, to get intermediate 259
588
. The reaction between compound 259 and the 
in-situ prepared Grignard 260 gave intermediate 261
589
. The following treatment of 
compound 261 with zinc in the presence of 10% NaOH
 
allowed to obtain lactone 262, instead 
of the desired intermediate
590
 (Scheme 21.). 
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Scheme 21. Attempt to obtain substrate 255b. 
 
 
To obtain the desired final compound 256b, I started from the reaction between 2-amino-6-
methylbenzoic acid and sodium nitrite (NaNO2) in the presence of 25% H2SO4, leading to 
intermediate 263
591
. The benzylation of 263, using benzyl bromide and tetrabutylammonium 
bromide
592
, allowed to obtain the disubstituted compound 264, and after the treatment with 
NaOH and lithium hydroxide (LiOH), I got the desired intermediate 265. The benzylation on 
m-cresol, performed with benzyl bromide and K2CO3 in anhydrous DMF, gave intermediate 
266
593
. With a Friedel-Crafts acylation between 265 and 266, in the presence of TFA and 
trifluoroacetic anhydride (TFAA) I obtained compound 267, and then with a Pd-catalyzed 
hydrogenation, I got intermediate 268. At this point, despite different conditions tried, the 
final reaction to obtain compound 256b did not work (Scheme 22.). 
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Scheme 22. Attempt to obtain substrate 256b. 
 
 
As previously said, since in literature there is one example of the final cyclization on a 
substrate that has more than two hydroxylic groups
594
, I decided to try to synthesize 
compound 256c. I started from a Vilsmeier reaction on orcinol in order to introduce the 
aldeidic function and get intermediate 269. The subsequent benzylation allowed to obtain 
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compound 270 and after a Pinnick oxidation using sodium chlorite (NaClO2), sodium 
dihydrogen phosphate (NaH2PO4) and 2-methyl-2-butene as a scavenger, I got compound 271 
in a quantitative yield. With a direct benzylation on orcinol I obtained intermediate 272. A 
Friedel-Crafts acylation between 271 and 272 gave molecule 273, and then a Pd-catalyzed 
hydrogenation allowed to obtain compound 274. But at this point, unfortunately, also in this 
case, the final reaction did not work (Scheme 23.). 
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Scheme 23. Attempt to obtain substrate 256c. 
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During my three months of internship at the Department of Organic Chemistry at the 
University of Basel, I worked in the Prof. Dr. Baudoin’s research group on projects related to 
Pd(0)-catalyzed reactions. I synthesized a key intermediate to obtain the innovative 
bifunctional ligand to employ in enantioselective Pd(0)-catalyzed C-H activation reactions. 
Some of these reactions were performed in order to obtain new compounds both in racemic 
and enantioenriched form. I also attempted to develop high-yield synthetic routes to get new 
substrates to employ in these reactions. 
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CHAPTER 7. Experimental section  
Starting materials were purchased from Merck-Sigma Aldrich (Milan, Italy), Alfa Aesar 
(Lancashire, United Kingdom) and Fluorochem Ltd. (United Kingdom). Melting points (Mp) 
were determined with a Büchi B-540 apparatus and are uncorrected. 
1
H-NMR spectra were 
recorded in a CDCl3, CD3OD or DMSO-d6 solution using a Bruker Avance DPX400 (400 
MHz), Adavance 500 (500MHz) or a Varian Gemini 200 (200 MHz). Chemical shifts are 
reported as δ (ppm) relative to TMS as the internal standard, coupling constant (J) in hertz 
(Hz) and integration. 
1
H patterns are described using the following abbreviations: s = singlet, 
d = doublet, t = triplet, q = quartet, m = multiplet and/or multiplet resonances and br = broad. 
IR spectra were measured in KBr or CHCl3 with a Perkin-Elmer 398 spectrophotometer. 
13
C-
NMR spectra were recorded at 100 MHz on a Bruker AC200F. Microwave reactions were 
conducted using a CEM Discover Synthesis Unit (CEM Corp., Matthews, NC). GC-MS 
analyses were performed with a Shimadzu QP2010SB GCMS apparatus on a Rtx
®
-5ms-Low-
Bleed column lined with a mass (EI) detection system. Mass spectra (MS) data were obtained 
using an Agilent 1100 LC/MSD VL system (G1946C) with a 0.4 mL/min flow rate using a 
binary solvent system of 95:5 methanol/water. Mass spectra were acquired in positive mode 
scanning over the mass range 105-1500 m/z, using a variable fragmentor voltage of 10-70 
mV. LC was performed using an LC-20AD liquid chromatograph. HPLC analyses were 
performed using a Shimadzu Prominence system with SIL-20A auto sample, CTO-20AC 
column oven, LC-20AD pump system, DGU-20A3 degasser and SPD-M20A Diode Array or 
UV/VIS detector. The following chiral columns from Daicel Chemical Industries were used: 
OJ-H (Chiralcel®), IA (Chiralpak®) in 4.6 x 250 mm size. The MW-SPPS was performed 
using Fmoc strategy on a Liberty™ Microwave Peptide Synthesizer (CEM Corporation, 
Matthews, NC), an additional module of Discover™ (CEM Corporation, Matthews, NC). 
TLC (thin layer chromatography) was carried out using Merck TLC plates silica gel 60 F254. 
UV detection was monitored at 254 nm. Chromatographic purifications were performed on 
columns packed with silica gel 60 Å (220-440 mesh) or  Florisil
®
 (100-200 mesh). Analysis 
for C, H, N and S were determined using Thermo Scientific Flash 2000 and results were 
within ± 0.4% of the theoretical value. All target compounds possessed a purity of ≥95% as 
verified by elemental analyses by comparison with the theoretical values. 
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To a stirred solution of acetophenone (3.8 mL, 33.00 mmol) in EtOH (50 mL), a solution of 
p-tolualdehyde (3.8 mL, 33.00 mmol) in EtOH (50 mL) and 4 N NaOH (20.6 mL) were 
added. The mixture was stirred at room temperature for 6 h. The reaction was quenched with 
2 N HCl and filtered, then the solvent was partially evaporated under vacuum. The residue 
was dissolved in AcOEt (30 mL x 3), washed with water (90 mL), dried over Na2SO4, filtered 
and concentrated under reduced pressure. The solid obtained was decanted with EtOH 
furnishing the pure chalcone as a pale yellow solid.  
 
Yield: 7.26 g, 99% 
Mp: 189-190 °C 
MW = 222.28  
Anal. calcd. for C16H14O: C 86.45, H 6.35; found: C 86.47, H 6.45. 
1
H-NMR (400 MHz, CDCl3): δ (ppm) 2.38 (s, 3H, CH3), 7.22 (d, J = 7.6 Hz, 2H Ar), 7.47-
7.59 (m, 6H, 5H Ar + 1H CH=CHCO), 7.79 (d, J = 15.6 Hz, 1H, CH=CHCO), 7.97 (d, J = 
7.6 Hz, 2H Ar). 
13
C-NMR (100 MHz, CDCl3): δ (ppm) 190.27, 144.74, 140.96, 138.29, 132.60, 132.09, 
129.65, 128.52, 128.46, 128.43, 120.94, 21.45.  
IR (KBr): cm
-1
 3022 (CH=CH), 1656 (CO).  
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To a solution of sodium (0.19 g, 8.10 mmol) in anhydrous MeOH (22 mL) under N2 
atmosphere, chalcone 170 (0.90 g, 4.05 mmol) and cyanothioacetamide (0.41 g, 4.05 mmol) 
were added. The reaction was stirred at reflux for 90 min. After cooling, the mixture was 
quenched with 1 N HCl and partially evaporated under vacuum. The residue was diluted in 
CH2Cl2 and then extracted (20 mL x 3), washed with water (60 mL), dried over Na2SO4, 
filtered and concentrated under reduced pressure. The pure yellow solid obtained was used 
directly in the next step. 
 
Yield: 3.81 g, 94%  
Mp: 105-133 °C 
MW = 304.41 
Anal. calcd. for C19H16N2S: C 74.97, H 5.30, N 9.20, S 10.53; found: C 74.86, H 5.68, N 8.84, 
S 10.73. 
1
H-NMR (400 MHz, CDCl3): δ (ppm) 2.04 (s, 1H, SH), 2.35 (s, 3H, CH3), 5.79 (s, 1H, H-4), 
5.92 (d, J = 4.8 Hz, 1H, H-5), 7.13-7.46 and 7.55-7.59 (2 m, 9H Ar), 9.11 (br s, 1H, NH). 
13
C-NMR (100 MHz, CDCl3): δ (ppm) 137.38, 132.95, 129.91, 129.74, 129.21, 128.04, 
127.52, 125.34, 116.26, 108.90, 108.64, 49.13, 48.38, 42.15, 21.04.  
IR (KBr): cm
-1
 3203 (NH), 2196 (CN).  
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To a stirred solution of 171 (0.70 g, 2.23 mmol) in CH2Cl2 (15 mL), DDQ (1.01 g, 4.46 
mmol) was added. The mixture was stirred at room temperature for 3 h, then filtered and 
evaporated under reduced pressure. The dark solid obtained was suspended several times in 
MeOH, water and n-hexane and, after decantation, recrystallized from MeOH, obtaining an 
off-white solid.  
 
Yield: 0.57 g, 84%  
Mp: 204-207 °C  
MW = 302.39 
Anal. calcd. for C19H14N2S: C 75.47, H 4.67, N 9.26, S 10.60; found: C 75.24, H 4.38, N 9.57, 
S 10.58. 
1
H-NMR (400 MHz, CDCl3): δ (ppm) 1.56 (s, 1H, SH), 2.46 (s, 3H, CH3), 7.35-7.40 (m, 5H 
Ar), 7.53 (d, J = 8.0 Hz, 2H Ar), 7.61 (s, 1H, H-5), 7.95 (d, J = 7.2 Hz, 2H Ar). 
13
C-NMR (100 MHz, CDCl3): δ (ppm) 160.57, 158.83, 154.86, 142.72, 140.58, 136.74, 
132.85, 130.64, 129.76, 128.82, 128.27, 127.32, 117.35, 115.48, 21.31.  
IR (KBr): cm
-1
 2215 (CN).  
CHAPTER 7. Experimental section 
PhD Thesis in Pharmaceutical, Food and Cosmetic Sciences 
Ilaria Giacchello 
184 




To a solution of 172 (0.42 g, 1.38 mmol) in DMF (6 mL), 10% KOH (1.70 mL, 3.04 mmol) 
and a solution of 2-bromoacetic acid (0.21 g, 1.52 mmol) in DMF (1 mL) were added. The 
dark red mixture was stirred at room temperature for 3 h. Then, the reaction was treated with 
3 N HCl, becoming yellow, and extracted with AcOEt (20 mL x 3). The organic phase was 
washed with water (60 mL), dried over Na2SO4, filtered and concentrated under reduced 
pressure. The crude solid residue was purified through recrystallization from MeOH, to give 
compound 173 as yellow crystals.  
 
Yield: 0.73 g, 75% 
Mp: 218-220 °C  
MW = 360.43 
Anal. calcd. for C21H16N2O2S: C 69.98, H 4.47, N 7.77, S 8.90; found: C 69.73, H 4.78, N 
8.13, S 8.51. 
1
H-NMR (400 MHz, DMSO-d6): δ (ppm) 2.39 (s, 3H, CH3), 4.16 (s, 2H, CH2), 7.38 (d, J = 
8.0 Hz, 2H Ar), 7.50-7.52 (m, 3H Ar), 7.64 (d, J = 8.0 Hz, 2H Ar), 7.88 (s, 1H, H-5), 8.23-
8.24 (m, 2H Ar). 
13
C-NMR (100 MHz, DMSO-d6): δ (ppm) 170.29, 162.50, 158.40, 154.56, 140.47, 137.01, 
133.11, 131.16, 129.84, 129.25, 128.97, 128.05, 116.44, 116.12, 102.81, 33.37, 21.27. 
IR (KBr): cm
-1
 3200-2400 (OH), 2219 (CN), 1710 (CO).  
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Synthesis of methyl N-({[3-cyano-4-(4-methylphenyl)-6-phenylpyridin-2-yl]thio}acetyl)-




To a stirred solution of 173 (0.10 g, 0.28 mmol) in anhydrous DMF (1 mL) at 0 °C under N2 
atmosphere, a solution of L-Val methyl ester (hydrochloride salt; 0.05 g, 0.30 mmol) in 
anhydrous DMF (1 mL) was added dropwise. Then, EDC (0.05 g, 0.28 mmol), HOBt (0.04 g, 
0.28 mmol) and dry DIPEA (0.06 mL, 0.40 mmol) were added. The mixture was stirred at 0 
°C for 30 min. and then at room temperature for 5 h. The reaction was quenched with water 
and then extracted with AcOEt (20 mL x 3). The organic phase was washed with water (60 
mL), dried over Na2SO4, filtered and concentrated under reduced pressure. The crude residue 
was purified through flash chromatography on silica gel, using as eluent n-hexane/AcOEt 
(7:3), to obtain the final product as a white solid. 
 
Yield: 0.03 g, 20%  
MW = 473.59 
Anal. calcd. for C27H27N3O3S: C 68.48, H 5.75, N 8.87, S 6.77; found: C 68.37, H 5.59, N 
8.77, S 6.64. 
1
H-NMR (400 MHz, CDCl3): δ (ppm) 0.62 and 0.69 (2 d, J = 6.8 Hz, 3H, CH(CH3)2), 1.97-
2.05 (m, 1H, CH(CH3)2), 2.44 (s, 3H, CH3), 3.53 (s, 3H, OCH3), 4.01 (q, JAB = 16.0 Hz, 2H, 
CH2S), 4.45-4.51 (m, 1H, CHNH), 7.17 (d, J = 6.4 Hz, 1H, NH), 7.35 (d, J = 7.6 Hz, 2H Ar), 
7.50-7.55 (m, 5H Ar), 7.60 (s, 1H, H-5), 8.03-8.07 (m, 2H Ar). 
13
C-NMR (100 MHz, CDCl3): δ (ppm) 167.92, 161.62, 158.97, 154.90, 140.65, 136.74, 
132.83, 130.74, 129.75, 129.03, 128.22, 127.39, 116.52, 115.36, 103.79, 57.34, 51.84, 33.89, 
30.87, 21.29, 18.60, 17.43.  
IR (KBr): cm
-1
 3359 (NH), 2220 (CN), 1749 (CO ester), 1646 (CO amide).  
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Synthesis of N-({[3-cyano-4-(4-methylphenyl)-6-phenylpyridin-2-yl]thio}acetyl)-L-valine 




To a stirred solution of 167a (0.05 g, 0.10 mmol) in a mixture of THF/EtOH/H2O (3:1:0.5) (4 
mL), 1 N NaOH (0.44 mL) was added. The mixture was stirred at room temperature for 15 
min. until the solution becomes yellow. The reaction was quenched with 2 N HCl and 
extracted with AcOEt (10 mL x 3). The organic phase was washed with water (30 mL), dried 
over Na2SO4, filtered and concentrated under reduced pressure. The crude residue was 
purified through flash chromatography on silica gel, eluting with AcOEt/MeOH/AcOH 
(9:1:0.5), to give pure 167b.  
 
Yield: 0.02 g, 40%  
MW = 459.56 
Anal. calcd. for C26H25N3O3S: C 67.95, H 5.48, N 9.14, S 6.98; found: C 68.02, H 5.33, N 
8.96, S 6.79. 
1
H-NMR (400 MHz, CD3OD): δ (ppm) 0.73 and 0.74 (2 d, J = 6.0 Hz, 3H, CH(CH3)2), 2.06 
(m, 1H, CH(CH3)2), 2.44 (s, 3H, CH3), 4.17 (q, JAB = 16.0 Hz, 2H, CH2S), 4.22-4.26 (m, 1H, 
CHNH), 7.38 (d, J = 8.0 Hz, 2H Ar), 7.48-7.52 (m, 3H Ar), 7.58 (d, J = 8.0 Hz, 2H Ar), 7.76 
(s, 1H, H-5), 8.19 (d, J = 8.0 Hz, 2H Ar). 
13
C-NMR (100 MHz, CD3OD): δ (ppm) 174.15, 171.31, 162.55, 158.39, 154.47, 140.11, 
137.09, 133.22, 131.31, 129.74, 129.31, 128.80, 128.15, 116.41, 116.21, 102.78, 31.10, 30.40, 
23.40, 21.30, 18.99.  
IR (KBr): cm
-1
 3450-3100 (OH), 3362 (NH), 2221 (CN), 1690 (CO acid), 1646 (CO amide). 
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It was used the same amidation protocol described before: to a stirring solution of Fmoc-L-
valine (0.5 g, 1.47 mmol) in anhydrous DMF (5 mL) under N2 atmosphere, a solution of L-
aspartate dimethyl ester (hydrochloride salt; 0.29 g, 1.47 mmol) in the same solvent (5.3 mL) 
was added dropwise. Then, EDC (0.28 g, 1.47 mmol), HOBt (0.20 g, 1.47 mmol) and dry 
DIPEA (0.31 mL, 1.77 mmol) were added. The mixture was stirred at 0 °C for 30 min. and 
then at room temperature for 4 h. The reaction was quenched with water and extracted with 
AcOEt (20 mL x 3). The organic phase was washed with water (60 mL), dried over Na2SO4, 
filtered and concentrated under reduced pressure. The crude residue was purified through 
flash chromatography on silica gel, using n-hexane/AcOEt (1:1) as eluent.  
 
Yield: 0.56 g, 79%  
MW = 482.53 
Anal. calcd. for C26H30N2O7: C 64.72, H 6.27, N 5.81; found: C 64.51, H 6.25, N 6.09. 
1
H-NMR (400 MHz, CDCl3): δ (ppm) 0.96 and 0.99 (2 d, J = 6.0 Hz, 3H, CH(CH3)2), 2.13-
2.18 (m, 1H, CH(CH3)2), 2.83-3.04 (m, 2H, CH2CO), 3.73 and 3.66 (2 s, 3H, OCH3), 4.10-
4.13 (m, 1H, CHNH), 4.21 (t, J = 6.8 Hz, 1H, CHCH2), 4.37 (m, 2H, CH2O), 4.89-4.93 (m, 
1H, CH Fmoc), 5.56 (d, J = 8.4 Hz, 1H, NH), 6.92 (d, J = 7.6 Hz, 1H, NH), 7.29 and 7.38 (2 t, 
J = 7.2 Hz, 4H Ar), 7.58 (d, J = 6.4 Hz, 2H Ar), 7.74 (d, J = 8.0 Hz, 2H Ar). 
13
C-NMR (100 MHz, CDCl3) δ (ppm) 171.08, 170.70, 156.23, 143.71, 141.21, 127.62, 
126.99, 125.08, 119.79, 67.10, 60.06, 52.68, 52.04, 48.32, 47.06, 35.80, 31.44, 18.88, 17.62. 
IR (KBr): cm
-1
 3362 (NHCO), 1745 (CO ester), 1649 (CO amide).  
CHAPTER 7. Experimental section 
PhD Thesis in Pharmaceutical, Food and Cosmetic Sciences 
Ilaria Giacchello 
188 




To a stirred solution of 174 (0.27 g, 0.56 mmol) in DMF (7 mL), NaN3 (0.07 g, 1.12 mmol) 
was added. The mixture was stirred at 50 °C for 12 h. The reaction was quenched with water 
and extracted with AcOEt (20 mL x 3). The organic phase was washed with water (60 mL), 
dried over Na2SO4, filtered and concentrated under reduced pressure. The crude residue was 
used in the next step without further purification. 
 
MW = 260.28 





Synthesis of dimethyl N-({[3-cyano-4-(4-methylphenyl)-6-phenylpyridin-2-




To 175 (0.19 g, 0.31 mmol), anhydrous DMF (3 mL) was added under N2 atmosphere. Then, 
a solution of 173 (0.11 g, 0.31 mmol) in the same solvent (3 mL), EDC (0.04 g, 0.31 mmol), 
HOBt (0.06 g, 0.31 mmol) and dry DIPEA (0.06 mL, 0.37 mmol) were added. The mixture 
was stirred at 0 °C for 30 min. and then at room temperature for 12 h. The reaction was 
quenched with water and then extracted with AcOEt (20 mL x 3). The organic phase was 
washed with water (60 mL), dried over Na2SO4, filtered and concentrated under reduced 
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pressure. The crude residue was purified through flash chromatography on silica gel using 
AcOEt as eluent.  
 
Yield: (over two steps): 0.04 g, 21%  
MW = 602.70 
Anal. calcd. for C32H34N4O6S: C 63.77, H 5.69, N 9.30, S 5.32; found: C 63.81, H 5.75, N 
9.09, S 5.64. 
1
H-NMR (400 MHz, CDCl3): δ (ppm) 0.67 and 0.75 (2 d, J = 6.8 Hz, 3H, CH(CH3)2), 1.93-
1.97 (m, 1H, CH(CH3)2), 2.43 (s, 3H, CH3), 2.62-2.91 (m, 2H, CH2CO), 3.64 and 3.69 (2 s, 
3H, OCH3), 4.00 (q, JAB = 15.6 Hz, 2H, CH2S), 4.14-4.18 (m, 1H, CHNH), 4.23-4.27 (m, 1H, 
CHCH2), 4.71-4.75 and 6.77-6.81 (2 m, 1H, NH), 7.27-7.31, 7.46-7.50 and 7.51-7.55 (3 m, 
7H Ar), 7.58 (s, 1H, H-5), 8.04 (d, J = 6.0 Hz, 2H Ar).  
13
C-NMR (100 MHz, CDCl3): δ (ppm) 171.08, 170.70, 156.23, 143.85, 130.73, 129.97, 
129.76, 129.04, 128.23, 127.40, 116.58, 115.37, 79.41, 58.60, 52.67, 52.02, 48.15, 35.65, 
31.82, 29.59, 29.24, 26.30, 22.58, 21.28, 18.66, 17.54, 14.01.  
IR (KBr): cm
-1








To a stirred solution of 168a (0.07 g, 0.10 mmol) in a mixture of THF/EtOH/H2O (3:1:0.5) (4 
mL), 1 N NaOH (0.44 mL) was added. The mixture was stirred at room temperature for 15 
min. until the solution became yellow. The reaction was quenched with 2 N HCl and 
extracted with AcOEt (10 mL x 3). The organic phase was washed with water (30 mL), dried 
over Na2SO4, filtered and concentrated under reduced pressure. The crude residue was 
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purified through flash chromatography on silica gel, eluting with AcOEt/MeOH/AcOH 
(9:1:0.5) to give pure 168b.  
 
Yield: 0.04 g, 61%   
MW = 574.65 
Anal. calcd. for C30H30N4O6S: C 62.70, H 5.26, N 9.75, S 5.58; found: C 62.80, H 5.35, N 
9.89, S 5.62. 
1
H-NMR (400 MHz, CD3OD): δ (ppm) 1.01 and 1.02 (2 d, J = 7.2 Hz, 3H, CH(CH3)2), 2.18-
2.22 (m, 2H, CH2CO), 2.43 (s, 3H, CH3), 3.14-3.18 (m, 1H, CH(CH3)2), 3.83 (q, JAB = 15.6 
Hz, 2H, CH2S), 4.39-4.44 (m, 1H, CHNH), 4.63-4.67 (m, 1H, CHCH2), 7.40-7.54 (2 m, 7H 
Ar), 7.56 (s, 1H, H-5), 8.04 (d, J = 6.8 Hz, 2H Ar). 
13
C-NMR (100 MHz, CD3OD): δ (ppm) 173.08, 171.90, 165.58, 160.06, 156.68, 148.15, 
145.94, 139.17, 137.92, 129.29, 128.42, 128.23, 127.72, 126.88, 121.38, 118.27, 98.30, 63.48, 
58.54, 49.71, 36.71, 30.82, 29.25, 19.87, 18.39, 17.39. 
IR (KBr): cm
-1
 3420-3090 (OH), 3361 (NH), 2225 (CN), 1688 (CO acid), 1640 (CO amide).  
 
 
Synthesis of the resin-bounded tripeptide 176 
 
 
Compound 176 has been obtained by MW-SPPS (microwave solid phase peptide synthesis) 
using an Fmoc strategy on a MW automated CEM Peptide Synthesizer, with Wang resin as 
the solid support. In detail, the instrument was charged with Fmoc-methionine on Wang resin 
(0.17 g), previously swallowed in DMF through a fritted buchner funnel under N2 flux for 2 h. 
The degree of functionalization was of 0.60 mmol per gram of resin. The instrument was also 
charged with: Fmoc-Val-OH (2 N, 0.41 g in 6 mL of DMF), Fmoc-Asp(OtBu)-OH (2 N, 0.49 
g in 6 mL of DMF), the activating agents HOBt and HBTU (0.27 g and 0.76 g respectively in 
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4 mL of DMF); DIPEA (2 mL of 34.8% v/v DMF) as base and piperidine (100 mL of 20% 
v/v DMF) as deprotecting agent; CH2Cl2 (2 L); DMF (2 L). Then, the instrument was set and 
the synthetic procedure lasted for 3 h and 37 min. The coupling was performed in DMF and 
the peptide chain assembled under computer control of the synthesizer. The synthesis cycles 
were composed of Fmoc-deprotection and coupling, both under microwave irradiation. 
Finally, several washing cycles were performed with DMF and CH2Cl2. All parameters (t, p, 
T, Q) have been established automatically by the instrument and were different in every cycle. 
 
 
Synthesis of N-[(9H-fluoren-9-ylmethoxy)carbonyl]-L-valyl-L-α-aspartyl-L-methionine 




Resin-bounded compound 176 was charged in a gooch filter and treated with a cleavage 
solution of TFA/TIPS/H2O/DTT (88:2:5:5) (20 mL) under an upward flux of N2, to quench 
reactive intermediates under microwave irradiation and to prevent the oxidation of the 
thioether side chain of methionine. After 1 h the resin was filtered and the filtrate was 
recovered and evaporated under reduced pressure. The C-terminal end and the carboxylic 
aspartate side chain of the peptide are obtained as free carboxylic acids. The white solid 
obtained was washed with n-hexane and toluene and used directly in the next step. 
 
MW = 585.67 
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To a stirred solution of 177 (0.17 g, 0.29 mmol) in anhydrous MeOH (10 mL), freshly 
distilled SOCl2 (0.22 mL) was added at 0 °C. The mixture was stirred at 0 °C for 30 min and 
then at room temperature for 6 h. The solvent was removed under reduced pressure and the 
crude residue was purified through flash chromatography on silica gel, eluting with AcOEt to 
give 178.  
 
Yield: 0.05 g, 28% 
MW = 613.72 
Anal. calcd. for C31H39N3O8S: C 60.67, H 6.41, N 6.85, S 5.22; found: C 60.42, H 6.35, N 
7.09, S 5.44. 
1
H-NMR (400 MHz, CDCl3): δ (ppm) 0.95 and 0.98 (2 d, J = 6.8 Hz, 3H, CH(CH3)2), 1.99-
2.04 (m, 1H, CH(CH3)2), 2.16 (s, 3H, SCH3), 2.51-2.55 (m, 2H, CH2CO), 2.67-2.72 (m, 2H, 
CH2S), 2.83-3.04 (m, 2H, CH2CH2), 3.68 and 3.72 (2 s, 3H, OCH3), 3.00 (m, 1H, CHNH), 
4.21-4.25 (m, 1H, CHCH2CH2), 4.42-4.46 (m, 2H, CH2O), 4.60-4.62 (m, 1H, NH), 4.80-4.84 
(m, 1H, CH Fmoc), 5.38-5.42 (m, 1H, NH), 7.31 and 7.39 (2 t, J = 7.6 Hz, 4H Ar), 7.58 (d, J 
= 7.2 Hz 2H Ar), 7.75 (d, J = 7.6 Hz, 2H Ar). 
13
C-NMR (100 MHz, DMSO-d6): δ (ppm) 172.91, 170.70, 170.31, 156.23, 143.71, 141.21, 
127.62, 126.99, 125.08, 119.98, 119.79, 67.10, 65.69, 60.06, 55.11, 52.04, 51.89, 48.32, 
47.06, 35.80, 31.44, 31.00, 27.91, 18.88, 17.62, 15.47. 
IR (KBr): cm
-1
 3361 (NH), 1742 (CO ester), 1651 (CO amide).  
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It was used the same deprotection protocol employed for 175. To a stirred solution of 178 
(0.05 g, 0.79 mmol) in DMF (10 mL), NaN3 (0.01 g, 0.20 mmol) was added. The mixture was 
stirred at 50 °C for 4 h. The reaction was quenched with water and extracted with AcOEt (10 
mL x 3). The organic phase was washed with water (30 mL), dried over Na2SO4, filtered and 
concentrated under reduced pressure. The crude residue was purified through flash 
chromatography on silica gel, eluting with AcOEt/MeOH (9:1).  
 
Yield: 0.19 g, 62% 
MW = 391.48 
Anal. calcd. for C16H29N3O6S: C 49.09, H 7.47, N 10.73, S 8.19; found: C 49.24, H 7.38, N 
10.89, S 8.44. 
1
H-NMR (400 MHz, CDCl3): δ (ppm) 0.96 and 0.99 (2 d, J = 6.8 Hz, 3H, CH(CH3)2), 1.95-
2.00 (m, 1H, CH(CH3)2), 2.17 (s, 3H, SCH3), 2.50-2.54 (m, 2H, CH2CO), 2.65-2-70 (m, 2H, 
CH2S), 2.82-3.03 (m, 2H, CH2CH2), 3.05-3.11 (m, 1H, CHNH), 3.69 and 3.74 (2 s, 3H, 
OCH3), 4.20-4.25 (m, 1H, CHNH), 4.55-4.61 (m, 1H, CHNH). 
IR (KBr): cm
-1
 3401 (NH), 3361 (NHCO), 1742 (CO ester), 1651 (CO amide). 
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Synthesis of dimethyl-N-({[3-cyano-4-(4-methylphenyl)-6-phenylpyridin-2-yl]thio}acetyl) 




To a stirring solution of 179 (0.04 g, 0.10 mmol) in anhydrous DMF (5 mL) under N2 
atmosphere, a solution of 173 (0.02 g, 0.10 mmol) in the same solvent (2.50 mL) was added 
dropwise. Then, EDC (0.10 g, 0.10 mmol), HOBt (0.10 g, 0.10 mmol) and dry DIPEA (0.05 
mL, 0.10 mmol) were added. The mixture was stirred at 0 °C for 30 min. and then at room 
temperature for 12 h. The reaction was quenched with water and then extracted with AcOEt 
(10 mL x 3). The organic phase was washed with water (30 mL), dried over Na2SO4, filtered 
and concentrated under reduced pressure. The crude residue was purified through flash 
chromatography on silica gel, eluting with AcOEt. 
 
Yield: 0.03 g, 41% 
MW = 733.90 
Anal. calcd. for C37H43N5O7S2: C 60.55, H 5.91, N 9.54, S 8.74; found: C 60.41, H 6.15, N 
9.59, S 8.84. 
1
H-NMR (400 MHz, CD3OD): δ (ppm) 0.76 and 0.81 (2 d, J = 6.8 Hz, 3H, CH(CH3)2), 1.90-
1.95 (m, 1H, CH(CH3)2), 2.00 (s, 3H, SCH3), 2.20-2.29 (m, 2H, CH2CO), 2.44 (s, 3H, CH3), 
2.50-2.54 (m, 2H, CH2CH2), 2.82-3.03 (m, 2H, CH2S), 3.30 (s, 6H, 2 OCH3), 3.70-3.76 (m, 
2H, COCH2S), 4.43-4.48 (m, 1H, CHCH2CH2), 4.52-4.57 (m, 1H, CHCH2CO), 4.94-5.00 (m, 
1H, CHCH), 7.38 (d, J = 8.0 Hz, 2H Ar), 7.49-7.53 (m, 3H Ar), 7.60 (d, J = 8.0 Hz, 2H Ar), 
7.77 (s, 1H, H-5), 8.17-8.21 (m, 2H Ar), 
13
C-NMR (100 MHz, DMSO-d6): δ (ppm) 172.09, 171.65, 156.25, 143.70, 130.69, 129.97, 
129.76, 129.04, 128.25, 127.50, 116.45, 115.37, 79.41, 58.60, 55.10, 52.00, 48.15, 35.65, 
31.82, 31.09, 29.59, 29.31, 29.24, 26.30, 23.33, 22.49, 21.28, 18.66, 17.54, 15.13, 14.01.  
IR (KBr): cm
-1
 3369 (NH), 2218 (CN), 1749 (CO ester), 1647 (CO amide).  
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It was used the same amidation protocol employed for the synthesis of 167a. To a stirred 
solution of 173 (0.10 g, 0.28 mmol) in anhydrous DMF (1 mL) at 0 °C under N2 atmosphere, 
a solution of the appropriate L or D-amino acid methyl ester (hydrochloride salt) or benzyl 
ester (p-toluenesulfonate salt) (0.30 mmol) in anhydrous DMF (1 mL) was added dropwise, 
under N2 atmosphere. Then, EDC (0.05 g, 0.28 mmol), HOBt (0.04 g, 0.28 mmol) and dry 
DIPEA (0.06 mL, 0.40 mmol) were added. The mixture was stirred at 0 °C for 30 min. and 
then at room temperature for 5 h. The reaction was quenched with water and then extracted 
with AcOEt (20 mL x 3). The organic phase was washed with water (60 mL), dried over 
Na2SO4, filtered and concentrated under reduced pressure. The crude residue was purified 
through flash chromatography on silica gel, using as eluent n-hexane/AcOEt (7:3) (180a, 
180b, 180e), (6:4) (180f), (1:1) (180g), AcOEt/MeOH (9:1) (180c), CH2Cl2/MeOH (9:1) 
(180d) CH2Cl2 (181a-e), to obtain the final products as white solids. 
 
Methyl N-({[3-cyano-4-(4-methylphenyl)-6-phenylpyridin-2-yl]thio}acetyl)-L-leucinate 
(L-leucine methyl ester adduct) 180a 
Yield: 0.04 g, 31%  
Mp: 150-151 °C 
MW = 487.61 
Anal. calcd. for C28H29N3O3S: C 68.97, H 5.99, N 8.62, S 6.58; found: C 69.01, H 5.87, N 
8.50, S 6.53. 
1
H-NMR (400 MHz, CDCl3): δ (ppm) 0.27 and 0.31 (2 d, J = 6.4 Hz, 3H, CH(CH3)2), 1.21-
1.32 (m, 1H, CH(CH3)2), 1.38-1.43 (m, 2H, CHCH2), 2.44 (s, 3H, CH3), 3.54 (s, 3H, OCH3), 
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4.05 (q, JAB = 15.6 Hz, 2H, CH2S), 4.52-4.58 (m, 1H, CHNH), 7.13 (d, J = 8.0 Hz, 1H, NH), 
7.34 (d, J = 7.6 Hz, 2H Ar), 7.49-7.55 (m, 5H Ar), 7.60 (s, 1H, H-5), 8.06 (d, J = 7.6 Hz, 2H 
Ar). 
13
C-NMR (100 MHz, CDCl3): δ (ppm) 172.73, 167.71, 161.64, 158.87, 154.90, 140.6, 136.65, 
132.82, 130.81, 129.78, 129.07, 128.20, 127.37, 116.43, 103.77, 52.02, 50.81, 41.12, 33.85, 
24.53 22.50, 21.50, 21.31.  
IR (KBr): cm
-1
 3362 (NH), 2222 (CN), 1745 (CO ester), 1650 (CO amide).  
 
Methyl N-({[3-cyano-4-(4-methylphenyl)-6-phenylpyridin-2-yl]thio}acetyl)-L-isoleucinate 
(L-isoleucine methyl ester adduct) 180b 
Yield: 0.04 g, 31%  
Mp: 163-165 °C 
MW = 487.61  
Anal. calcd. for C28H29N3O3S: C 68.97, H 5.99, N 8.62, S 6.58; found: C 68.75, H 5.97, N 
8.72, S 6.43. 
1
H-NMR (400 MHz, CDCl3): δ (ppm) 0.65-0.66 (m, 6H, CH3CH2 + CH3CH), 1.13-1.14 (m, 
1H, CH3CH), 1.63-1.71 (m, 2H, CH3CH2), 2.43 (s, 3H, CH3), 3.52 (s, 3H, OCH3), 4.06 (q, JAB 
= 15.6 Hz, 2H, CH2S), 4.48-4.51 (m, 1H, CHNH), 7.18 (d, J = 8.4 Hz, 1H, NH), 7.34 (d, J = 
7.6 Hz, 2H Ar), 7.48-7.55 (m, 5H Ar), 7.60 (s, 1H, H-5), 8.01-8.06 (m, 2H Ar). 
13
C-NMR (100 MHz, CDCl3): δ (ppm) 171.66, 167.78, 161.64, 158.96, 154.89, 140.66, 
136.73, 132.82, 130.78, 129.76, 129.04, 128.22, 127.40, 116.50, 115.37, 103.37, 56.68, 51.79, 
37.51, 33.88, 24.83, 21.30, 15.07, 11.23.  
IR (KBr): cm
-1 
3369 (NH), 2215 (CN), 1732 (CO ester), 1657 (CO amide).  
 
Methyl N-({[3-cyano-4-(4-methylphenyl)-6-phenylpyridin-2-yl]thio}acetyl)-L-histidinate 
(L-Histidine methyl ester adduct) 180c 
Yield: 0.04 g, 30% 
Mp: 135-141 °C 
MW = 511.59 
Anal. calcd. for C28H25N5O3S: C 65.74, H 4.93, N 13.69, S 6.27; found: C 65.41, H 4.70, N 
14.07, S 6.44. 
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H-NMR (400 MHz, CDCl3): δ (ppm) 1.13-1.17 (m, 1H, CHCH2), 2.44 (s, 3H, CH3), 2.89 
and 3.02 (2 q, J = 15.0 Hz, 2H, CH2CH), 3.54 (s, 3H, OCH3), 4.11 (s, 2H, CH2S), 4.78-4.82 
(m, 1H, CHNH), 6.62 (s, 1H, NCHNH), 7.34 (d, J = 8.0 Hz, 2H Ar), 7.39 (s, 1H, NH), 7.50-
7.54 (m, 5H Ar), 7.57 (s, 1H, H-5), 7.94 (d, J = 7.2 Hz, 1H, CHN), 8.06-8.08 (m, 2H Ar). 
13
C-NMR (100 MHz, CDCl3): δ (ppm) 171.42, 167.99, 161.54, 158.70, 154.80, 140.08, 
140.04, 136.77, 133.10, 132.96, 130.74, 129.76, 129.02, 128.21, 127.42, 116.33, 115.62, 
99.42, 90.97, 52.32, 52.21, 45.20, 29.04, 21.28. 
IR (KBr): cm
-1 





(L-arginine methyl ester adduct) 180d 
Yield: 0.04 g, 27% 
Mp: 161-171 °C 
MW = 530.64 
Anal. calcd. for C28H30N6O3S: C 63.38, H 5.70, N 15.84, S 6.04; found: C 63.44, H 5.44, N 
15.75, S 6.42. 
1
H-NMR (400 MHz, CD3OD): δ (ppm) 1.43-1.47 (m, 2H, CH2CH2CH2), 1.59-1.66 and 1.77-
1.86 (2 m, 2H, CH2CH), 2.43 (s, 3H, CH3), 2.98-3.06 (m, 2H, CH2NH), 3.59 (s, 3H, OCH3), 
4.22 (q, JAB = 16.0 Hz, 2H, CH2S), 4.44-4.47 (m, 1H, CHNH), 7.37 (d, J = 8.0 Hz, 2H Ar), 
7.50-7.51 (m, 3H Ar), 7.57 (d, J = 8.0 Hz, 2H Ar), 7.74 (s, 1H, H-5), 8.18-8.20 (m, 2H Ar). 
13
C-NMR (100 MHz, CD3OD): δ (ppm) 171.90, 169.20, 161.91, 158.74, 154.86, 140.40, 
136.90, 133.01, 132.02, 130.40, 129.30, 129.25, 128.71, 128.17, 127.49, 126.60, 115.13, 
48.16, 47.94, 47.09, 46.87, 40.29, 29.01, 24.59.  
IR (KBr): cm
-1
 3364 (NH), 2225 (CN), 1744 (CO ester), 1653 (CO amide). 
 
Methyl N-({[3-cyano-4-(4-methylphenyl)-6-phenylpyridin-2-yl]thio}acetyl)-L-
phenylalaninate (L-phenylalanine methyl ester adduct) 180e 
Yield: 0.05 g, 34%  
Mp: 167-173 °C 
MW = 521.63 
Anal. calcd. for C31H27N3O3S: C 71.38, H 5.22, N 8.06, S 6.15; found: C 71.21, H 5.30, N 
8.11, S 5.78. 
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H-NMR (400 MHz, DMSO-d6): δ (ppm) 2.40 (s, 3H, CH3), 2.85 and 2.99 (2 q, J = 14.0 Hz, 
2H, CH2CH), 3.49 (s, 3H, OCH3), 4.14 (s, 2H, CH2S), 4.46-4.49 (m, 1H, CHCH2), 7.08-7.15 
(m, 5H Ar Phe), 7.39 (d, J = 7.6 Hz, 2H Ar), 7.50-7.51 (m, 3H Ar), 7.64 (d, J = 7.6 Hz, 2H 
Ar), 7.87 (s, 1H, H-5), 8.25 (m, 2H Ar) 8.65 (d, J = 7.6 Hz, 1H, NH). 
13
C-NMR (100 MHz, DMSO-d6): δ (ppm) 171.37, 167.67, 161.43, 158.77, 154.73, 140.71, 
136.60, 135.43, 132.88, 130.80, 129.84, 129.06, 128.71, 128.52, 128.21, 127.35, 126.80, 
116.37, 115.32, 103.54, 53.15, 52.12, 37.52, 33.38, 24.04.  
IR (KBr): cm
-1
 3300 (NH), 2217 (CN), 1742 (CO ester), 1655 (CO amide).  
 
Methyl N-({[3-cyano-4-(4-methylphenyl)-6-phenylpyridin-2-yl]thio}acetyl)-L-tyrosinate (L-
tyrosine methyl ester adduct) 180f 
Yield: 0.03 g, 21% 
Mp: 215-217 °C 
MW = 537.63 
Anal. calcd. for C31H27N3O4S: C 69.25, H 5.06, N 7.82, S 5.96; found: C 69.61, H 5.32, N 
7.99, S 5.83. 
1
H-NMR (400 MHz, CDCl3): δ (ppm) 2.45 (s, 3H, CH3), 2.75 and 2.94 (2 q, J = 14.0 Hz, 2H, 
CH2CH), 3.57 (s, 3H, OCH3), 4.00 (q, JAB = 15.6 Hz, 2H, CH2S), 4.75-4.80 (m, 1H, CHCH2), 
5.12 (br s, 1H, OH), 6.45 and 6.68 (2 d, J = 8.2 Hz, 2H Ar Tyr), 7.10 (d, J = 8.0 Hz, 1H, NH), 
7.25 (s, 1H, H-5), 7.36 (d, J = 7.6 Hz, 2H Ar), 7.49-7.50 (m, 3H Ar), 7.58 (d, J = 8.0 Hz, 2H 
Ar), 8.02-8.04 (m, 2H Ar). 
13
C-NMR (100 MHz, CDCl3): δ (ppm) 171.47, 167.80, 161.42, 158.90, 154.81, 144.96, 
140.69, 136.59, 132.84, 130.94, 129.79, 129.12, 129.02, 128.39, 127.57, 127.15, 116.56, 
116.10, 115.40, 103.46, 53.17, 49.84, 36.58, 31.31, 21.29.  
IR (KBr): cm
-1
 3400-3200 (OH), 3306 (NH), 2218 (CN), 1730 (CO ester), 1656 (CO amide).  
 
Dimethyl N-({[3-cyano-4-(4-methylphenyl)-6-phenylpyridin-2-yl]thio}acetyl)-L-glutamate 
(L-glutammate methyl diester adduct) 180g 
Yield: 0.04 g, 27%  
Mp: 179-193 °C 
MW = 517.60 
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Anal. calcd. for C28H27N3O5S: C 64.97, H 5.26, N 8.12, S 6.19; found: C 65.01, H 5.43, N 
8.49, S 6.06. 
1
H-NMR (400 MHz, CDCl3): δ (ppm) δ 1.76-1.80 and 2.03-2.15 (2 m, 4H, CH2CH2), 2.44 (s, 
3H, CH3), 3.54 and 3.55 (2 s, 3H, OCH3), 4.06 (q, JAB = 15.8 Hz, 2H, CH2S), 4.57-4.58 (m, 
1H, CHCH2), 7.25 (s, 1H, NH), 7.35 (d, J = 7.6 Hz, 2H Ar), 7.49-7.51 (m, 3H Ar), 7.54 (d, J 
= 7.6 Hz, 2H Ar), 7.61 (s, 1H, H-5), 8.05-8.07 (m, 2H Ar). 
13
C-NMR (100 MHz, CDCl3): δ (ppm) 171.30, 168.01, 162.70, 161.80, 158.97, 155.00, 
140.66, 136.66, 132.85, 130.80, 129.78, 129.11, 128.29, 127.47, 116.61, 115.37, 103.86, 
59.91, 59.12, 53.05, 52.20, 41.80, 37.02, 20.50.  
IR (KBr): cm
-1
 3312 (NH), 2215 (CN), 1732 (CO ester), 1653 (CO amide). 
 
Benzyl N-({[3-cyano-4-(4-methylphenyl)-6-phenylpyridin-2-yl]thio}acetyl)-L-valinate 
(L-valine benzyl ester adduct) 181a 
Yield: 0.12 g, 80% 
MW = 549.68 
Anal. calcd. for C33H31N3O3S: C 72.11, H 5.68, N 7.64, S 5.83; found: C 72.01, H 5.59, N 
7.84, S 5.94. 
1
H-NMR (400 MHz, CDCl3): δ (ppm) 0.33 and 0.68 (2 d, J = 6.8 Hz, 3H, CH(CH3)2), 1.97-
2.02 (m, 1H, CH(CH3)2), 2.44 (s, 3H, CH3), 4.53-4.56 (m, 1H, CHNH), 4.99 (q, JAB = 16.0 
Hz, 2H, CH2S), 5.01 (q, JAB = 12.0 Hz, 2H, CH2O), 7.21 (d, J = 8.0 Hz, 1H, NH) 7.26-7.30 
(m, 3H Ar), 7.35 (d, J = 8.0 Hz, 2H Ar), 7.49-7.56 (m, 5H Ar), 7.58 (s, 1H, H-5), 8.04-8.06 
(m, 2H Ar). 
13
C-NMR (100 MHz, CDCl3): δ (ppm) 173.25, 171.29, 162.54, 158.27, 154.45, 140.21, 
137.00, 136.02, 133.23, 131.32, 129.76, 129.31, 128.88, 128.19, 128.07, 127.43, 116.45, 
116.27, 102.78, 66.41, 57.38, 31.10, 30.40, 23.45, 21.30, 18.99. 
IR (KBr): cm
-1
 3290 (NH), 2218 (CN), 1736 (CO ester), 1650 (CO amide). 
 
Methyl N-({[3-cyano-4-(4-methylphenyl)-6-phenylpyridin-2-yl]thio}acetyl)-D-valinate 
(D-valine methyl ester adduct) 181b 
Yield: 0.07 g, 55%  
Mp: 159-161 °C 
MW = 473.59 
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Anal. calcd. for C27H27N3O3S: C 68.48, H 5.75, N 8.87, S 6.77; found: C 68.30, H 5.97, N 
8.51, S 6.40. 
1
H-NMR (400 MHz, CDCl3): δ (ppm) 0.62 and 0.70 (2 d, J = 6.8 Hz, 3H, CH(CH3)2), 1.94-
2.02 (m, 1H, CH(CH3)2), 2.45 (s, 3H, CH3), 3.53 (s, 3H, OCH3), 4.09 (q, JAB = 16.0 Hz, 2H, 
CH2S), 4.46-4.50 (m, 1H, CHNH), 7.17 (d, J = 8.4 Hz, 1H, NH), 7.35 (d, J = 7.6 Hz, 2H Ar), 
7.50-7.57 (m, 5H Ar), 7.61 (s, 1H, H-5), 8.05-8.07 (m, 2H Ar). 
13
C-NMR (100 MHz, CDCl3): δ (ppm) 167.93, 161.65, 158.99, 154.91, 140.66, 136.74, 
132.84, 130.76, 129.77, 129.04, 128.23, 127.42, 116.54, 115.37, 103.81, 57.36, 51.86, 33.93, 
30.91, 21.32, 18.63, 17.45.  
IR (KBr): cm
-1
 3287 (NH), 2215 (CN), 1740 (CO ester), 1659 (CO amide).  
 
Benzyl N-({[3-cyano-4-(4-methylphenyl)-6-phenylpyridin-2-yl]thio}acetyl)-D-valinate 
(D-valine benzyl ester adduct) 181c 
Yield: 0.09 g, 61%  
Mp: 133-135 °C 
MW = 549.68 
Anal. calcd. for C33H31N3O3S: C 72.11, H 5.68, N 7.64, S 5.83; found: C 72.11, H 5.50, N 
7.78, S 5.90. 
1
H-NMR (400 MHz, CDCl3): δ (ppm) 0.59 and 0.68 (2 d, J = 6.8 Hz, 3H, CH(CH3)2), 1.97-
2.02 (m, 1H, CH(CH3)2), 2.45 (s, 3H, CH3), 4.08 (q, JAB = 16.0 Hz, 2H, CH2S), 4.52-4.55 (m, 
1H, CHNH), 4.98 (q, JAB = 12.0 Hz, 2H, CH2O), 7.21 (d, J = 8.0 Hz, 1H, NH) 7.26-7.30 (m, 
3H Ar), 7.35 (d, J = 8.0 Hz, 2H Ar), 7.48-7.55 (m, 5H Ar), 7.58 (s, 1H, H-5), 8.04-8.05 (m, 
2H Ar). 
13
C-NMR (100 MHz, CDCl3): δ (ppm) 171.07, 167.92, 161.62, 158.99, 154.88, 140.65, 
136.77, 135.50, 132.84, 130.73, 129.76, 129.04, 128.44, 128.25, 128.06, 127.42, 116.56, 
115.37, 103.79, 66.71, 57.36, 33.96, 30.95, 21.32, 18.65, 17.34.  
IR (KBr): cm
-1
 3288 (NH), 2217 (CN), 1735 (CO ester), 1652 (CO amide).  
 
Benzyl N-({[3-cyano-4-(4-methylphenyl)-6-phenylpyridin-2-yl]thio}acetyl)-L-leucinate 
(L-leucine benzyl ester adduct) 181d 
Yield: 0.08 g, 50%  
Mp: 151-153 °C 
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MW = 563.71 
Anal. calcd. for C34H33N3O3S: C 72.44, H 5.90, N 7.45, S 5.69; found: C 72.46, H 6.22, N 
7.66, S 6.03. 
1
H-NMR (400 MHz, CDCl3): δ (ppm) 0.64 and 0.67 (2 d, J = 6.0 Hz, 3H, CH(CH3)2), 1.23-
1.28 (m, 1H, CH(CH3)2), 1.39-1.44 (m, 2H, CHCH2), 2.46 (s, 3H, CH3), 4.05 (q, JAB = 15.6 
Hz, 2H, CH2S), 4.60-4.64 (m, 1H, CHNH), 5.00 (s, 2H, CH2O), 7.19-7.37 (m, 8H, 7H Ar + 
NH), 7.49-7.55 (m, 5H Ar), 7.59 (s, 1H, H-5), 8.06 (m, 2H Ar). 
13
C-NMR (100 MHz, CDCl3): δ (ppm) 172.13, 167.79, 161.68, 158.91, 154.90, 140.68, 
136.68, 132.84, 130.92, 129.90, 129.68, 129.20, 128.98, 128.59, 128.32, 128.10, 127.80, 
127.41, 116.54, 116.44, 115.38, 103.80, 66.76, 50.97, 24.54, 22.58, 21.34. 
IR (KBr): cm
-1
 3362 (NH), 2222 (CN), 1745 (CO ester), 1650 (CO amide).  
 
Benzyl N-({[3-cyano-4-(4-methylphenyl)-6-phenylpyridin-2-yl]thio}acetyl)-L-isoleucinate 
(L-isoleucine benzyl ester adduct) 181e 
Yield: 0.05 g, 34%  
Mp: 122-126 °C 
MW = 563.71 
Anal. calcd. for C34H33N3O3S: C 72.44, H 5.90, N 7.45, S 5.69; found: C 72.48, H 5.94, N 
7.78, S 5.58. 
1
H-NMR (400 MHz, CDCl3): δ (ppm) 0.65-0.69 (m, 6H, CH3CH2 + CH3CH), 0.73-0.85 (m, 
1H, CH3CH), 1.08-1.14 (m, 2H, CH3CH2), 2.45 (s, 3H, CH3), 4.07 (q, JAB = 15.6 Hz, 2H, 
CH2S), 4.55-4.58 (m, 1H, CHNH), 4.99 (q, J = 12.4 Hz, 2H, CH2O), 7.21-7.31 (m, 6H, 5H Ar 
+ NH), 7.36 (d, J = 8.0 Hz, 2H Ar), 7.49-7.55 (m, 5H Ar), 7.59 (s, 1H, H-5), 8.04-8.05 (m, 2H 
Ar). 
13
C-NMR (100 MHz, CDCl3): δ (ppm) 171.07, 167.85, 161.67, 158.99, 154.89, 140.66, 
136.76, 135.24, 132.85, 130.76, 129.76, 129.06, 128.44, 128.26, 128.07, 127.43, 116.55, 
115.37, 103.37, 66.68, 56.76, 37.58, 33.94, 24.75, 21.31, 15.11, 11.25.  
IR (KBr): cm
-1
 3369 (NH), 2215 (CN), 1732 (CO ester), 1657 (CO amide).  
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To a solution of 2,4,6-trichloropyrimidine (1.00 g, 5.45 mmol) in THF (9 mL), the opportune 
phenylboronic acid (4.52 mmol), Pd(OAc)2 (24.47 mg, 0.11 mmol), PPh3 (57.70 mg, 0.22 
mmol) and 1 M Na2CO3 (9 mL) were added. The resulting mixture was stirred at reflux under 
nitrogen atmosphere for 3 h. Then, the solvent was removed under vacuum and the reaction 
extracted with CH2Cl2 (3 x 30 mL). The organic phase was washed with water (90 mL), dried 
over Na2SO4, filtered and concentrated under reduced pressure. The crude product was 
purified by column chromatography using PE (bp 40-60 °C)/AcOEt (95:5) as eluent, to afford 
the pure products as white solids.  
 
2,4-Dichloro-6-phenylpyrimidine 184a 
Yield: 0.92 g, 90%  
Mp: 73-74 °C 
MW = 225.07 
Anal. calcd. for C10H6Cl2N2: C 53.36, H 2.69, N 12.45; found C 53.65, H 2.58, N 12.37. 
1
H-NMR (200 MHz, CDCl3): δ (ppm) 7.55-7.61 (m, 3H Ar), 7.71 (s, 1H pyr), 8.07-8.13 (m, 
2H Ar).  
 
2,4-Dichloro-6-(4-chlorophenyl)pyrimidine 184b  
Yield: 0.97 g, 83%  
Mp: 128-132 °C  
MW = 259.52 
Anal. calcd. for C10H5Cl3N2: C 46.28, H 1.94, N 10.79; found C 46.47, H 2.14, N 10.51. 
1
H-NMR (200 MHz, CDCl3): δ (ppm) 7.53 (d, J = 8.0 Hz, 2H Ar), 7.68 (s, 1H pyr), 8.06 (d, J 
= 8.0 Hz, 2H Ar).  
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Mp: 134-135 °C 
MW = 243.06 
Anal. calcd. for C10H5Cl2FN2: C 49.41, H 2.07, N 11.53; found C 49.59, H 1.96, N 11.13. 
1








To a solution of the opportune intermediate 184a-c (2.00 mmol) in DME (10 mL), 
naphthalene boronic acid (0.38 g, 2.20 mmol), Pd(OAc)2 (22.45 mg, 0.10 mmol), PPh3 (52.36 
mg, 0.20 mmol) and Na2CO3 (0.66 g, 6.20 mmol) dissolved in the minimum amount of water, 
were added. The resulting mixture was stirred at reflux under nitrogen atmosphere for 3 h. 
Then, solvent was removed under vacuum and the reaction extracted with CH2Cl2 (3 x 30 
mL). The organic phase was washed with water (90 mL), dried over Na2SO4, filtered and 
concentrated under reduced pressure. The crude product was purified by column 
chromatography using PE (bp 40-60 °C)/Et2O (8:2) (185a), CH2Cl2 (185b), n-hexane/AcOEt 
(9:1) (185c) as eluent, to afford the pure products as white solids. 
 
2-Chloro-4-(1-naphthyl)-6-phenylpyrimidine 185a 
Yield: 0.27 g, 43%  
Mp: 99-101 °C 
MW = 316.78 
Anal. calcd. for  C20H13ClN2: C 75.83, H 4.14, N 8.84; found C 75.93, H 4.21, N 8.69.  
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H-NMR (200 MHz, CDCl3): δ (ppm) 7.58-7.65 (m, 6H, 3H Ar + 3H naph), 7.75 (s, 1H pyr), 
7.96-7.98 and 8.00-8.20 (2 m, 6H, 4H naph + 2H Ar). 
 
2-Chloro-4-(4-chlorophenyl)-6-(1-naphthyl)pyrimidine 185b  
Yield: 0.25 g, 36% 
Mp: 122-123 °C 
MW = 351.23 
Anal. calcd. for  C20H12Cl2N2: C 68.39, H 3.44, N 7.98; found C 68.30, H 3.31, N 8.33.  
1
H-NMR (200 MHz, CDCl3): δ (ppm) 7.52-7.63 (m, 5H, 2H Ar + 3H naph), 7.94 (s, 1H pyr), 
7.96-8.17 (m, 6H, 4H naph + 2H Ar).  
 
2-Chloro-4-(4-fluorophenyl)-6-(1-naphthyl)pyrimidine 185c 
Yield: 0.49 g, 73%  
Mp: 123-124 °C 
MW = 334.77 
Anal. calcd. for C20H12ClFN2: C 71.75, H 3.61, N 8.37; found C 71.63, H 3.46, N 8.30. 
1
H-NMR (200 MHz, CDCl3) : δ (ppm) 7.21-7.25, 7.58-7.66 and 7.75-7.79 (3 m, 7H, 2H Ar + 
5H naph) 7.92 (s, 1H pyr), 7.93-8.06 and 8.18-8.25 (2 m, 4H, 2H Ar + 2H naph). 
 
 




To a solution of NaOH (0.43 g, 1.07 mmol) in water (7 mL) and acetone (7 mL), thiophenol 
(0.14 mL, 1.33 mmol) was added; the mixture was stirred at room temperature for 1 h. Then, 
184a (0.30 g, 1.33 mmol) was added. The mixture was stirred at room temperature and after 2 
h NaOH pellets (0.43 g, 1.07 mmol) was added. The reaction was stirred at room temperature 
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for an additional 1 h. Then, acetone was removed under vacuum and the reaction extracted 
with AcOEt (3 x 20 mL). The organic phase was washed with water (60 mL), dried over 
Na2SO4, filtered and concentrated under reduced pressure. The crude was purified by column 
chromatography using PE (bp 40-60 °C)/CH2Cl2 (6:4) as eluent, obtaining 185d as a white 
solid. 
 
Yield: 0.28 g, 71%  
Mp: 87-88 °C 
MW = 298.79 
Anal. calcd. for C16H11ClN2S: C 64.32, H 3.71, N 9.38, S 10.73; found C 64.44, H 3.80, N 
9.68, S 10.53. 
1








To a suspension of NaH (60% dispersion in mineral oil, 0.16 g, 4.00 mmol) in anhydrous 
DMF (9 mL) at 0 °C, thiophenol (0.10 mL, 1.00 mmol) was added. The mixture was stirred at 
0 °C under nitrogen atmosphere for 1 h, then a solution of the opportune derivative 184b,c 
(1.00 mmol) in anhydrous DMF (2 mL) was added. The reaction was stirred at room 
temperature under nitrogen atmosphere for 3 h. Then, water was added dropwise, cooling in 
ice bath, and the reaction extracted with CH2Cl2 (3 x 30 mL). The organic phase was washed 
with water (90 mL), dried over Na2SO4, filtered and concentrated under reduced pressure. The 
crude product was purified by column chromatography using n-hexane/AcOEt (95:5) to 
afford the pure products as white solids. 
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2-Chloro-4-(4-chlorophenyl)-6-(phenylthio)pyrimidine 185e  
Yield: 0.16 g, 47% 
Mp: 101-105 °C  
MW = 333.24 
Anal. calcd. for C16H10Cl2N2S: C 57.67, H 3.02, N 8.41, S 9.62; found C 57.55, H 3.31, N 
8.76, S 9.92. 
1
H-NMR (200 MHz, CDCl3): δ (ppm) 6.86 (s, 1H pyr), 7.33-7.48 and 7.57-7.69 (2 m, 9H Ar). 
 
2-Chloro-4-(4-fluorophenyl-6-(phenylthio)pyrimidine 185f   
Yield: 0.22 g, 71% 
Mp: 98-99 °C  
MW = 316.78 
Anal. calcd. for C16H10ClFN2S: C 60.66, H 3.18, N 8.84, S 10.12; found C 60.52, H 3.30, N 
8.51, S 10.50. 
1
H-NMR (200 MHz, CDCl3): δ (ppm) 6.85 (s, 1H pyr), 7.41-7.43, 7.57-7.62 and 7.65-7.75 (3 
m, 9H Ar). 
 
 




It was used the same procedure employed to obtain intermediate 185a-c. To a solution of 
intermediates 184a,b (1.00 g, 5.45 mmol) in THF (9 mL), the opportune phenylboronic acid 
(5.45 mmol), Pd(OAc)2 (24.47 mg, 0.11 mmol), PPh3 (42.88 mg, 0.16 mmol) and 1 M Na2CO3 
(9 mL) were added. The resulting mixture was stirred at reflux under nitrogen atmosphere for 
3 h. Then, the solvent was removed under vacuum and the reaction extracted with CH2Cl2 (3 
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x 30 mL). The organic phase was washed with water (90 mL), dried over Na2SO4, filtered and 
concentrated under reduced pressure. The crude product was purified by column 
chromatography using PE (bp 40-60 °C)/AcOEt (95:5) (185g), n-hexane/AcOEt (95:5) (185h) 
or (98:2) (185i) as eluent, to afford the pure products as white solids.  
 
2-Chloro-4-(4-chlorophenyl)-6-phenylpyrimidine 185g 
Yield: 0.74 g, 45% 
Mp: 137-140 °C  
MW = 301.17 
Anal. calcd. for C16H10Cl2N2: C 63.81, H 3.35, N 9.30; found C 63.65, H 3.37, N 9.31. 
1
H-NMR (200 MHz, CDCl3): δ (ppm) 7.57-7.60 (m, 5H Ar), 8.02 (s, 1H pyr), 8.15-8.19 (m, 
4H Ar).  
 
2-Chloro-4-(4-fluorophenyl)-6-phenylpyrimidine 185h 
Yield: 0.98 g, 63%  
Mp: 121-124 °C 
MW = 284.72 
Anal. calcd. for C16H10ClFN2: C 67.50, H 3.54, N 9.84; found C 67.44, H 3.84, N 9.89. 
1
H-NMR (200 MHz, CDCl3): δ (ppm) 7.24-7.30 and 7.56-7.60 (2 m, 5H Ar), 8.00 (s, 1H pyr), 
8.15-8.21 (m, 4H Ar).  
 
2-Chloro-4-(4-chlorophenyl)-6-(4-fluorophenyl)pyrimidine 185i 
Yield: 0.42 g, 24% 
Mp: 147-149 °C 
MW = 319.16  
Anal. calcd. for  C16H9Cl2FN2: C 60.21, H 2.84, N 8.78; found C 60.09, H 2.78, N 8.98. 
1
H-NMR (200 MHz, CDCl3): δ (ppm) 7.26-7.30 and 7.52-7.57 (2 m, 4H Ar), 7.97 (s, 1H pyr), 
8.11-8.21 (m, 4H Ar).  
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To a solution of 2,4,6-trichloropyrimidine (1.00 g, 5.45 mmol) in THF (9 mL), an excess of 
the opportune phenylboronic acid (10.90 mmol), Pd(OAc)2 (24.47 mg, 0.11 mmol,), PPh3 
(42.88 mg, 0.16 mmol) and 1 M Na2CO3 (9 mL) were added. The resulting mixture was stirred 
at reflux under nitrogen atmosphere for 3 h. Then, solvent was removed under vacuum and 
the reaction extracted with CH2Cl2 (3 x 40 mL). The organic phase was washed with water 
(100 mL), dried over Na2SO4, filtered and concentrated under reduced pressure. The crude 
was purified by column chromatography using PE (bp 40-60 °C)/CH2Cl2 (6:4) (186a) or (1:1) 
(186b) as eluent, obtaining the final products as white solids. 
 
2-Chloro-4,6-bis(4-chlorophenyl)pyrimidine 186a 
Yield: 1.12 g, 61% 
Mp: 133-138 °C  
MW = 335.62 
Anal. calcd. for C16H9Cl3N2: C 57.26, H 2.70, N 8.35; found C 57.19, H 2.64, N 8.20. 
1
H-NMR (200 MHz, CDCl3): δ (ppm) 7.52-7.56 (m, 4H Ar), 7.99 (s, 1H pyr), 8.04-8.15 (m, 
4H Ar).  
 
2-Chloro-4,6-bis(4-fluorophenyl)pyrimidine 186b 
Yield: 0.78 g, 47%  
Mp: 153-154 °C  
MW = 302.71 
Anal. calcd. for C16H9ClF2N2: C 63.48, H 3.00, N 9.25; found C 63.47, H 3.28, N 9.44. 
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H-NMR (200 MHz, CDCl3): δ (ppm) 7.21-7.28 (m, 4H Ar), 7.95 (s, 1H, pyr), 8.15-8.22 (m, 
4H Ar).  
 
 




To a solution of 2,6-dichloropyrimidine-4-carboxylic acid (0.50 g, 2.59 mmol) in THF (5 
mL), phenylboronic acid (0.26 g, 2.15 mmol), Pd(OAc)2 (11.63 mg, 0.05 mmol), PPh3 (20.38 
mg, 0.08 mmol) and 1 M Na2CO3 (4.50 mL) were added. The resulting mixture was stirred at 
reflux under nitrogen atmosphere for 6 h. Then, the solvent was removed under vacuum, 1 N 
HCl was added and the reaction extracted with CH2Cl2 (3 x 30 mL). The organic phase was 
washed with water (90 mL), dried over Na2SO4, filtered and concentrated under reduced 
pressure. The crude residue was used in the next reaction without any further purification. 
 
MW = 234.64  
LRMS (ESI) m/z = 235.8 [M+H]
+
. 
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To a solution of intermediate 187 (0.61 g, 2.60 mmol) in anhydrous DMF (8 mL), aniline 
(0.28 mL, 3.13 mmol), EDC (0.60 g, 3.13 mmol) and HOBt (0.35 g, 2.60 mmol) were added. 
The mixture was stirred under nitrogen atmosphere at room temperature for 3 h. Then, the 
reaction was quenched with water and extracted with AcOEt (3 x 30 mL). The organic phase 
was washed with saturated NaHCO3 solution (2 x 30 mL) and with saturated NaCl solution (2 
x 30 mL), dried over Na2SO4, filtered and concentrated under reduced pressure. The crude 
product was purified by column chromatography using n-hexane/AcOEt (7:3) as eluent, to 
obtain the desired compound as an off-white solid. 
 
Yield: 0.09 g, 20%  
Mp: 182-183 °C  
MW = 309.75 
Anal. calcd. for C17H12ClN3O: C 65.92, H 3.90, N 13.57; found C 66.04, H 3.98, N 13.49. 
1
H-NMR (200 MHz, CDCl3): δ (ppm) 7.24-7.27, 7.42-7.62, 7.81-7.84 and 8.23-8.28 (4 m, 
10H, Ar), 8.60 (s, 1H pyr), 9.70 (br s, 1H, NH).  
IR (KBr): cm
-1
 3364 (NH), 1692 (CO), 1531 (NH). 
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To a suspension of the appropriate intermediate 185a-i, 186a,b or 188 (1.00 mmol) in 
anhydrous MeCN at 0 °C, 2-mercapto-N-(m-tolyl)acetamide (0.20 g, 1.10 mmol) and 
anhydrous K2CO3 (0.21 g, 1.50 mmol) were added. The reaction was stirred at room 
temperature under nitrogen atmosphere for 5 h. Then, the solvent was removed under vacuum 
and the reaction extracted with CH2Cl2 (3 x 30 mL). The organic phase was washed with 
water (90 mL), dried over Na2SO4, filtered and concentrated under reduced pressure. The 
crude product was purified by column chromatography using CH2Cl2 as eluent, to obtain the 
final products as white solids. 
 
N-(3-Methylphenyl)-2-{[4-(1-naphthyl)-6-phenylpyrimidin-2-yl]thio}acetamide 183a 
Yield: 0.09 g, 20%  
Mp: 147-148 °C 
MW = 461.58 
Anal. calcd. for C29H23N3OS: C 75.46, H 5.02, N 9.10, S 6.95; found C 75.23, H 5.29, N 8.81, 
S 6.60. 
1
H-NMR (400 MHz, CDCl3): δ (ppm) 2.04 (s, 3H, CH3), 4.01 (s, 2H, CH2), 6.58 (s, 1H, Ha), 
6.73-6.75 (m, 1H, Hb), 6.94-7.01 (m, 2H, Hc + Hd), 7.52-7.64 and 7.75-7.78 (2 m, 8H, 3H Ar 
+ 4H naph + H-5), 7.97 and 8.04 (2 d, J = 8.0 Hz, 1H naph), 8.15-8.20 (m, 3H, 2H Ar + 1H 
naph), 9.32 (br s, 1H, NH).  
13
C-NMR (100 MHz, CDCl3): δ (ppm) 203.06, 192.71, 183.39, 167.57, 167.22, 165.07, 
157.51, 151.29, 138.42, 133.91, 130.77, 129.16, 128.72, 128.50, 127.45, 127.35, 126.49, 
125.24, 124.65, 124.54, 119.74, 116.33, 113.79, 78.82, 68.74, 35.86, 21.07. 
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Yield: 0.10 g, 20% 
Mp: 103-107 °C 
MW = 496.02 
Anal. calcd. for C29H22ClN3OS: C 70.22, H 4.47, N 8.47, S 6.46; found 70.45, H 4.73, N 8.15, 
S 6.80. 
1
H-NMR (400 MHz, CDCl3): δ (ppm) 2.06 (s, 3H, CH3), 4.00 (s, 2H, CH2), 6.60 (s, 1H, Ha), 
6.75-6.76 (m, 1H, Hb), 6.96-6.99 (m, 2H, Hc + Hd), 7.51-7.65 and 7.75-7.78 (2 m, 7H, 2H Ar 
+ 4H naph + H-5), 7.98 (d, J = 8.0 Hz, 1H naph), 8.04-8.06 and 8.10-8.12 (2 m, 3H, 2H Ar + 
1H naph), 8.19 (d, J = 7.6 Hz, 1H naph), 9.25 (br s, 1H, NH). 
13
C-NMR (100 MHz, CDCl3): δ (ppm) 203.01, 192.71, 183.39, 167.72, 167.02, 163.05, 
138.49, 138.00, 137.67, 134.27, 133.94, 130.89, 130.35, 129.41, 128.74, 128.55, 127.99, 
127.43, 126.56, 125.25, 124.66, 124.57, 119.75, 116.36, 113.46, 35.89, 21.07. 
IR (KBr): cm
-1




Yield: 0.26 g, 55% 
Mp: 145-147 °C 
MW = 479.57 
Anal. calcd. for C29H22FN3OS: C 72.63, H 4.62, N 8.76, S 6.69; found C 72.49, H 4.36, N 
8.42, S 6.93. 
1
H-NMR (400 MHz, CDCl3): δ (ppm) 2.05 (s, 3H, CH3), 3.99 (s, 2H, CH2), 6.61 (s, 1H, Ha), 
6.75-6.79 (m, 1H, Hb), 6.95-6.99 (m, 2H, Hc + Hd), 7.20-7.26, 7.52-7.64 and 7.73-7.76 (3 m, 
7H, 2H Ar + 4H naph + H-5), 7.97 and 8.04 (2 d, J = 8.0 Hz, 1H naph), 8.14-8.16 (m, 3H, 2H 
Ar + 1H naph), 9.27 (br s, 1H, NH).  
13
C-NMR (100 MHz, CDCl3): δ (ppm) 198.01, 189.39, 167.75, 167.05, 163.05, 138.49, 
137.65, 133.93, 131.91, 130.91, 130.33, 129.73, 129.65, 128.79, 128.54, 128.02, 127.43, 
126.56, 125.25, 124.69, 124.55, 119.80, 116.39, 116.16, 113.38, 35.86, 21.07. 
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 3241-2916 (NH), 1665 (CO). 
 
N-(3-Methylphenyl)-2-{[4-phenyl-6-(phenylthio)pyrimidin-2-yl]thio}acetamide 183d  
Yield: 0.12 g, 27% 
Mp: 127-128 °C 
MW = 443.58 
Anal. calcd. for C25H21N3OS2: C 67.69, H 4.77, N 9.47, S 14.46; found C 67.75, H 4.77, N 
9.47, S 14.10. 
1
H-NMR (400 MHz, CDCl3): δ (ppm) 2.34 (s, 3H, CH3), 3.70 (s, 2H, CH2), 6.91 (d, J = 7.6 
Hz, 1H, Hb), 7.21-7.27 (m, 3H, Ha + Hc + Hd), 7.31-7.50 (m, 6H Ar), 7.51 (s, 1H, H-5), 7.68 
(d, J = 7.2 Hz, 2H Ar), 7.92 (d, J = 7.6 Hz, 2H Ar), 8.61 (br s, 1H, NH).  
13
C-NMR (100 MHz, CDCl3): δ (ppm) 203.06, 171.98, 171.09, 169.19, 166.77, 138.66, 
137.64, 135.20, 131.42, 129.59, 129.21, 128.84, 128.60, 127.25, 125.33, 124.95, 120.55, 
117.00, 110.02, 33.44, 21.39. 
IR (KBr): cm
-1




Yield: 0.10 g, 20%  
Mp: 150-154 °C  
MW = 478.03 
Anal. calcd. for C25H20ClN3OS2: C 62.81, H 4.22, N 8.79, S 13.42; found C 62.51, H 4.38, N 
9.19, S 13.46. 
1
H-NMR (400 MHz, CDCl3): δ (ppm) 2.34 (s, 3H, CH3), 3.70 (s, 2H, CH2), 6.91 (d, J = 7.2 
Hz, 1H, Hb), 7.17-7.21 and 7.25-7.31 (2 m, 4H, Ha + Hd + Hc + H-5), 7.37-7.46 (m, 5H Ar), 
7.67 (d, J = 7.2 Hz, 2H Ar), 7.85 (d, J = 8.4 Hz, 2H Ar), 8.61 (br s, 1H, NH). 
13
C-NMR (100 MHz, CDCl3): δ (ppm) 202.01, 172.18, 169.48, 166.67, 138.50, 137.76, 
137.60, 135.51, 133.68, 129.68, 129.25, 129.14, 128.63, 128.50, 125.01, 120.55, 116.99, 
116.10, 109.76, 33.47, 21.40.  
IR (KBr): cm
-1
 3240-2926 (NH), 1667 (CO). 
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Yield: 0.09 g, 20% 
Mp: 146-147 °C 
MW = 461.57 
Anal. calcd. for C25H20FN3OS2: C 65.05, H 4.37, N 9.10, S 13.89; found C 65.03, H 4.31, N 
9.28, S 13.89.     
1
H-NMR (400 MHz, CDCl3) : δ (ppm) 2.34 (s, 3H, CH3), 3.70 (s, 2H, CH2), 6.91 (d, J = 7.2 
Hz, 1H, Hb), 7.10-7.13 and 7.17-7.21 (2 m, 3H, Ha + Hd + Hc), 7.25-7.27 (m, 2H Ar), 7.31 
(s, 1H, H-5), 7.37-7.46 (m, 3H Ar), 7.67 (d, J = 7.2 Hz, 2H Ar), 7.90-7.93 (m, 2H Ar), 8.53 
(br s, 1H, NH). 
13
C-NMR (100 MHz, CDCl3): δ (ppm) 201.95, 172.10, 169.30, 166.73, 161.49, 138.67, 
137.62, 135.50, 129.65, 129.44, 129.36, 129.25, 128.63, 124.98, 120.55, 116.99, 116.07, 
115.86, 109.61, 33.47, 21.41. 
IR (KBr): cm
-1
 3235-2915 (NH), 1659 (CO). 
 
2-{[4-(4-Chlorophenyl)-6-phenylpyrimidin-2-yl]thio}-N-(3-methylphenyl)acetamide 183g 
Yield: 0.09 g, 20% 
Mp: 204-206 °C  
MW = 445.96 
Anal. calcd. for C25H20ClN3OS2: C 67.33, H 4.52, N 9.42, S 7.19; found C 67.25, H 4.54, N 
9.10, S 7.40. 
1
H-NMR (400 MHz, CDCl3): δ (ppm) 2.19 (s, 3H, CH3), 4.09 (s, 2H, CH2), 6.81 (d, J = 7.6 
Hz, 1H, Hb), 6.91 (s, 1H, Ha), 7.03-7.14 (m, 2H, Hc + Hd), 7.51-7.57 (m, 5H Ar), 7.82 (s, 
1H, H-5), 8.09-8.15 (m, 4H Ar), 9.14 (br s, 1H, NH).  
13
C-NMR (100 MHz, CDCl3): δ (ppm) 201.50, 170.99, 167.05, 164.28, 138.60, 137.68, 
136.04, 134.51, 131.58, 129.36, 129.19, 129.05, 128.66, 127.37, 124.82, 120.10, 116.55, 
116.10, 108.76, 35.89, 21.24. 
IR (KBr): cm
-1
 3239-2914 (NH), 1663 (CO). 
 
2-{[4-(4-Fluorophenyl)-6-phenylpyrimidin-2-yl]thio}-N-(3-methylphenyl)acetamide 183h 
Yield: 0.09 g, 20% 
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Mp: 186-190 °C  
MW = 429.51 
Anal. calcd. for C25H20FN3OS: C 69.91, H 4.69, N 9.78, S 7.47; found C 69.75, H 4.82, N 
10.05, S 7.41.     
1
H-NMR (400 MHz, CDCl3): 2.16 (s, 3H, CH3), 4.05 (s, 2H, CH2), 6.81 (d, J = 7.2 Hz, 1H, 
Hb), 6.92 (s, 1H, Ha), 7.03-7.13 (m, 2H, Hc + Hd), 7.21-7.26 and 7.56-7.59 (2 m, 5H Ar), 
7.82 (s, 1H, H-5), 8.14-8.17 (m, 4H Ar), 9.17 (br s, 1H, NH).  
13
C-NMR (100 MHz, CDCl3): δ (ppm) 202.95, 170.05, 167.13, 165.51, 137.70, 136.09, 
131.55, 129.62, 129.52, 129.20, 128.64, 127.39, 124.82, 120.13, 116.58, 116.34, 116.12, 
114.48, 108.70, 35.97, 21.23. 
IR (KBr): cm
-1




Yield: 0.11 g, 23% 
Mp: 213-217 °C 
MW = 463.95 
Anal. calcd. for C25H19ClFN3OS: C 64.72, H 4.13, N 9.06, S 6.91; found C 64.88, H 4.49, N 
9.46, S 7.24. 
1
H-NMR (400 MHz, CDCl3): 2.19 (s, 3H, CH3), 4.04 (s, 2H, CH2), 6.83 (d, J = 7.2 Hz, 1H, 
Hb), 6.98 (s, 1H, Ha), 7.06-7.16 (m, 2H, Hc + Hd), 7.23-7.26 and 7.51-7.52 (2 m, 4H Ar), 
7.77 (s, 1H, H-5), 8.08-8.16 (m, 4H Ar), 8.98 (br s, 1H, NH). 
13
C-NMR (100 MHz, CDCl3): δ (ppm) 201.05, 170.93, 166.88, 164.48, 138.69, 137.87, 
137.60, 134.48, 132.13, 129.60, 129.52, 129.41, 128.66, 124.95, 120.17, 116.61, 116.39, 
116.17, 108.37, 35.98, 21.26. 
IR (KBr): cm
-1
 3241-2914 (NH), 1665 (CO). 
 
2-{[4,6-Bis(4-chlorophenyl)pyrimidin-2-yl]thio}-N-(3-methylphenyl)acetamide 183l 
Yield: 0.10 g, 20% 
Mp: 225-227 °C  
MW = 480.41 
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Anal. calcd. for C25H19Cl2N3OS: C 62.50, H 3.99, N 8.75, S 6.67; found C 62.43, H 4.25, N 
8.83, S 6.60. 
1
H-NMR (400 MHz, CDCl3): δ (ppm) 2.19 (s, 3H, CH3), 4.03 (s, 2H, CH2), 6.83 (d, J = 8.0 
Hz, 1H, Hb), 6.96 (s, 1H, Ha), 7.08 and 7.15 (2 t, J = 8.0 Hz, 2H, Hc + Hd), 7.52 (d, J = 8.4 
Hz, 4H Ar), 7.78 (s, 1H, H-5), 8.09 (d, J = 8.4 Hz, 4H Ar), 8.96 (br s, 1H, NH).  
13
C-NMR (100 MHz, CDCl3): δ (ppm) 203.05, 167.10, 164.41, 163.50, 137.94, 134.41, 
129.41, 128.71, 128.63, 124.96, 120.12, 116.56, 112.15, 108.39, 35.81, 21.23. 
IR (KBr): cm
-1
 3238-2912 (NH), 1661 (CO). 
 
2-{[4,6-Bis(4-fluorophenyl)pyrimidin-2-yl]thio}-N-(3-methylphenyl)acetamide 183m 
Yield: 0.10 g, 23% 
Mp: 210-211 °C  
MW = 447.50 
Anal. calcd. for C25H19F2N3OS: C 67.10, H 4.28, N 9.39, S 7.17; found C 67.42, H 4.11, N 
9.34, S 6.80. 
1
H-NMR (400 MHz, CDCl3): δ (ppm) 2.18 (s, 3H, CH3), 4.04 (s, 2H, CH2), 6.82 (d, J = 7.2 
Hz, 1H, Hb), 6.99 (s, 1H, Ha), 7.07 (t, J = 7.8 Hz, 1H, Hc), 7.13 (d, J = 8.0 Hz, 1H, Hd), 7.21-
7.26 (m, 4H Ar), 7.76 (s, 1H, H-5), 8.14-8.17 (m, 4H Ar) 9.03 (br s, 1H, NH).  
13
C-NMR (100 MHz, CDCl3): δ (ppm) 203.06, 166.92, 164.36, 163.66, 137.63, 129.55, 
129.46, 128.69, 124.92, 120.12, 116.55, 116.37, 116.15, 108.20, 35.78, 21.23. 
IR (KBr): cm
-1




Yield: 0.28 g, 62%  
Mp: 181-182 °C  
MW = 454.54 
Anal. calcd. for C26H22N4O2S: C 68.70, H 4.88, N 12.33, S 7.05; found C 68.40, H 5.18, N 
12.14, S 6.70. 
1
H-NMR (400 MHz, DMSO-d6): δ (ppm) 2.19 (s, 3H, CH3), 4.21 (s, 2H, CH2), 6.83 (d, J = 
7.6 Hz, 1H, Hb), 7.13-7.19 (m, 3H, Ha + Hc + Hd), 7.36-7.43 and 7.46-7.50 (2 m, 5H Ar), 
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7.57 (t, J = 7.2 Hz, 1H Ar), 7.88 (d, J = 8.0 Hz, 2H Ar), 8.24-8.26 (m, 3H, 2H Ar + H-5), 
10.29 and 10.52 (2 br s, 1H, 2 NH). 
13
C-NMR (100 MHz, DMSO-d6): δ (ppm) 167.24, 166.23, 160.10, 158.50, 141.10, 139.21, 
138.33, 138.17, 135.48, 132.39, 129.52, 129.20, 128.98, 127.99, 125.01, 124.55, 120.93, 
120.20, 116.83, 109.95, 36.43, 21.48. 
IR (KBr): cm
-1
 3339-2911 (NH), 1695 and 1656 (2 CO). 
 
 




To a solution of 2,6-dichloro-4-iodopyridine (0.50 g, 1.83 mmol) in THF (6 mL), the 
opportune phenylboronic acid (2.01 mmol),  Pd(OAc)2  (8.20 mg, 0.04 mmol), PPh3 (14.36 
mg, 0.05 mmol) and 1 M Na2CO3 (4.50 mL) were added. The resulting mixture was stirred at 
reflux under nitrogen atmosphere for 3 h. Then, solvent was removed under vacuum and the 
reaction extracted with CH2Cl2 (3 x 30 mL). The organic phase was washed with water, dried 
over Na2SO4, filtered and concentrated under reduced pressure. The crude was purified by 
column chromatography using PE (bp 40-60 °C)/AcOEt (95:5) as eluent, to afford the pure 
products as white solids.  
 
2,6-Dichloro-4-phenylpyridine 190a  
Yield: 0.30 g, 73%  
Mp: 54-55 °C  
MW = 224.09 
Anal. calcd. for C11H7Cl2N: C 58.96, H 3.15, N 6.25; found C 58.88, H 3.12, N 5.96. 
1
H-NMR (200 MHz, CDCl3): δ (ppm) 7.49 (s, 2H pyr), 7.50-7.54 and 7.60-7.63 (2 m, 5H Ar).  
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Yield: 0.35 g, 74%  
Mp: 151-152 °C 
MW = 258.53  
Anal. calcd. for C11H6Cl3N: C 51.10, H 2.34, N 5.42; found C 51.14, H 2.25, N 5.07. 
1
H-NMR (200 MHz, CDCl3): δ (ppm) 7.47 (s, 2H pyr), 7.54-7.55 (m, 4H Ar).  
 
2,6-dichloro-4-(4-fluorophenyl)pyridine 190c 
Yield: 0.23 g, 53%  
Mp: 164-166 °C 
MW = 242.08 
Anal. calcd. for C11H6Cl2FN: C 54.58, H 2.50, N 5.79; found C 54.33, H 2.53, N 5.55.  
1
H-NMR (200 MHz, CDCl3): δ (ppm) 7.19-7.27 (m, 2H Ar), 7.46 (s, 2H pyr), 7.58-7.65 (m, 
2H Ar).  
 
 




To a suspension of NaH (60% dispersion in mineral oil, 0.16 g, 4.00 mmol) in anhydrous 
DMF (9 mL) at 0 °C, thiophenol (0.10 mL, 1.00 mmol) was added. The mixture was stirred at 
0 °C under nitrogen atmosphere for 1 h. Then, a solution of the opportune derivative 190a-c 
(1.00 mmol) in anhydrous DMF (2 mL) was added and the reaction was stirred at room 
temperature under nitrogen for 3 h (191a,b) or 24 h (191c). Water was added dropwise, 
cooling in ice bath, and the reaction extracted with CH2Cl2 (3 x 30 mL). The organic phase 
was washed with water, dried over Na2SO4, filtered and concentrated under reduced pressure. 
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The crude product was purified by column chromatography using n-hexane/AcOEt (95:5) 
(191a,b), or (9:1) (191c) as eluent, to afford the pure products as white solids.  
 
2-Chloro-4-phenyl-6-(phenylthio)pyridine 191a 
Yield: 0.28 g, 95%  
Mp: 57-58 °C  
MW = 297.80 
Anal. calcd. for C17H12ClNS: C 68.56, H 4.06, N 4.70, S 10.77; found C 68.41, H 3.90, N 
5.00, S 11.11. 
1
H-NMR (200 MHz, CDCl3): δ (ppm) 6.94 and 7.25 (2 s, 1H pyr), 7.44-7.51 and 7.63-7.70 (2 
m, 10H Ar). 
 
2-Chloro-4-(4-chlorophenyl)-6-(phenylthio)pyridine 191b 
Yield: 0.27 g, 82% 
Mp: 82-86 °C  
MW = 332.25 
Anal. calcd. for C17H11Cl2NS: C 61.45, H 3.34, N 4.22, S 9.65; found C 61.40, H 3.54, N 
4.45, S 9.82. 
1
H-NMR (200 MHz, CDCl3): δ (ppm) 6.88 and 7.21 (2 s, 1H pyr), 7.37-7.52 and 7.65-7.68 (2 
m, 9H Ar). 
 
2-Chloro-4-(4-fluorophenyl)-6-(phenylthio)pyridine 191c 
Yield: 0.32 g, quantitative 
Mp: 47-50 °C  
MW = 315.79 
Anal. calcd. for C17H11ClFNS: C 64.66, H 3.51, N 4.44, S 10.15; found C 64.65, H 3.41, N 
4.76, S 10.29. 
1
H-NMR (200 MHz, CDCl3): δ (ppm) 6.88 and 7.10 (2 s, 1H pyr), 7.14-7.22, 7.38-7.52 and 
7.66-7.67 (3 m, 9H Ar). 
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To a solution of the opportune intermediate 190a,b (2.00 mmol) in DME (10 mL), 
naphthalene boronic acid (0.28 g, 1.60 mmol), Pd(OAc)2 (22.45 mg, 0.10 mmol), PPh3 (52.36 
mg, 0.20 mmol) and Na2CO3 (0.66 g, 6.20 mmol) dissolved in the minimum amount of water, 
were added. The resulting mixture was stirred at reflux under nitrogen atmosphere for 3 h. 
Then, solvent was removed under vacuum and the reaction extracted with CH2Cl2 (3 x 30 
mL). The organic phase was washed with water, dried over Na2SO4, filtered and concentrated 
under reduced pressure. The product was purified by column chromatography using PE (bp 
40-60 °C)/CH2Cl2 (1:1) (191d) or n-hexane/AcOEt (95:5) (191e), to afford the pure products 
as white solids.  
 
2-Chloro-6-(1-naphthyl)-4-phenylpyridine 191d 
Yield: 0.21 g, 33% 
Mp: 128-130 °C  
MW = 315.80 
Anal. calcd. for C21H14ClN C 79.87, H 4.47, N 4.44, found C 79.69, H 4.41, N 4.71. 
1
H-NMR (200 MHz, CDCl3): δ (ppm) 7.52-7.77 (m, 11H, 5H Ar + 4H naph + 2H pyr), 7.96-
8.01 and 8.15-8.22 (2 m, 3H naph). 
 
2-Chloro-4-(4-chlorophenyl)-6-(1-naphthyl)pyridine 191e 
Yield: 0.14 g, 20% 
Mp: 112-113 °C  
MW = 350.24 
Anal. calcd. for C21H13Cl2N: C 72.01, H 3.74, N 4.00; found C 71.89, H 3.67, N 4.25. 
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H-NMR (200 MHz, CDCl3): δ (ppm) 7.50-7.73 (m, 10H, 4H Ar + 4H naph + 2H pyr), 7.94-
8.00 and 8.13-8.17 (2 m, 3H naph).  
 
 




To a solution of 2,6-dichloroisonicotinic acid (0.50 g, 2.60 mmol) or intermediate 192b (2.60 
mmol) in anhydrous DMF (8 mL), aniline (0.28 mL, 3.13 mmol), EDC (0.60 g, 3.13 mmol) 
and HOBt (0.35 g, 2.60 mmol) were added. The mixture was stirred under nitrogen 
atmosphere at room temperature for 2 h and then at 50 °C for 3 h. Then, the reaction was 
quenched with water and extracted with AcOEt (3 x 30 mL). The organic phase was washed 
with saturated NaHCO3 solution (2 x 30 mL) and with saturated NaCl solution (2 x 30 mL), 
dried over Na2SO4, filtered and concentrated under reduced pressure. The crude product was 
purified by column chromatography using n-hexane/AcOEt (8:2) (192a) or CH2Cl2 (193b) as 
eluent, to afford the pure products as off-white solids. 
 
2,6-dichloro-N-phenylisonicotinamide 192a 
Yield: 0.54 g, 78% 
Mp: 180-181 °C 
MW = 267.11 
Anal. calcd. for C12H8Cl2N2O: C 53.96, H 3.02, N 10.49; found C 53.78, H 3.00, N 10.50. 
1
H-NMR (200 MHz, CDCl3): δ (ppm) 7.21-7.29 (m, 1H Ar), 7.37 (t, J = 7.7 Hz, 2H Ar), 7.61 
(d, J = 8.0 Hz, 2H Ar), 7.69 (s, 2H, H-3 + H-5), 8.01 (br s, 1H, NH).  
IR (KBr): cm
-1
 3281 (NH), 1650 (CO). 
 
2-chloro-N,6-diphenylisonicotinamide 193b 
Yield: 0.09 g, 20%  
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Mp: 160-161 °C  
MW = 308.76 
Anal. calcd. for C18H13ClN2O: C 70.02, H 4.24, N 9.07; found C 70.04, H 4.02, N 8.86. 
1
H-NMR (200 MHz, CDCl3): δ (ppm) 7.24-7.29 and 7.39-7.52 (2 m, 6H, 5H Ar + H-3), 7.61 
(s, 1H, H-5), 7.67 (d, J = 8.0 Hz, 2H Ar),  8.03-8.07 (m, 3H Ar).  
IR (KBr): cm
-1
 3288 (NH), 1654 (CO). 
 
 




To a solution of 2,6-dichloropyrimidine-4-carboxylic acid (0.50 g, 2.59 mmol) in THF (5 
mL), phenylboronic acid (0.26 g, 2.15 mmol), Pd(OAc)2 (11.63 mg, 0.05 mmol), PPh3 (20.38 
mg, 0.08 mmol) and 1 M Na2CO3 (4.50 mL) were added. The resulting mixture was stirred at 
reflux under nitrogen atmosphere for 24 h. Then, the solvent was removed under vacuum, 1 N 
HCl was added and the reaction extracted with CH2Cl2 (3 x 30 mL). The organic phase was 
washed with water (90 mL), dried over Na2SO4, filtered and concentrated under reduced 
pressure. Compound 192b were used in the next reaction without any further purification. 
 
MW = 233.65  
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To a suspension of NaH (60% dispersion in mineral oil, 0.16 g, 4.00 mmol) in anhydrous 
DMF (9 mL) at 0 °C, thiophenol (0.10 mL, 1.00 mmol) was added. The mixture was stirred at 
0 °C under nitrogen atmosphere for 1 h, then a solution of 192a (0.27 g, 1.00 mmol) in 
anhydrous DMF (2 mL) was added. The reaction was stirred at room temperature under 
nitrogen atmosphere for 24 h. Then, water was added dropwise, cooling in ice bath, and the 
reaction extracted with CH2Cl2 (3 x 30 mL). The organic phase was washed with water (90 
mL), dried over Na2SO4, filtered and concentrated under reduced pressure. The crude product 
was purified by column chromatography using n-hexane/CH2Cl2/AcOEt (5:4:1), to afford the 
pure product as a white solid. 
 
Yield: 0.57 g, 89%  
Mp: 158-159 °C 
MW = 340.83 
Anal. calcd. for C18H13ClN2OS: C 63.43, H 3.84, N 8.22, S 9.41; found C 63.53, H 3.95, N 
8.05, S 9.15. 
1
H-NMR (200 MHz, CDCl3): δ (ppm) 7.10 (s, 1H, H-3), 7.17-7.25 and 7.35-7.63 (2 m, 11H, 
10H Ar + H-5), 7.83 (br s, 1H, NH).  
IR (KBr): cm
-1
 3329 (NH), 1682 (CO). 
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A round-bottom flask was charged with the appropriate intermediate 191a,b (1.00 mmol), 
anhydrous K2CO3 (0.28 g, 2.00 mmol), CuI (19.05 mg, 0.10 mmol) and L-proline (34.54 mg, 
0.30 mmol). The flask was evacuated and filled with nitrogen. 2-mercapto-N-(m-
tolyl)acetamide (0.20 g, 1.10 mmol) dissolved in anhydrous DME (5 mL) was introduced via 
syringe and the mixture was stirred at reflux under nitrogen atmosphere for 24 h. Then, the 
reaction was extracted with CH2Cl2 (3 x 30 mL), the organic phase was washed with saturated 
NaCl solution, dried over Na2SO4, filtered and concentrated under reduced pressure. The 
crude was purified by column chromatography, using CH2Cl2 as eluent, obtaining the final 
products as off-white solids. 
 
N-(3-methylphenyl)-2-{[4-phenyl-6-(phenylthio)pyridin-2-yl]thio}acetamide 189a 
Yield: 0.09 g, 20% 
Mp: 122-123 °C  
MW = 442.60 
Anal. calcd. for C26H22N2OS2: C 70.56, H 5.01, N 6.33, S 14.49; found C 70.52, H 5.31, N 
6.07, S 14.84. 
1
H-NMR (400 MHz, CDCl3): δ (ppm) 2.33 (s, 3H, CH3), 3.76 (s, 2H, CH2), 6.89 (d, J = 7.2 
Hz, 1H, Hb), 7.00 (s, 1H, Ha), 7.17-7.21 (m, 2H, Hc + Hd), 7.39-7.45 and 7.62-7.63 (2 m, 
12H, 10H Ar + 2H pyr), 9.34 (br s, 1H, NH).  
13
C-NMR (100 MHz, CDCl3): δ (ppm) 168.05, 167.50, 161.14, 150.29, 146.18, 138.59, 
138.16, 136.98, 135.00, 129.87, 129.74, 129.60, 129.10, 128.58, 126.94, 124.65, 120.45, 
116.88, 116.68, 116.31, 34.58, 21.41. 
IR (KBr): cm
-1
 3237-2913 (NH), 1666 (CO). 
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Yield: 0.10 g, 20% 
Mp: 93-95 °C 
MW = 477.04 
Anal. calcd. for C26H21ClN2OS2 C 65.46, H 4.44, N 5.87, S 13.44, found C 65.13, H 4.64, N 
6.20, S 13.58. 
1
H-NMR (400 MHz, CDCl3): δ (ppm) 2.34 (s, 3H, CH3), 3.74 (s, 2H, CH2), 6.90 (d, J = 7.2 
Hz, 1H, Hb), 7.01 (s, 1H, Ha), 7.16-7.20 (m, 2H, Hc + Hd), 7.37-7.44 and 7.61-7.62 (2 m, 
11H, 9H Ar + 2H pyr), 9.34 (br s, 1H, NH).  
13
C-NMR (100 MHz, CDCl3): δ (ppm) 181.05, 168.15, 161.30, 151.80, 146.20, 138.62, 
136.90, 135.02, 129.80, 129.55, 129.34, 128.59, 128.27, 128.16, 126.90, 124.90, 120.43, 
120.21, 116.80, 116.68, 29.59, 19.50. 
IR (KBr): cm
-1
 3237-2911 (NH), 1664 (CO). 
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To monohydrate hydrazine (12.50 g, 248.75 mmol) at 70 °C, 2-methyloxirane (2.75 g, 47.50 
mmol) was added dropwise. The reaction was stirred under reflux for 15 minutes and then the 
excess of hydrazine was removed under reduced pressure. The obtained residue was purified 
by bulb to bulb distillation with an oil pump, obtaining a colourless liquid which crystallized 
slowly. Compound 226a was used in the next reaction without any further characterization.  
 
Yield: 72% 
MW = 90.12 
 
 




A solution of 1-bromo-2-phenylpropane (1.99 g, 10.00 mmol) and hydrazine monohydrate 
(4.00 g, 80.00 mmol) in absolute EtOH (20 mL) was refluxed for 24 h. The solvent was 
evaporated under reduced pressure and the crude was treated with anhydrous K2CO3, then 
extracted with CHCl3 (3 x 20 mL). The organic solution was dried over Na2SO4, filtered and 
concentrated under reduced pressure. The crude was purified by bulb to bulb distillation to 
obtain the pure product, as pale yellow oil. Compound 226b was used in the next reaction 
without any further characterization.  
 
Yield: 0.95 g, 63% 
MW = 150.22 
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The appropriate hydrazine derivative 226a,b (5.00 mmol) was added to a solution of 
ethyl(ethoxymethylene)cyanoacetate (0.68 g, 5.00 mmol) in absolute EtOH (5 mL) and the 
mixture was refluxed for 8 h (227a) or for 5 h (227b). The solution was washed with water 
(10 mL), dried over Na2SO4 and concentrated under reduced pressure. The crude was purified 
by column chromatography using silica gel and CH2Cl2/MeOH (8:2) as eluent (227a) or 
Florisil
®
 and Et2O as eluent (227b), to afford the pure products. 
 
Ethyl 5-amino-1-(2-hydroxypropyl)-1H-pyrazole-4-carboxylate 227a 
Yield: 0.65 g, 61% 
Mp: 66-68 °C 
MW = 213.23 
Anal. calcd. for C9H15N3O3: C 50.69, H 7.09, N 19.71; found C 50.79, H 7.06, N 19.88.  
1
H-NMR (200 MHz, CDCl3): δ 1.26 (d, J = 6.4 Hz, 3H, CH3CH), 1.35 (t, J = 7.0 Hz, 3H, 
CH3CH2), 3.13 (br s, 1H, OH), 3.78-4.42 (m, 5H, CH2O + CH2N + CHCH3), 5.44 (br s, 2H, 
NH2), 7.61 (s, 1H, H-3). 
IR (KBr): cm
-1
 3426, 3390, 3313 (NH2 + OH), 1697 (CO). 
 
Ethyl 5-amino-1-(2-phenylpropyl)-1H-pyrazole-4-carboxylate 227b 
Yield: 0.82 g, 60% 
Mp: 85-86 °C 
MW = 273.33 
Anal. calcd for C15H19N3O2: C 65.91, H 7.01, N 15.37; found C 65.90, H 6.99, N 15.25. 
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H-NMR (200 MHz, CDCl3): δ 1.06-1.20 (m, 6H, 2 CH3), 3.24-3.26 (m, 1H, CH), 3.78-3.83 
and 3.85-3.90 (2 m, 2H, CH2N), 4.10 (q, J = 7.0 Hz, 2H, CH2O), 4.79 (br s, 2H, NH2), 7.00-
7.16 (m, 5H Ar), 7.55 (s, 1H, H-3). 
IR (KBr): cm
-1
 3400-3200 (NH2), 1681 (CO). 
 
 




To a solution of the opportune intermediate 227a,b (7.00 mmol) in EtOH (10 mL), 3.5 M 
NaOH (8 mL) was added and the reaction was stirred at reflux for 5 h. The solvent was 
removed under reduced pressure and the mixture was acidified with 6 N HCl, cooling with an 
ice-bath, obtaining a white solid. The solid was washed with water, filtered and recrystallized 
from absolute EtOH to obtain 228a,b as white solids. 
 
5-Amino-1-(2-hydroxypropyl)-1H-pyrazole-4-carboxylic acid 228a 
Yield: 0.99 g, 76% 
Mp: 142-143 °C 
MW = 185.18 
Anal. calcd for C7H11N3O3: C 45.40, H 5.99, N 22.69, found C 45.04, H 6.31, N 23.06. 
1
H-NMR (200 MHz, DMSO-d6): δ (ppm) 1.09 (d, J = 5.8 Hz, 3H, CH3CH), 3.99-4.06 (m, 
3H, CH2N + CHCH3), 5.71 (br s, 1H, OH), 7.91 (s, 1H, H-3). 
IR (KBr): cm
-1
 3400-2510 (OH), 3390-3307 (NH2), 1658 (CO). 
 
5-Amino-1-(2-phenylpropyl)-1H-pyrazole-4-carboxylic acid 228b  
Yield: 1.32 g, 77% 
Mp: 149-150 °C 
CHAPTER 7. Experimental section 
PhD Thesis in Pharmaceutical, Food and Cosmetic Sciences 
Ilaria Giacchello 
229 
MW = 245.28 
Anal. calcd for C13H15N3O2: C 63.66, H 6.16, N 17.13; found C 63.14, H 6.65, N 17.10. 
1
H-NMR (200 MHz, DMSO-d6): δ (ppm) 1.41-1.43 (m, 3H, CH3), 3.34-3.40 (m, 1H, CH), 
3.87-3.92 e 4.08-4.28 (2 m, 2H, CH2N), 4.75 (br s, 2H, NH2), 5.32 (br s, 1H, OH), 7.05-7.70 
(m, 5H Ar), 8.23 (s, 1H, H-3). 
IR (KBr): cm
-1
 3450-3100 (NH2), 1628 (CO). 
 
 




Intermediate 228a (5.00 mmol) was heated at 150 °C until the effervescence disappeared. 
Then, the reaction was cooled and Et2O (20 mL) was added. The precipitate was filtered and 
the crude obtained was used in the next reaction without any further purification. 
 
Yield: 0.38 g, 54%  
MW = 141.17 
 
 




Intermediate 228b (5.00 mmol) was heated at 150 °C until the effervescence disappeared. 
Then, after cooling, CHCl3 (15 mL) was added to the reaction, the mixture was washed with a 
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saturated NaHCO3 solution (15 mL), dried over Na2SO4, filtered and concentrated under 
reduced pressure The crude brown oil obtained was used in the next reaction without any 
further purification. 
 
Yield: 0.81 g, 80%  
MW = 201.27 
 
 




A mixture of the opportune intermediate 229a,b (5.00 mmol) and diethyletoxymethylene 
malonate (1.08 g, 5.00 mmol) was stirred at 120 °C for 2 h. After cooling, Et2O was added 
(20 mL) and a solid precipitated. It was filtered obtaining 230a as a pure white solid, while 
pure 230b was obtained after recrystallization with absolute EtOH.  
 
Diethyl ({[1-(2-hydroxypropyl)-1H-pyrazol-5-yl]amino}methylene)malonate 230a 
Yield: 1.53 g, 98% 
Mp: 111-113 °C 
MW = 311.33 
Anal. calcd for C14H21N3O5: C 54.01, H 6.80, N 13.50; found C 54.28, H 6.93, N 13.13. 
1
H-NMR (200 MHz, DMSO-d6): δ (ppm) 1.29 (d, J = 6.0 Hz, 3H, CH3CH), 1.42 (t, J = 6.0 
Hz, 6H, 2CH3), 4.00-4.37 (m, 7H, 2CH2O + CH2N + CHCH3), 6.14 (d, J = 4.04 Hz, 1H, H-3), 
7.51 (d, J = 4.04 Hz, 1H, H-4), 8.13 (d, J = 11.8 Hz, 1H, CHC), 11.18 (br s, 1H, OH). 
IR (KBr): cm
-1 
3448 (NH), 1689 (C=C), 1662, 1601 (2 CO). 
 
Diethyl ({[1-(2-phenylpropyl)-1H-pyrazol-5-yl]amino}methylene)malonate 230b 
Yield: 1.63 g, 88% 
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Mp: 88-89 °C 
MW = 371.43 
Anal. calcd for C20H25N3O4: C 64.67, H 6.78, N 11.31; found C 64.33, H 7.19, N 11.29. 
1
H-NMR (200 MHz, DMSO-d6): δ (ppm) 1.32-1.42 (m, 9H, 3 CH3), 3.43-3.52 (m, 1H, 
CHCH3), 4.11-4.13, 4.19-4.27 and 4.29-4.38 (3 m, 2H, CH2), 5.93 (d, J = 4.04 Hz, 1H, H-4), 
7.11-7.26 (m, 5H Ar), 7.28 (d, J = 4.04 Hz, 1H, H-3), 7.83 (d, J = 12.0 Hz, 1H, CHNH), 10.67 
(br s, 1H, NH). 
IR (KBr): cm
-1
 3222 (NH), 1720 (CO), 1606 (CH=CH). 
 
 




A solution of the opportune intermediate 230a,b (5.00 mmol) with POCl3 (6.00 g, 39.50 
mmol) was stirred at reflux for 18 h. After cooling, the mixture was quenched with ice-water 
(20 mL) and extracted with CH2Cl2 (20 mL x 3). The organic phase washed with water (60 
mL), dried over Na2SO4, filtered and concentrated under reduced pressure. The crude product 
was purified by column chromatography, using Florisil
®
 and CH2Cl2 as eluent, to obtain the 
desired compounds as yellow oils. 
 
Ethyl 4-chloro-1-(2-hydroxypropyl)-1H-pyrazolo[3,4-b]pyridine-5-carboxylate 231a 
Yield: 0.76 g, 54% 
MW = 283.71 
Anal. calcd for C12H14ClN3O3: C 50.80, H 4.97, N 14.81; found C 50.91, H 4.99, N 14.85. 
1
H-NMR (200 MHz, CDCl3): δ (ppm) 1.46 (t, J = 7.0 Hz, 3H, CH3CH2), 1.58 (d, J = 6.1 Hz, 




 1724 (CO). 
 
CHAPTER 7. Experimental section 




Ethyl 4-chloro-1-(2-phenylpropyl)-1H-pyrazolo[3,4-b]pyridine-5-carboxylate 231b 
Yield: 1.10 g, 64% 
MW = 343.81 
Anal. calcd for C18H18ClN3O2: C 62.88, H 5.28, N 12.22; found C 62.53, H 4.99, N 12.31. 
1
H-NMR (200 MHz, CDCl3): δ (ppm) 1.25-1.29 (m, 3H, CH3CH), 1.41 (t, J = 7.2 Hz, 3H, 
CH3CH2), 3.47-3.52 (m, 1H, CHCH3), 4.32 (q, J = 7.2 Hz, 2H, CH2O), 4.48-4.58 (m, 2H, 
CH2N), 7.00-7.50 (m, 5H Ar), 8.03 (s, 1H, H-3), 8.80 (s, 1H, H-6). 
IR (CHCl3): cm
-1
 1723 (CO). 
 
 




To a solution of the opportune intermediate 231a,b (1.00 mmol) in anhydrous toluene (10 
mL) the appropriate amine (4.00 mmol) was added and the mixture was stirred at room 
temperature for 48 h. The organic phase was washed with water (30 mL), dried over Na2SO4, 
filtered and concentrated under reduced pressure. The crude oils were purified with column 
chromatography using Florisil
® 
and Et2O as eluent, obtaining compounds 224a-f and 225a-g 
as white solids. 
 
Ethyl 4-(butylamino)-1-(2-chloropropyl)-1H-pyrazolo[3,4-b]pyridine-5-carboxylate 224a 
Yield: 0.21 g, 61% 
Mp: 69-70 °C 
MW = 338.83 
Anal. calcd for C16H23ClN4O2: C 56.72, H 6.84, N 16.54; found C 56.71, H 7.01, N 16.57. 
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H-NMR (200 MHz, DMSO-d6): δ (ppm) 1.10 (t, J = 7.4 Hz, 3H, CH3 but.) 1.44 (t, J = 7.0 
Hz, 3H, CH3CH2), 1.40-1.70 (m, 7H, 2 CH2 but. + CH3CH), 3.66-3.69 (m, 2H, CH2NH), 
4.40-4.72 (m, 5H, CH2O + CH2N + CHCH3), 8.24 (s, 1H, H-3), 9.03 (s, 1H, H-6).  
IR (KBr): cm
-1
 3278 (NH), 1674 (CO). 
 
Ethyl 4-(benzylamino)-1-(2-chloropropyl)-1H-pyrazolo[3,4-b]pyridine-5-carboxylate 224b 
Yield: 0.22 g, 59% 
Mp: 130-131 °C 
MW = 372.84 
Anal. calcd for C19H21ClN4O2: C 56.72, H 6.84, N 16.54; found C 56.71, H 7.01, N 16.57. 
1
H-NMR (200 MHz, DMSO-d6): δ (ppm) 1.45 (t, J = 7.0 Hz, 3H, CH3CH2), 1.58 (d, J = 6.1 
Hz, 3H, CH3CH), 4.40-4.52 and 4.60-4.72 (2 m, 7H, CH2O + CH2N + CH2NH + CHCH3), 
7.25-7.43 (m, 5H Ar), 8.25 (s, 1H, H-3), 9.07 (s, 1H, H-6). 
IR (KBr): cm
-1




Yield: 0.23 g, 58% 
Mp: 92-93 °C 
MW = 404.87 
Anal. calcd for C20H22ClFN4O2: C 59.33, H 5.48, N 13.84; found C 59.60, H 5.75, N 13.64. 
1
H-NMR (200 MHz, DMSO-d6): δ (ppm) 1.40 (t, J = 7.0 Hz, 3H, CH3CH2), 1.60 (d, J = 6.0 
Hz, 3H, CH3CH), 3.15 (t, J = 7.0 Hz, 2H, CH2Ar), 3.92 (q, J = 7.0 Hz, 2H, CH2NH), 4.43-
4.55 and 4.63-4.82 (2 m, 5H, CH2O + CH2N + CHCH3), 7.12-7.60 (m, 4H Ar), 8.12 (s, 1H, 
H-3), 8.88 (s, 1H, H-6). 
IR (KBr): cm
-1




Yield: 0.17 g, 43% 
Mp: 97-99 °C 
MW = 404.87 
Anal. calcd for C20H22ClFN4O2: C 59.33, H 5.48, N 13.84; found C 59.60, H 5.75, N 13.64. 
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H-NMR (200 MHz, DMSO-d6): δ (ppm) 1.41 (t, J = 7.0 Hz, 3H, CH3CH2), 1.60 (d, J = 6.0 
Hz, 3H, CH3CH), 3.11 (t, J = 7.0 Hz, 2H, CH2Ar), 3.93 (q, J = 7.0 Hz, 2H, CH2NH), 4.40-
4.55 and 4.64-4.80 (2 m, 5H, CH2O + CH2N + CHCH3), 7.15-7.58 (m, 4H Ar), 8.08 (s, 1H, 
H-3), 8.88 (s, 1H, H-6), 9.35 (br s, 1H, NH). 
IR (KBr): cm
-1




Yield: 0.21 g, 51% 
Mp: 84-85 °C 
MW = 404.87 
Anal. calcd for C20H22ClFN4O2: C 59.33, H 5.48, N 13.84; found C 59.60, H 5.75, N 13.64. 
1
H-NMR (200 MHz, DMSO-d6): δ (ppm) 1.41 (t, J = 7.0 Hz, 3H, CH3CH2), 1.61 (d, J = 6.0 
Hz, 3H, CH3CH), 3.12 (t, J = 7.0 Hz, 2H, CH2Ar), 3.92 (q, J = 7.0 Hz, 2H, CH2NH), 4.38-
4.54 and 4.65-4.78 (2 m, 5H, CH2O + CH2N + CHCH3), 7.13-7.48 (m, 4H Ar), 8.08 (s, 1H, 
H-3), 8.89 (s, 1H, H-6), 9.31 (br s, 1H, NH). 
IR (KBr): cm
-1




Yield: 0.23 g, 54% 
Mp: 52-53 °C 
MW = 416.90 
Anal. calcd for C21H25ClN4O3: C 60.50, H 6.04, N 13.44; found C 60.48, H 6.34, N 13.54. 
1
H-NMR (200 MHz, DMSO-d6): δ (ppm) 1.40 (t, J = 7.0 Hz, 3H, CH3CH2), 1.61 (d, J = 6.0 
Hz, 3H, CH3CH), 3.06 (t, J = 7.0 Hz, 2H, CH2Ar), 3.83 (s, 3H, OCH3), 3.88 (q, J = 7.0 Hz, 
2H, CH2NH), 4.37-4.54 and 4.62-4.74 (2 m, 5H, CH2O + CH2N + CHCH3), 7.13-7.45 (m, 4H 
Ar), 8.08 (s, 1H, H-3), 8.89 (s, 1H, H-6), 9.28 (br s, 1H, NH). 
IR (KBr): cm
-1
 3281 (NH), 1668 (CO). 
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Yield: 0.28 g, 66% 
Mp: 109-110 °C 
MW = 428.53 
Anal. calcd for C26H28N4O2: C 72.87, H 6.57, N 13.07; found C 72.64, H 6.76, N 12.70. 
1
H-NMR (200 MHz, CDCl3): δ (ppm) 1.23-1.28 (m, 3H, CH3CH), 1.42 (t, J = 7.2 Hz, 3H, 
CH3CH2), 3.08 (t, J = 6.8 Hz, 2H, CH2Ar), 3.57-3.75 (m, 1H, CHCH3), 3.95 (q, J = 6.8 Hz, 
2H, CH2NH), 4.37 (q, J = 7.2 Hz, 2H, CH2O), 4.51-4.65 (m, 2H, CH2N), 7.00-7.30 (m, 10H 
Ar), 8.03 (s, 1H, H-3), 8.85 (s, 1H, H-6), 9.25 (br s, 1H, NH). 
IR (KBr): cm
-1




Yield: 0.28 g, 60% 
Mp: 96-97 °C 
MW = 462.97 
Anal. calcd for C26H27ClN4O2: C 67.45, H 5.88, N 12.10; found C 67.47, H 6.09, N 12.08. 
1
H-NMR (200 MHz, CDCl3): δ 1.20-1.27 (m, 3H, CH3CH), 1.38 (t, J = 7.2 Hz, 3H, CH3CH2), 
3.07 (t, J = 6.8 Hz, 2H, CH2Ar), 3.58-3.61 (m, 1H, CHCH3), 3.90 (q, J = 6.8 Hz, 2H, 
CH2NH), 4.33 (q, J = 7.2 Hz, 2H, CH2O), 4.54-4.60 (m, 2H, CH2N), 7.15-7.33 (m, 9H Ar), 
8.02 (s, 1H, H-3), 8.84 (s, 1H, H-6), 9.26 (br s, 1H, NH). 
IR (KBr): cm
-1




Yield: 0.31 g, 69% 
Mp: 86-87 °C 
MW = 446.52 
Anal. calcd for C26H27FN4O2: C 69.94, H 6.09, N 12.55; found C 70.23, H 6.38, N 12.22. 
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H-NMR (200 MHz, CDCl3): δ (ppm) 1.21-1.30 (m, 3H, CH3CH), 1.34 (t, J = 7.2 Hz, 3H, 
CH3CH2), 3.04 (t, J = 6.8 Hz, 2H, CH2Ar), 3.55-3.63 (m, 1H, CHCH3), 3.85 (q, J = 6.8 Hz, 
2H, CH2NH), 4.32 (q, J = 7.2 Hz, 2H, CH2O), 4.49-4.55 (m, 2H, CH2N), 7.08-7.29 (m, 9H 
Ar), 8.05 (s, 1H, H-3), 8.82 (s, 1H, H-6), 9.24 (br s, 1H, NH). 
IR (KBr): cm
-1




Yield: 0.32 g, 71% 
Mp: 85-86 °C 
MW = 446.52 
Anal. calcd for C26H27FN4O2: C 69.94, H 6.09, N 12.55; found C 69.92, H 5.93, N 12.34. 
1
H-NMR (200 MHz, CDCl3): δ (ppm) 1.20-1.24 (m, 3H, CH3CH), 1.33 (t, J = 7.2 Hz, 3H, 
CH3CH2), 3.01 (t, J = 6.8 Hz, 2H, CH2Ar), 3.50-3.59 (m, 1H, CHCH3), 3.88 (q, J = 6.8 Hz, 
2H, CH2NH), 4.30 (q, J = 7.2 Hz, 2H, CH2O), 4.50-4.57 (m, 2H, CH2N), 7.11-7.35 (m, 9H 
Ar), 8.00 (s, 1H, H-3), 8.77 (s, 1H, H-6), 9.19 (br s, 1H, NH). 
IR (KBr): cm
-1




Yield: 0.34 g, 77% 
Mp: 93-94 °C 
MW = 446.52 
Anal. calcd for C26H27FN4O2: C 69.94, H 6.09, N 12.55; found C 69.78, H 6.33, N 12.19. 
1
H-NMR (200 MHz, CDCl3): δ (ppm) 1.22-1.28 (m, 3H, CH3CH), 1.39 (t, J = 7.2 Hz, 3H, 
CH3CH2), 3.09 (t, J = 6.8 Hz, 2H, CH2Ar), 3.59-3.63 (m, 1H, CHCH3), 3.91 (q, J = 6.8 Hz, 
2H, CH2NH), 4.34 (q, J = 7.2 Hz, 2H, CH2O), 4.53-4.60 (m, 2H, CH2N), 7.10-7.32 (m, 9H 
Ar), 8.03 (s, 1H, H-3), 8.80 (s, 1H, H-6), 9.23 (br s, 1H, NH). 
IR (KBr): cm
-1
 3282 (NH), 1660 (CO). 
CHAPTER 7. Experimental section 





Yield: 0.26 g, 56% 
Mp: 99-100 °C 
MW = 458.55 
Anal. calcd for C27H30N4O3: C 70.72, H 6.59, N 12.22; found C 71.06, H 6.41, N 11.88. 
1
H-NMR (200 MHz, CDCl3): δ 1.22-1.27 (m, 3H, CH3CH), 1.41 (t, J = 7.2 Hz, 3H, CH3CH2), 
3.07 (t, J = 6.8 Hz, 2H, CH2Ar), 3.55-3.71 (m, 1H, CHCH3), 3.90-4.00 (m, 5H, OCH3 + 
CH2NH), 4.35 (q, J = 7.2 Hz, 2H, CH2O), 4.50-4.63 (m, 2H, CH2N), 6.83-7.44 (m, 9H Ar), 
8.07 (s, 1H, H-3), 8.86 (s, 1H, H-6), 9.25 (br s, 1H, NH). 
IR (KBr): cm
-1




Yield: 0.24 g, 55% 
Mp: 120-121 °C 
MW = 442.55 
Anal. calcd for C27H30N4O2: C 73.28, H 6.83, N 12.66; found C 73.64, H 7.19, N 12.96. 
1
H-NMR (200 MHz, CDCl3): δ 1.21-1.27 (m, 3H, CH3CH), 1.38 (t, J = 7.2 Hz, 3H, CH3CH2), 
2.35 (s, 3H, CH3Ar), 3.06 (t, J = 6.8 Hz, 2H, CH2Ar), 3.55-3.60 (m, 1H, CHCH3), 3.89 (q, J = 
6.8 Hz, 2H, CH2NH), 4.34 (q, J = 7.2 Hz, 2H, CH2O), 4.52-4.57 (m, 2H, CH2N), 7.15-7.28 
(m, 9H Ar), 8.04 (s, 1H, H-3), 8.84 (s, 1H, H-6), 9.24 (br s, 1H, NH). 
IR (KBr): cm
-1
 3284 (NH), 1663 (CO). 
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To a solution of intermediate 231a (0.37 g, 1.22 mmol) in absolute EtOH (5 mL) aniline (0.23 
g, 2.44 mmol) was added and the reaction was stirred at reflux for 5 h. The solvent was 
removed under vacuum, water (40 mL) was added and the mixture was extracted with CH2Cl2 
(40 mL x 3). The organic phase was washed with water (80 mL), dried over Na2SO4, filtered 
and concentrated under reduced pressure. The obtained solid was filtered using Et2O to get 
the final desired compound 224g as a white solid.  
 
Yield: 0.20 g, 46% 
Mp: 126-128 °C 
MW = 358.82 
Anal. calcd for C18H19ClN4O2: C 60.25, H 5.34, N 15.61; found C 60.16, H 5.70, N 15.24. 
1
H-NMR (200 MHz, DMSO-d6): 1.44 (t, J = 7.0 Hz, 3H, CH3CH2), 1.60 (d, J = 6.0 Hz, 3H, 
CH3CH), 4.41 (q, J = 7.2 Hz, 2H, CH2O), 4.62-4.94 (m, 3H, CH2N + CHCH3), 6.67 (s, 1H, 
H-3), 7.25-7.45 (m, 5H Ar), 8.96 (s, 1H, H-6), 9.57 (br s, 1H, NH). 
IR (KBr): cm
-1
 3261 (NH), 1664 (CO). 
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A schlenk tube was charged with the opportune in-house naphtyl intermediate (1.00 g, 2.54 
mmol), phenylboronic acid (0.47 g, 3.82 mmol) and Ba(OH)2 octahydrate (1.30 g, 7.63 
mmol). In the glovebox, Pd(PPh3)4 (300 mg, 0.25 mmol) was added. The tube was sealed with 
a rubber septum and taken out of the glovebox. The tube was placed under argon and dioxane 
(5 mL) and water (1.25 mL) were added sequentially via syringe. The septum was replaced by 
a glass lid and the reaction mixture stirred at 100 °C for 24 h. Then, the reaction was cooled to 
room temperature and filtered over celite. Dioxane was removed under vacuum and the 
residue was extracted with CH2Cl2 (30 mL x 3). The combined organic phase was washed 
with saturated NaCl solution (90 mL), dried over Na2SO4, filtered and concentrated under 
reduced pressure. The crude product was purified by column chromatography using PE (bp 
40-60 °C)/CH2Cl2  (7:3) as eluent, to obtain compound 248 as a white solid.  
 
Yield: 0.42 g, 42% 
MW = 390.47 
C28H22O2 
1
H-NMR (500 MHz, CDCl3): δ (ppm) 3.10 and 3.80 (2 s, 3H, CH3), 7.13-7.15, 7.20-7.39 and 
7.43-7.47 (3 m, 10H naph), 7.75 (d, J = 5.0 Hz, 2H Ar), 7.80-7.90 and 7.95-7.99 (2 m, 4H, 3H 
Ar + 1H naph). 
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To a solution of compound 248 (0.50 g, 1.28 mmol) in CH2Cl2 (40 mL) at 0 °C under argon 
atmosphere, BBr3 (0.30 mL, 3.08 mmol) was added dropwise. The reaction was allowed to 
warm up and was stirred at room temperature overnight. The mixture was cooled down to 0 
°C and was quenched with water (75 mL). The organic phase was washed with water and 
saturated NaCl solution (40 mL), dried over Na2SO4, filtered and concentrated under reduced 
pressure. The crude product was purified by column chromatography using PE (bp 40-60 
°C)/AcOEt as eluent with a gradient elution (9:1 → 8:2), obtaining the desired compound as a 
white solid. 
 
Yield: 0.42 g, 90%  
MW = 362.42 
C26H18O2 
1
H-NMR (500 MHz, CDCl3): δ (ppm) 5.07 and 5.29 (2 br s, 2H, 2 OH), 7.10-7.12, 7.17-7.38 
and 7.45-7.47 (3 m, 10H naph), 7.70 (d, J = 5.0 Hz, 2H Ar), 7.82-7.90 (m, 3H Ar), 7.97 (s, 1H 
naph). 
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To a solution of compound 249 (0.5 g, 1.38 mmol) and pyridine (0.45 mL, 5.52 mmol) in 
CH2Cl2 (10 mL) at 0 °C under argon atmosphere, triflic anhydride (0.70 mL, 4.14 mmol) was 
added dropwise. The reaction was allowed to warm up and was stirred at room temperature 
overnight. The mixture was cooled down to 0 °C, quenched with 1 M HCl (10 mL) and 
diluted with CH2Cl2 (20 mL). The organic phase was washed with 1 M HCl (10 mL x 2) and 
saturated NaCl solution (10 mL), dried over Na2SO4, filtered and concentrated under reduced 
pressure. The crude was purified by column chromatography using PE (bp 40-60 °C)/AcOEt 
(9:1) as eluent, to obtain compound 250 as a white solid. 
 
Yield: 0.66 g, 76%  
MW = 626.54 
C28H16F6O6S2 
1
H-NMR (500 MHz, CDCl3): δ (ppm) 7.21-7.23, 7.34-7.57 and 7.62-7.63 (3 m, 12H, 9H naph 
+ 3H Ar), 7.98 (d, J = 5.0 Hz, 2H Ar), 8.09 (s, 1H naph), 8.12-8.14 (m, 1H naph).  
19
F-NMR (500 MHz, CDCl3): -74.74 and -74.51 (2 s, 3F, CF3). 
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A schlenk tube was charged with compound 250 (0.50 g, 0.80 mmol) and the phosphine oxide 
(0.44 g, 1.60 mmol). In the glovebox, Pd(OAc)2 (17.94 mg, 0.08 mmol) and Dppb (33.97 mg, 
0.08 mmol) were added. The tube was sealed with a rubber septum and taken out of the 
glovebox. Anhydrous DMSO (4 mL) and DIPEA (0.55 mL, 3.20 mmol) were added 
sequentially via syringe. The rubber septum was replaced by a glass stopper and the reaction 
mixture was stirred at 100 °C for 12 h. After cooling down at room temperature, anhydrous 
DMSO was partially removed under vacuum. The residue was diluted in AcOEt (30 mL) and 
washed with a mixture water/saturated NaCl solution (1:1) (10 mL x 3). The organic phase 
was dried over Na2SO4, filtered and concentrated under reduced pressure. The crude product 
was purified by column chromatography using PE (bp 40-60 °C)/AcOEt as eluent, with a 
gradient elution (7:3 → 6:4), to obtain the desired compound as a white solid.  
 
Yield: 0.53 g, 90% 
MW = 734.76 
C43H34F3O4PS 
1
H-NMR (500 MHz, CDCl3): δ (ppm) 2.04 and 2.29 (2 s, 3H, CH3), 6.74 (s, 1H Ar), 6.90-
6.95, 7.12-7.17, 7.26-7.49, 7.55-7.57, 7.66-7.72 and 7.78-7.80 (6 m, 18H, 10H Ar + 8H naph) 
7.89 (s, 1H naph), 7.94-7.95 and 8.01-8.03 (2 m, 2H naph).  
19
F-NMR (500 MHz, CDCl3): -74.64 (s, 3F, CF3).  
31
P-NMR (500 MHz, CDCl3): 27.31 (s, 1P, PO). 
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Compound 251 (0.50 g, 0.68 mmol), 3 M NaOH solution (1.40 mL, 4.08 mmol), dioxane 
(2.80 mL) and MeOH (1.40 mL) were added to a flask and the mixture was stirred at room 
temperature for 12 h. Then, the reaction was acidified by the addition of a few drops of 
concentrated HCl and extracted with AcOEt (30 mL x 3). The organic phase was dried over 
Na2SO4, filtered and concentrated under reduced pressure. The crude was purified by column 
chromatography using PE (bp 40-60 °C)/AcOEt (8:2) as eluent, to get compound 247 as a 
white solid.  
 
Yield: 0.29 g, 70% 
MW = 602.70 
C42H35O2P 
1
H-NMR (500 MHz, CDCl3): δ (ppm) 1.88 and 2.37 (2 s, 3H, CH3), 6.35-6.40, 6.81-6.84 and 
6.94-6.98 (3 m, 5H Ar), 7.09-7.13, 7.21-7.23, 7.34-7.38 and 7.43-7.59 (4 m, 12H, 6H Ar + 6H 
naph), 7.70 (s, 1H naph), 7.81-7.84 and 7.89-7.93 (2 m, 4H naph), 8.85 (br s, 1H, OH). 
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General procedure for the synthesis of racemic compounds 252a and 253a  
 
An oven-dried pyrex tube was charged with the opportune in-house substrate (1.00 mmol). In 
the glovebox, Cs2CO3 (0.49 g, 1.50 mmol), PCy·HBF4 (36.80 mg, 0.10 mmol), CsOPiv (0.07 
g, 0.30 mmol), Pd(OAc)2 (11.25 mg, 0.05 mmol) and molecular sieves (1.50 mmol) were 
added. The flask was sealed and taken out of the glovebox. Anhydrous xylenes (10 mL) was 
added, the rubber septum was replaced by a glass stopper and the reaction was stirred at 140 
°C for 16 h. The mixture was allowed to cool to room temperature, diluted with AcOEt (20 
mL) and filtrated through a pad of celite. The filtrate was concentrated under reduced pressure 
and purified by column chromatography, using PE (bp 40-60 °C)/AcOEt (98:2) as eluent.  
 
 
General procedure for the synthesis of enantioenriched compounds 252b and 253b  
 
An oven-dried J-Young tube was charged with the opportune in-house substrate (1.00 mmol). 
In the glovebox, Cs2CO3 (0.49 g, 1.50 mmol), chiral bifunctional ligand (56.90 mg, 0.10 
mmol), Pd(dba)3·CHCl3 (26.00 mg, 2.50 mmol%) and molecular sieves (2.00 mmol) were 
added. The tube was sealed, taken out of the glovebox, and anhydrous and degassed DME (10 
mL) was added under argon flux. The reaction mixture was degassed by three freeze-pump-
thaw cycles and heated at 140 °C for 24 h. Then, the reaction was cooled to room 
temperature, diluted with AcOEt (20 mL) and filtrated through a pad of celite. The crude was 
purified with a column chromatography, using PE (bp 40-60 °C)/AcOEt (98:2) as eluent 
(253b). 
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3-fluoro-12b-methoxy-8,8-dimethyl-8,12b-dihydrobenzo[a]aceanthrylene 252a (racemic) 
and 253b (enantioenriched) 
Yield: 0.29 g, 88% (racemic); 0.17 g, 50% (enantioenriched) 
MW = 330.39 
C23H19FO 
1
H-NMR (500 MHz, CDCl3): δ (ppm) 1.82 and 1.87 (2 s, 3H, CH3), 2.71 (s, 3H, OCH3), 7.14 
(ddd, J = 8.0 Hz, J = 1.2 Hz, J = 0.6 Hz, 1H Ar), 7.29 (ddd, J = 7.6 Hz, J = 7.6 Hz, J = 1.3 
Hz, 1H Ar), 7.34-7.43 and 7.48-7.51 (m, 5H Ar), 7.69 (dd, J = 8.0 Hz, J = 0.6 Hz, 1H Ar), 
7.93-7.97 (m, 2H Ar)  
GS-MS: 299 (330-OCH3), 284 (299-CH3). 
252b e.r.77:23 (chiral HPLC) 
 
10-fluoro-12b-methoxy-12bH-indeno[1,2,3-kl]xanthene 253a (racemic) and 253b 
(enantioenriched) 
MW = 304.31 
C20H13FO2 
GS-MS (on the crude): 273 (304-OCH3). 
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To a cold (-10 °C) solution of m-toluidine (3.00 g, 28.00 mmol) in anhydrous toluene (35 
mL), BCl3 (1 M in heptane, 5.32 mL, 33.60 mmol) was slowly added. After the addition was 
complete, the cooling bath was removed and the mixture was stirred at room temperature for 
1 h. Then, a solution of o-tolunitrile (3.65 mL, 30.80 mmol) in anhydrous toluene and AlCl3 
(4.11 g, 30.80 mmol) were added. The mixture was stirred at reflux under N2 atmosphere for 
24 h. The reaction was cooled and quenched by the addition of 18 N H2SO4 (60 mL), with 
vigorous stirring. The organic layer was separated and washed with additional 18 N H2SO4 
(60 mL). The acid extracts were combined and back-washed once with Et2O (120 mL). The 
acid layer was cooled to 5 °C before the pH was adjusted to ~ 10 by treatment with 20% 
NaOH solution. The aqueous layer was extracted with Et2O (150 mL) and the organic phase 
was washed with water (150 mL x 3), filtered and concentrated under reduced pressure. The 
crude was purified with column chromatography using CH2Cl2/MeOH (98:2) as eluent, to 
obtain immine 257 as a brownish solid. 
 
Yield: 2.51 g, 40% 
MW = 224.30 
C15H16N2 
1
H-NMR (400 MHz, CDCl3): δ (ppm) 2.32 and 2.49 (2 s, 3H, CH3), 6.82-6.85, 7.19-7.30 and 
7.43-7.44 (3 m, 7H Ar).  
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To a stirred suspension of maleic anhydride (1.00 g, 10.20 mmol) in anhydrous Et2O (1.00 
mL) at room temperature, dimethylfurane (1.09 mL, 10.20 mmol) was added and the mixture 
was stirred overnight. The resulting crystals were filtered and washed with anhydrous Et2O. 
The mother liquid was concentrated and the second crop of crystals were combined with those 
obtained previously, getting endoxide 258 as a brown solid. 
 
Yield: 0.83 g, 42% 
MW = 194.18 
C10H10O4 
1
H-NMR (400 MHz, CDCl3): δ (ppm) 1.77 (s, 6H, 2 CH3), 3.16 (s, 2H, 2 CH), 6.35 (s, 2H, 
CH=CH). 
 




Endoxide 258 (4.00 g, 20.00 mmol) was added in small portions to concentrated H2SO4 (40 
mL) cooled at -6 °C. The mixture was stirred vigorously, not allowing the temperature to rise 
above 0 °C. After all the endoxide was added and the mixture became orange in colour, it was 
poured slowly into crushed ice. The resulting white crystals were collected and washed with 
ice-water. The crystals were then dissolved in a solution 25 M NaOH, and AcOH (5 mL) was 
added to the solution. The solution was filtered to remove the insoluble materials and 
acidified with 36% HCl (3 mL). The resulting precipitate was collected and washed with 
water until the washing was neutral, to obtain compound 259 as a white solid. 
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Yield: 1.45 g, 41% 
MW = 176.17 
C10H8O3 
1
H-NMR (400 MHz, CDCl3): δ (ppm) 2.67 (s, 6H, 2 CH3), 7.50 (s, 2H Ar). 
 
 




In a two-necks flask filled with Mg powder (0.39 g, 16.00 mmol) and placed under argon 
flow, anhydrous Et2O (15 mL) was added. Then, bromo-2,5-dimethylbenzene (2.24 mL, 
16.00 mmol) was added dropwise and the reaction was stirred at reflux for 1 h. The obtained 
Grignard 260 was not isolated but used immediately in the next reaction. 
 
MW = 209.37    
 
  




To an ice-cold Et2O solution of Grignard 260 (3.40 g, 16.24 mmol), the solution of compound 
259 (2.38 g, 13.53 mmol) in toluene (33 mL) was added dropwise. The mixture was stirred at 
room temperature overnight. Then, the reaction was quenched with a saturated NH4Cl 
solution (40 mL) and extracted with AcOEt (40 mL x 3). The organic phase was dried over 
Na2SO4, filtered and concentrated under reduced pressure. The crude product was purified 
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with column chromatography, using PE (bp 40-60 °C)/AcOEt  as eluent, with a gradient 
elution (7:3 → 6:4), to obtain compound 261 as a white solid. 
 
Yield: 2.33 g, 61% 
MW = 282.33 
C18H18O3 
1
H-NMR (400 MHz, CDCl3): δ (ppm) 2.07, 2.10, 2.31 and 2.62 (4 s, 3H, CH3), 7.03, 7.08, 
7.24, 7.29 (4 d, J = 8.0 Hz, 1H Ar), 7.42 (s, 1H Ar). 
 
 




To a well-stirred solution of compound 261 (2.00 g, 7.08 mmol) in 10% NaOH (220 mL) 
heated at reflux, zinc dust (7.52 g, 115.00 mmol) was added over a period of 48 h. The 
mixture was refluxed for an additional 48 h and then filtered. The filter cake was washed with 
10% NaOH and with boiling water. The treatment of the filter cake with boiling ethanol, 
followed by concentration under reduced pressure gave compound 262 as white needles, and 
also the acidification of the filtrates with concentrated HCl and the extraction with toluene 
gave compound 262, instead of the desired one.  
 
Yield: 1.57 g, 83% 
MW = 266.33 
C18H18O2 
1
H-NMR (400 MHz, CDCl3): δ (ppm) 1.96, 2.18, 2.45 and 2.72 (4 s, 3H, CH3), 6.50 (s, 1H, 
CH), 6.52 (s, 1H Ar), 7.05, 7.12, 7.24 and 7.30 (4 d, J = 8.0 Hz, 1H Ar). 
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A solution of 2-amino-6-methylbenzoic acid (5.00 g, 6.62 mmol) and 25% H2SO4 (50 mL) 
was stirred until the amino acid dissolved. Then, the reaction was cooled to 0 °C and a 
solution of NaNO2 (3.00 g, 8.70 mmol) in 50 mL of water was added dropwise. After stirring 
1 h at 0 °C, the diazonium salt was decomposed by slowly adding the reaction mixture to a 
boiling solution of H2SO4 (20 mL) in 200 mL of water. The solution was cooled to room 
temperature and then to 0 °C before filtration. Recrystallization from boiling water with 
decolorizing carbon gave compound 263 as light yellow needles. 
 
Yield: 0.69 g, 69% 
MW = 152.15 
C8H8O3 
1
H-NMR (400 MHz, CDCl3): δ (ppm) 2.63 (s, 3H, CH3), 6.77 and 6.87 (2 d, J = 8.0 Hz, 1H 
Ar), 7.35 (t, J = 8.0 Hz, 1H Ar), 11.03 (br s, 1H, OH). 
 
 




A two-phase mixture of compound 263 (2.00 g, 13.14 mmol), NaOH (1.58 g, 39.43 mmol), 
benzyl bromide (4.69 mL, 39.43 mmol) and tetrabutylammonium bromide (0.42 g, 1.31 
mmol) in water (10 mL) and CH2Cl2 (10 mL) was stirred at room temperature for 24 h. The 
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residue was diluted with water and extracted with AcOEt (30 mL x 3). After a column 
chromatography using PE (bp 40-60 °C)/AcOEt (95:5) as eluent, compound 264 was obtained 
as a white solid.   
 
Yield: 2.62 g, 60% 
MW = 332.29 
C22H20O3 
1
H-NMR (400 MHz, CDCl3): δ (ppm) 2.29 (s, 3H, CH3), 5.09 and 5.36 (2 s, 2H, CH2), 6.78-
6.81 (m, 2H Ar), 7.20 (t, J = 8.0 Hz, 1H Ar), 7.18-7.40 (m, 10H Ar). 
 
 




A flask containing compound 264 (2.00 g, 6.02 mmol), LiOH (0.43 g, 18.06 mmol) and 
NaOH (0.72 g, 18.06 mmol) in a mixture of H2O/THF/MeOH (15:15:15 mL) was stirred at 
room temperature overnight. Then, the reaction was acidified by addition of few drops of 
concentrated HCl and extracted with AcOEt (50 mL x 3). The organic phase was dried over 
Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by 
column chromatography, using cyclohexane/AcOEt as eluent with a gradient elution (6:4 → 
1:1), to afford the desired compound as a clear oil.   
 
Yield: 0.58 g, 40% 
MW = 242.27 
C15H14O3 
1
H-NMR (400 MHz, CDCl3): δ (ppm) 2.49 (s, 3H, CH3), 5.18 (s, 2H, CH2), 6.88-7.00 and 
7.26-7.44 (2 m, 8H Ar). 
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To a well-stirred solution of m-cresol (1.00 g, 9.25 mmol) dissolved in DMF (8 mL), K2CO3 
(0.26 g, 18.49 mmol) was added. After 2 h, benzyl bromide (1.65 mL, 13.87 mmol) was 
added dropwise over a period of 45 minutes and the reaction was stirred at 60 °C for 12 h. 
The reaction mixture was poured on ice-water (35 mL) and extracted with AcOEt (30 mL x 
3). The organic phase was washed with saturated NaCl solution, dried over Na2SO4, filtered 
and concentrated under reduced pressure. After the purification of the crude with a column 
chromatography, using cyclohexane/AcOEt as eluent with a gradient elution (98:2 → 95:5), 
compound 266 was obtained as a clear oil. 
 
Yield: 1.56 g, 85% 
MW = 198.26 
C14H14O    
1
H-NMR (400 MHz, CDCl3): δ (ppm) 2.34 (s, 3H, CH3), 5.06 (s, 2H, CH2), 6.78-6.83 (m, 3H 
Ar), 7.18 (t, J = 8.0 Hz, 1H Ar), 7.31-7.46 (m, 5H Ar). 
 
 




To a solution of compound 265 (1.00 g, 4.13 mmol) in ethanol-free CHCl3 (45 mL), 
compound 266 (2.05 g, 10.32 mmol), TFAA (8.32 mL, 59.85 mmol) and TFA (1.59 mL, 
20.64 mmol) were added. The reaction mixture was stirred at reflux under argon overnight. 
The solvent was removed under vacuum and the residual oil was extracted with Et2O (50 mL 
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x 3), washed with diluted aqueous KOH (150 mL) and saturated NaCl solution (150 mL), 
dried over Na2SO4 and concentrated under reduced pressure. The crude was purified by 
column chromatography, using cyclohexane/AcOEt (9:1) as eluent with a gradient elution 
(10:0 → 9:1), to obtain compound 267 as clear oil. 
 
Yield: 1.19 g, 68% 
MW = 422.51 
C29H26O3 
1
H-NMR (400 MHz, CDCl3): δ (ppm) 2.21 and 2.63 (2 s, 3H, CH3), 4.95 and 5.10 (2 s, 2H, 
CH2), 6.70 (dd, J = 8.0 Hz, 1H Ar), 6.78 (d, J = 8.0 Hz, 1H Ar), 6.84-6.88, 7.01-7.04, 7.18-
7.22 and 7.33-7.44 (4 m, 14H Ar). 
 
 




A solution of compound 267 (1.00 g, 2.37 mmol) in AcOEt (28 mL) and absolute EtOH (44 
mL) was hydrogenated overnight at room temperature and atmospheric pressure over 10% 
Pd/C (0.19 g, 1.77 mmol). The reaction was filtered over celite and concentrated under 
reduced pressure, to give the clean product 268 as a brown oil. 
 
Yield: 0.57 g, quantitative 
MW = 242.27 
C15H14O3 
1
H-NMR (400 MHz, CDCl3): δ (ppm) 1.90 and 2.41 (2 s, 3H, CH3), 6.65 and 6.69 (2 d, J = 
8.0 Hz, 1H Ar), 6.72-6.75 (m, 1H Ar), 6.87 and 7.17 (2 d, J = 8.0 Hz, 1H Ar), 7.28-7.30 (m, 
1H Ar).  
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To a solution of POCl3 (4.51 mL, 48.33 mmol) in anhydrous DMF (13 mL) a solution of 3,5-
dihydroxy toluene (3.00 g, 24.17 mmol) in the same solvent (12 mL) was slowly added. The 
reaction was stirred at room temperature for 12 h. Then, it was cooled to 0 °C, treated with ice 
water and then with 10% NaOH to pH ~ 10. The resulting mixture was heated at reflux for 30 
minutes and then acidified to pH ~ 3 with concentrated HCl. The precipitate was collected by 
filtration and washed with water, to get the desired product as a yellow powder. 
 
Yield: 4.41 g, 60%  
MW = 152.15 
C8H8O3 
1
H-NMR (400 MHz, CDCl3): δ (ppm) 2.46 (s, 3H, CH3), 6.13 and 6.21 (2 s, 1H Ar), 10.06 (br 
s, 1H, OH), 10.68 (s, 1H, CHO), 12.06 (br s, 1H, OH). 
 
 




To a solution of compound 269 (2.00 g, 13.15 mmol) and benzyl bromide (5.62 g, 32.86 
mmol) in acetone (75 mL), K2CO3 (7.27 g, 52.58 mmol) was added. The mixture was stirred 
at reflux for 2.5 h. Then, the reaction was filtered and the solvent evaporated under reduced 
pressure. The crude was purified by column chromatography using pentane/Et2O (8:2) as 
eluent, to obtain the desired compound as a pale green solid. 
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Yield: 3.54 g, 81% 
MW = 332.39 
C22H20O3 
1
H-NMR (400 MHz, CDCl3): 2.60 (s, 3H, CH3), 5.10 and 5.12 (2 s, 2H, CH2), 6.42-6.48 and 
7.34-7.42 (2 m, 6H Ar), 10.61 (s, 1H, CHO). 
 
 




A mixture of compound 270 (3.00 g, 9.03 mmol) in t-BuOH (112 mL) under nitrogen was 
sonicated at 40 °C until it was fully dissolved. Subsequently, 2-methyl-2-butene (9.56 mL, 
90.30 mmol) and a solution of NaClO2 (1.96 g, 21.66 mmol) and NaH2PO4 (6.50 g, 54.15 
mmol) in water (30 mL) were added dropwise. The reaction was stirred under nitrogen at 
room temperature overnight. Then, the mixture was concentrated under vacuum and extracted 
with CH2Cl2 (30 mL x 3) and 10% HCl (30 mL). The organic phase was washed with 
saturated NaCl solution (90 mL), dried over Na2SO4, filtered and concentrated under reduced 
pressure, to give the pure compound 271 as a light yellow solid. 
 
Yield: 3.15 g, quantitative 
MW = 348.39  
C22H20O4 
NMR (400 MHz, CDCl3): 2.60 (s, 3H, CH3), 5.09 and 5.15 (2 s, 2H, CH2), 6.54-6.56 and 
7.34-7.41 (2 m, 12H Ar). 
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To a well-stirred solution of orcinol (1.00 g, 8.06 mmol) in DMF (8 mL), K2CO3 (4.45 g,  
32.23 mmol) was added. After 2 h, benzyl bromide (2.87 mL,  24.17 mmol) was added 
dropwise over a period of 45 minutes and the reaction was stirred at 60 °C for 12 h. The 
reaction mixture was poured on ice-water (100 mL) and extracted with AcOEt (50 mL x 3). 
The organic phase was washed with saturated NaCl solution, dried over Na2SO4, filtered and 
concentrated under reduced pressure. The crude was purified by column chromatography, 
using PE (bp 40-60 °C)/AcOEt (98:2) as eluent, to obtain compound 272 as a clear oil. 
 
Yield: 1.47 g, 60% 
MW = 304.38 
C21H20O2 
1
H-NMR (400 MHz, CDCl3) 2.31 (s, 3H, CH3), 5.02 (s, 4H, 2 CH2), 6.45 (s, 3H Ar), 7.33-
7.44 (m, 10H Ar). 
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To a solution of compound 271 (1.50 g, 4.31 mmol) in ethanol-free CHCl3 (70 mL), 
compound 272 (3.25 g, 10.68 mmol), TFAA (8.68 mL, 62.43 mmol) and TFA (1.66 mL, 
21.53 mmol) were added and the reaction mixture was stirred at reflux under nitrogen 
overnight. The solvent was removed under vacuum and the residual oil extracted with Et2O 
(30 mL x 3), washed with dilute aqueous KOH and saturated NaCl solution (90 mL), dried 
over Na2SO4 and concentrated under reduced pressure. The crude was purified by column 
chromatography using PE (bp 40-60 °C)/AcOEt (98:2) as eluent, to obtain compound 273 as a 
yellowish oil. 
 
Yield: 1.42 g, 52% 
MW = 634.76 
C43H38O5 
1
H-NMR (400 MHz, CDCl3) 2.26 (s, 6H, 2 CH3), 5.04 and 5.06 (2 s, 4H, 2 CH2), 6.45 and 
6.48 (2 s, 2H Ar), 7.30-7.41 (m, 20H Ar). 
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A solution of compound 273 (1.00 g, 1.58 mmol) in AcOEt (28 mL) and absolute EtOH (44 
mL) was hydrogenated overnight at room temperature and atmospheric pressure over 10% 
Pd/C (0.38 g, 3.57 mmol). The reaction was filtered over celite and concentrated under 
reduced pressure to give the clean product 274 as a yellow oil. 
 
Yield: 0.43 g, quantitative 
MW = 274.27 
C15H14O5 
1
H-NMR (400 MHz) 2.47 (2 s, 3H, CH3), 6.30 (s, 4H Ar).  
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